y4565z‚ŧ[‚đ‚ĒG 498yJP Morgan Healthcare Conferencez

1ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:01:19.41ID:rjzKPc/a0
Ķ‘OƒXƒŒ
y4565z‚ŧ[‚đ‚ĒG 497yJP Morgan Healthcare Conference (1/15)z
https://hayabusa9.5ch.net/test/read.cgi/livemarket1/1577653199

2ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:02:33.81ID:rjzKPc/a0
EventsF

ĶJP Morgan Healthcare Conference:
E"Novartis" (1/13 Today 8:00 Presenting) https://jpmorgan.metameetings.net/events/hc20/sessions/29835-novartis/webcast
E"Daiichi Sankyo" (1/13 Today 14:00 Presenting)
E"Roche" (1/14 9:30 Presenting)
E"Pfizer" (1/14 15:30 Presenting)
E"Takeda Pharmaceutical" (1/14 16:00 Presenting)
E"Sosei Group" (1/15 10:30 Presenting) https://jpmorgan.metameetings.net/events/hc20/sessions/29872-sosei-group-corporation

3ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:02:51.72ID:rjzKPc/a0
E"MorphoSys" (1/15 13:30 Presenting)
E"Vectura" (1/16 10:00 Presenting) https://jpmorgan.metameetings.net/events/hc20/sessions/29892-vectura-group-plc
ĶASCO 2020: "First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)": Debashis Sarker. (1/24 12:00 Presenting)
ĶPfizer Quarterly Corporate Performance - Q4 2019 Results. (1/28)
ĶNovartis Q4 and Full Year Results 2019 and Annual Report 2019 Publication. (1/29)
ĶPatients as Partners Europe: "Patient Involvement in Regulatory Decisions: How Regulations are Incorporating the Patient Voice": Domenico Merante, MD, VP, Clinical Development, Sosei Heptares. (1/27 16:15-16:45 Presenting)
ĶR•DŽx‰‡ƒZƒ“ƒ^[ŽåÃƒyƒvƒ`ƒhƒZƒ~ƒi[uƒyƒvƒ`ƒhˆã–ō•iŒī–ō‚Ėŧ‘ĒƒvƒƒZƒXŠJ”­‚ƃXƒP[ƒ‹ƒAƒbƒv‚Ė—ŊˆÓ“_vJITSUBO ŒĪ‹†ŠJ”­•” •”’· ŽRúą‹MŽjB(1/31 12:30-16:30)
Ķ‘æˆęŽO‹Ī2020”N3ŒŽŠú‘æ3Žl”žŠúŒˆŽZ (1/31)

4ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:03:16.09ID:rjzKPc/a0
ĶSosei Group 2019”N12ŒŽŠúŒˆŽZ”­•\ (2/13Ķ)
Ķƒyƒvƒ`ƒhƒŠ[ƒ€2019”N12ŒŽŠúŒˆŽZ (2/13)
ĶAstrazeneca Full-Year 2019 Results. (2/14)
ĶAllergan Q4 and Full-Year 2019 Results. (2/19 Projected)
ĶSMi RNA Therapeutics: "Small Activating RNAs(saRNAs) - A Novel Therapeutic Class of Oligonucleotides with Broad Therapeutic Potential": David Blakey, MiNA Therapeutics. (2/19 13:20-14:00 Presenting)
ĶICDD (International Conference on Drug Discovery) 2020: Speaker Dr. Jonathan Mason, Sosei Heptares. (2/29-3/2)
ĶŽl‹G•ņ2020”N2Wt†F(Žl‹G•ņæŽæ‚čF3ŒŽã{AŽl‹G•ņXVF3/16”­”„)
ĶSosei Group ‘æ30‰ņ’莞Š”Žå‘‰ï (3ŒŽ‰š{)
EEE

5ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:31:11.36ID:rjzKPc/a0
ŽŸ‚Č‚é”ō–ô‚ցB’…ŽĀ‚Ȑi’ŧ‚Æ‹Ī‚ɍX‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂĐU‚é‚Ēˆį‚ŋ‚ä‚­‘ŠęBT‚Ķ‚éÞ—ŋ‚Æ‹Ī‚ɐ…€’ųģBÎB
Ž’·ŠúB—\’č‚ģ‚ę‚Ä‚Ē‚―‹ÆŅ‚Ė‹}Ž’·‚Æ‹Ī‚ɍX‚Ȃ鐎’·í—Š‚Ši“WB‡’ē‚ČR&DEPL“™‚ĖŠg[EŠg‘å‚Ė‰Á‘ŽBÎB
EEE
ĶSOSEI‚ĖŽ’·‘Šę‚Ė“ŪŒüF‘O‰ņ‚Ė‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē’ēŪ‚ŠI‚čAÄ‚Ņ‚Ėãļ(…€’ųģ)‘Šę‚͏‡’ē‚ɐ„ˆÚBÎB‹ÆŅ‘Šę‚Ö‚Ė“ŪˆÓ‘Ō‚ŋBÎB
2010/12/30 (I’l_338) E(2010/10/15ĶÅˆĀ’l_163A2010/12/27Å‚’l_437) ĶQVA149‘æ‡V‘ŠŠJŽn
2011/12/30 (I’l_318) E(2011/_3/15ĶÅˆĀ’l_173A2011/_6/30Å‚’l_420) Ķƒmƒ‹ƒŒƒ{ģ”F(2/23Ķ)
2012/12/28 (I’l_522) E(2012/_6/_6ĶÅˆĀ’l_238A2012/_9/_7Å‚’l_742) ĶSeebri‰ĒBĨ“ú–{ģ”F
2013/12/30 (I’l1079) E(2013/_1/_4ĶÅˆĀ’l_513A2013/_5/_7Å‚’l1525) ĶUltibro‰ĒBĨ“ú–{ģ”F
2014/12/30 (I’l1093) E(2014/_4/12ĶÅˆĀ’l_464A2014/_9/_8Å‚’l1500) Ķ’†’·ŠúŒv‰æ”­•\(5/13Ķ)[E‚ĒęĶ][Ž’·‰ņŽûŠú‚Ė“üŒû]

6ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:31:34.84ID:rjzKPc/a0
2015/12/30 (I’l2488) E(2015/_3/16ĶÅˆĀ’l_713A2015/12/14Å‚’l2645) ĶHeptares(2/20Ķ)[ŽŒũ‚Ė˜Í]ĻĶ•Ä‘ģ”F(10/30Ķ)[ŽŸ‚Č‚é”ō–ô‚Ö]
2016/12/30 (I’l3363) E(2016/_1/18ĶÅˆĀ’l2270A2016/_5/_9Å‚’l6545) ĶAllergan(4/7)[‹­‹C‘Šę]ĻĶ“úXŒö•\‰ðœ(6/28)[‹­‹C‘Šę‰ðœ]
2017/12/29 (I’l2735) E(2017/_9/_6ĶÅˆĀ’l2148A2017/_1/_6Å‚’l3645) Ķ[ã”ē‚ŊŒ—‚Å‚ĖŽžŠÔŽē’ēŪ‚͏‡’ē‚ɐ„ˆÚ]ĻĶ[U‚é‚ĒęEE‚Ēę‚Ö]
2018/12/28 (I’l_799) E(2018/12/25ĶÅˆĀ’l_748A2018/_1/25Å‚’l3195) ĶSoseiHeptaresŽn“Ū[Ä‚Ņ‚ĖE‚Ēę(’ę’l)Ķ][‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē’ēŪ‚ŠI—đ]
2019/12/30 (I’l2171) E(2019/_1/_4ĶÅˆĀ’l_780A2019/_8/_5Å‚’l2794) Ķ“c‘šCEO•œ‹AĶ[ãļƒgƒŒƒ“ƒh‚Ö“]Š·]ĶQVM149‰ĒB\ŋ(5/24) [—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋ]
2020/_1/10 (I’l2115) E(2020/_1/_8ĶÅˆĀ’l1977A2020/_1/_6Å‚’l2176) Ķ1/7:MiNA Collaboration with AstraZeneca.

Ä‚Ņ‚ĖE‚Ēę(’ę’l)‚Đ‚į‚Ė…€’ųģ‚Í3”{Œ—ƒXƒe[ƒW‚ɂē‚ɐ„ˆÚBÎB—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋBÎB200“úü’ēŪBÎB
ŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—Š‚́A’…ŽĀ‚ČŠg[‚Æ‹Ī‚ɁA‡’ē‚ɐi“WBÎBX‚Ȃ鐎’·‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎB
Œo‰cí—Š‚Ė“]Š·‚É‚æ‚鍕Žš’č’…‰ŧBÎBĄ‰ņ‚Ėãļ‘Šę‚ā–Ę”’‚­‚Č‚čAˆŦ’n‡‚Ē‚ɂĐV”N‘Šę‚ŠŠJŽnBÎB

7ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:32:10.86ID:rjzKPc/a0
ĶSosei Group ‹ÆŅ‚Ė•Ï‘JF

E2010”N03ŒŽŠúŽĀŅF”„ã‚__ 919•S–œ‰~A‰c‹Æ—˜‰v-1,854•S–œ‰~AÅ‘O—˜‰v-1,781•S–œ‰~Aƒ—˜‰v-1,769•S–œ‰~A1Š”‰v-150.0‰~
E2011”N03ŒŽŠúŽĀŅF”„ã‚__ 716•S–œ‰~A‰c‹Æ—˜‰v-1,876•S–œ‰~AÅ‘O—˜‰v-1,962•S–œ‰~Aƒ—˜‰v-1,871•S–œ‰~A1Š”‰v-158.6‰~
E2012”N03ŒŽŠúŽĀŅF”„ã‚__ 862•S–œ‰~A‰c‹Æ—˜‰v-1,962•S–œ‰~AÅ‘O—˜‰v-1,950•S–œ‰~Aƒ—˜‰v-1,954•S–œ‰~A1Š”‰v-165.1‰~
E2013”N03ŒŽŠúŽĀŅF”„ã‚ 1,958•S–œ‰~A‰c‹Æ—˜‰v_ -953•S–œ‰~AÅ‘O—˜‰v_ -788•S–œ‰~Aƒ—˜‰v_ -646•S–œ‰~A1Š”‰v-54.5‰~
E2014”N03ŒŽŠúŽĀŅF”„ã‚ 2,069•S–œ‰~A‰c‹Æ—˜‰v-1,185•S–œ‰~AÅ‘O—˜‰v-1,065•S–œ‰~Aƒ—˜‰v_ -122•S–œ‰~A1Š”‰v -2.5‰~
E2015”N03ŒŽŠúŽĀŅF”„ã‚ 3,671•S–œ‰~A‰c‹Æ—˜‰v 1,108•S–œ‰~AÅ‘O—˜‰v 1,366•S–œ‰~Aƒ—˜‰v__ 568•S–œ‰~A1Š”‰v 10.3‰~
E2016”N03ŒŽŠúŽĀŅF”„ã‚ 8,151•S–œ‰~A‰c‹Æ—˜‰v 1,075•S–œ‰~AÅ‘O—˜‰v-3,297•S–œ‰~Aƒ—˜‰v-1,432•S–œ‰~A1Š”‰v-23.4‰~

8ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:32:50.54ID:rjzKPc/a0
E2017”N03ŒŽŠúŽĀŅF”„ã‚18,901•S–œ‰~A‰c‹Æ—˜‰v12,398•S–œ‰~AÅ‘O—˜‰v12,483•S–œ‰~Aƒ—˜‰v9,311•S–œ‰~A1Š”‰v137.8‰~
E2018”N03ŒŽŠúŽĀŅF”„ã‚ 6,955•S–œ‰~A‰c‹Æ—˜‰v-2,291•S–œ‰~AÅ‘O—˜‰v-3,702•S–œ‰~Aƒ—˜‰v-2,654•S–œ‰~A1Š”‰v-37.5‰~
E2018”N12ŒŽŠúŽĀŅF”„ã‚ 2,872•S–œ‰~A‰c‹Æ—˜‰v-5,734•S–œ‰~AÅ‘O—˜‰v-7,243•S–œ‰~Aƒ—˜‰v-5,977•S–œ‰~A1Š”‰v-78.4‰~
2019”N12ŒŽŠúF
E‘æ1Žl”žŠúŽĀŅ(_5/14)F”„ã‚3,136•S–œ‰~A‰c‹Æ—˜‰v1,061•S–œ‰~AÅ‘O—˜‰v929•S–œ‰~Aƒ—˜‰v1,018•S–œ‰~A1Š”‰v13.3‰~
E‘æ2Žl”žŠúŽĀŅ(_8/13)F”„ã‚5,056•S–œ‰~A‰c‹Æ—˜‰v ,731•S–œ‰~AÅ‘O—˜‰v ,292•S–œ‰~Aƒ—˜‰v ,395•S–œ‰~A1Š”‰v5.13‰~
E‘æ3Žl”žŠúŽĀŅ(11/12)F”„ã‚7,770•S–œ‰~A‰c‹Æ—˜‰v1,094•S–œ‰~AÅ‘O—˜‰v1,142•S–œ‰~Aƒ—˜‰v1,461•S–œ‰~A1Š”‰v18.9‰~
Ŧ
ĶSosei Group 2019”N12ŒŽŠúŒˆŽZ”­•\EŒˆŽZā–ū (2/13Ķ)
EEE

9ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:33:32.60ID:rjzKPc/a0
‚ŋ‚Č‚Ý‚É‹ÆŅ—\‘zF

ĶSosei GroupF2019”N12ŒŽŠú‚Ė˜AŒ‹‹ÆŅ—\‘z (11/12)
Žû‰vŦ’Į‹‚Ė‚―‚߁AŒo‰cŽ‘Œđ‚ÆŽ‘–{‚Ėƒoƒ‰ƒ“ƒX‚ð‚æ‚讝‘ą‰Â”\‚Č‚ā‚Ė‚Æ‚·‚é‚ą‚Æ‚É‚æ‚čA“–ŽÐƒOƒ‹[ƒv‚Ė‹ÆŅŒĐž‚݂͐˜‚Ķ’u‚ŦB
EŒĪ‹†ŠJ”­”Šz‚Í4,320•S–œ‰~‚Đ‚į4,860•S–œ‰~‚ðŒĐž‚Ý‚Ü‚·B(˜‚Ķ’u‚Ŧ)
Eˆę”ĘŠĮ—”ï‚ÉŒW‚éŒŧ‹āŽxo‚Í1,620•S–œ‰~‚Đ‚į2,160•S–œ‰~‚ðŒĐž‚Ý‚Ü‚·B(˜‚Ķ’u‚Ŧ)
EŒĪ‹†ŠJ”­‚ÉŠÖ‚·‚éŠų‘ķ‚Ė’ņŒgæ‚Đ‚į‚Ėƒ}ƒCƒ‹ƒXƒgƒ“‚ÉŠÖ‚·‚éŽû‰v‚ðŒĐž‚Ý‚Ü‚·B(Ķ12/23:Pfizer‘æ‡T‘ŠŠJŽn(–ņ5‰­4700–œ‰~) Ķ12/24:PfizerŽO”Ԗڐi’ŧ(–ņ3‰­2800–œ‰~)
Eˆø‚Ŧ‘ą‚Ŧ“ŠŽ‘‚ð‚æ‚čW’†“I‚ɍs‚ĒAƒRƒXƒgƒx[ƒX‚ĖŠĮ—“O’ę‚ð–ÚŽw‚ĩ‚Ü‚·B
E“–ŽÐƒOƒ‹[ƒv‚́A2021”N‚Ü‚Å‚ĖŽ–‹ÆŠˆ“Ū‚Ė‚―‚ß‚Ė\•Š‚ČŽ‘‹ā‚ðŠm•Û‚ĩ‚Ä‚Ļ‚čA2022”NŒã”ž‚Ü‚Å‚ĖŽ‘‹ā‚ðŠm•Û‚Å‚Ŧ‚é‚æ‚ĪÏ‹É“I‚É“w‚ß‚Ü‚·B

10ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:33:53.69ID:rjzKPc/a0
Ķ“Œ—mŒoÏ(Žl‹G•ņ)Fy4565F‚ŧ[‚đ‚ĒƒOƒ‹[ƒvzF(‹ÆŅ—\‘z11/21XVAæŽæ‚č12/3”zMAŽl‹G•ņ12/13XVE”­”„)
y•Žš’č’…zV‹K’ņŒg‚É‚æ‚éˆęŽž‹ā“™Žû“üãæ‚đBŒĪ‹†ŠJ”­ƒRƒXƒg—}§‚ō•Žš•‚ãB20”N12ŒŽŠú‚ÍŠų‘ķ’ņŒgi’ŧ‚Ėƒ}ƒCƒ‹ƒXƒg[ƒ“A”Ė”„ƒƒCƒ„ƒ‹ƒeƒB‚ɐV‹K’ņŒg‚ĖˆęŽž‹ā“™Žû“ü‰Á‚í‚éBŒĪ‹†ŠJ”­”ï“™ƒRƒXƒgˆģk—]’nkŽ‚āAŽ•‰c‹Æ‘‰vB
y”ŽÔzŽ–‹ÆŠJ”­‹­‰ŧ‚ĩ‚Ä‘O—Տ°’iŠK‚Đ‚į‚ĖÏ‹É’ņŒgí—Š‚ð‰Á‘ŽB’ņŒgæE‰pƒAƒXƒgƒ‰ƒ[ƒlƒJ‚Ė‚Š‚ņ‘ΏÛ2ŽĄŒą‚Ėi’ŧ‡’ēB
E2019”N12ŒŽŠú—\‘zF”„ã‚10,600•S–œ‰~A‰c‹Æ—˜‰v 1,600•S–œ‰~AŒoí—˜‰v1,600•S–œ‰~A“–Šú—˜‰v1,500•S–œ‰~A1Š”‰v 19.5‰~
E2020”N12ŒŽŠú—\‘zF”„ã‚10,800•S–œ‰~A‰c‹Æ—˜‰v 1,700•S–œ‰~AŒoí—˜‰v1,700•S–œ‰~A“–Šú—˜‰v1,550•S–œ‰~A1Š”‰v 20.1‰~

11ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:34:20.77ID:rjzKPc/a0
ĶSMBC“ú‹ŧØŒ”F‹ÆŅ—\‘z‚ðXVB(12/23XV)
Š”ŽŪŽsę‚Đ‚į•]‰ŋ‚ģ‚ę‚é‚É‚ÍHeptares‚ĖŠJ”­ƒpƒCƒvƒ‰ƒCƒ“‚Ši“W‚·‚é‚ą‚Æ‚Šd—vBAZD4635‚ĖPhase2ƒtƒ‹ƒf[ƒ^‚Å‚ĖˆĀ‘SŦE—LŒøŦ‚ĖŽĀØAHTL0018318‚ĖŽĄŒąÄŠJ‚ŠŠ”‰ŋãļ‚ĖŒ_‹@‚Æ‚Č‚é‚Æ‘z’čB
Žå‚Č•ÏX“_‚Æ‚ĩ‚āASeebriAUltibroAQVM149‚ĖŽû‰vvŒĢ‚Š2026”N‚ɂďI—đ‚·‚é‘O’ņ‚Å‚ ‚Á‚―‚ŠA‚ŧ‚ĖŒã‚āŽû‰vvŒĢ‚·‚é‚ā‚Ė‚Æ‚·‚éBPfizerAGenentechA•“c–ō•iH‹Æ‚Ė’ņŒg‚É‚æ‚éŽû‰v‚ð‹ÆŅ‚ɉÁ–Ą‚·‚éB
ƒJƒ^ƒŠƒXƒg‚Æ‚ĩ‚ẮAQVM149‰ĒBģ”F(2020”N“x‘O”ž)AQVM149“ú–{ģ”F(2020”N“xŒã”ž)AQVM149ARGONŽŽŒąŒ‹‰ĘŠJŽĶ(2020”N“x)AAllergan‚É‚æ‚éˆÓŽvŒˆ’č(2020”N“x)AV‹Kƒ‰ƒCƒZƒ“ƒXŒ_–ņ’ũŒ‹‚Č‚ĮB
E2019”N12ŒŽŠú—\‘zF”„ã‚ 9,087•S–œ‰~A‰c‹Æ—˜‰v1,087•S–œ‰~AÅ‘O—˜‰v1,087•S–œ‰~A“–Šú—˜‰v ,924•S–œ‰~A1Š”‰v12.1‰~
E2020”N12ŒŽŠú—\‘zF”„ã‚ 8,661•S–œ‰~A‰c‹Æ—˜‰v ,689•S–œ‰~AÅ‘O—˜‰v ,586•S–œ‰~A“–Šú—˜‰v ,498•S–œ‰~A1Š”‰v6.8‰~
E2021”N12ŒŽŠú—\‘zF”„ã‚ 8,821•S–œ‰~A‰c‹Æ—˜‰v ,646•S–œ‰~AÅ‘O—˜‰v ,646•S–œ‰~A“–Šú—˜‰v ,549•S–œ‰~A1Š”‰v 7.5‰~

12ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:34:47.57ID:rjzKPc/a0
ĶReutersFy4565FSosei Groupz2019-2021‹ÆŅ—\‘zƒRƒ“ƒZƒ“ƒTƒX(Number of Analysts 6)F(12/24update)
E2019”N12ŒŽŠú—\‘zF”„ã‚ 8,894•S–œ‰~AEBITDA 6,045•S–œ‰~A‰c‹Æ—˜‰v 1,851•S–œ‰~AÅ‘O—˜‰v 4,704•S–œ‰~A“–Šú—˜‰v 3,458•S–œ‰~A1Š”‰v 45.3‰~
E2020”N12ŒŽŠú—\‘zF”„ã‚11,444•S–œ‰~AEBITDA 6,887•S–œ‰~A‰c‹Æ—˜‰v 4,689•S–œ‰~AÅ‘O—˜‰v 5,225•S–œ‰~A“–Šú—˜‰v 4,313•S–œ‰~A1Š”‰v 56.5‰~
E2021”N12ŒŽŠú—\‘zF”„ã‚14,206•S–œ‰~AEBITDA 7,510•S–œ‰~A‰c‹Æ—˜‰v 6,802•S–œ‰~AÅ‘O—˜‰v 6,907•S–œ‰~A“–Šú—˜‰v 5,000•S–œ‰~A1Š”‰v 72.7‰~
EAverage Target Price 2,950 JP (Number of Analysts 6)

13ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:35:14.98ID:rjzKPc/a0
ĶƒAƒCƒtƒBƒXŠ”—\•ņFy4565F‚ŧ[‚đ‚ĒƒOƒ‹[ƒvz2019-2021‹ÆŅ—\‘zƒRƒ“ƒZƒ“ƒTƒX(ƒAƒiƒŠƒXƒg”6l)F(Ķ1/9XV)
E2019”N12ŒŽŠú‹ÆŅ—\‘zF”„ã‚11,099•S–œ‰~A‰c‹Æ—˜‰v 2,745•S–œ‰~AŒoí—˜‰v 2,899•S–œ‰~A“–Šú—˜‰v 2,479•S–œ‰~
E2020”N12ŒŽŠú‹ÆŅ—\‘zF”„ã‚10,820•S–œ‰~A‰c‹Æ—˜‰v 2,598•S–œ‰~AŒoí—˜‰v 1,572•S–œ‰~A“–Šú—˜‰v 1,291•S–œ‰~
E‚ŧ[‚đ‚ĒƒOƒ‹[ƒv‚ĖŒoí—˜‰v—\‘zƒRƒ“ƒZƒ“ƒTƒX‚́A‘OT’l‚Ė1,912•S–œ‰~‚Đ‚į51.6%ãļ‚ĩA2,899•S–œ‰~‚Æ‚Č‚Á‚―B
Eˆö‚݂ɃŒ[ƒeƒBƒ“ƒOƒRƒ“ƒZƒ“ƒTƒX‚Í4.0‚Å•Ï‚í‚į‚ļ‚Ė‚܂܁B–Ú•WŠ”‰ŋƒRƒ“ƒZƒ“ƒTƒX‚Í2,950‰~(ƒAƒiƒŠƒXƒg”6l)B

EEE

14ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:47:01.63ID:rjzKPc/a0
ĶSOSEI‚ĖŽ’·‘Šę‚Ė“ŪŒüF‘O‰ņ‚Ė‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē‚Å‚Ė’ēŪ‚ŠI‚čAÄ‚Ņ‚Ė’ę’l(2018/12/25:ÅˆĀ’l748)‚Đ‚į‚Ėãļ‘Šę‚͏‡’ē‚ɐ„ˆÚBÎB—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋBÎB
E2019”N(1/4:‘å”­‰ïŽn’l_784A1/4:ÅˆĀ’l_780A8/5:Å‚’l:2794A12/30:‘å”[‰ïI’l2171)
E2020”N(1/6:‘å”­‰ïŽn’l2150A1/8:ÅˆĀ’l1977A1/6:Å‚’l:2176A1/10:I’l2115)

Ķ“ú‘ŦF25“úĨ200“úGC(3/29)A75“úĨ200“úGC(4/22) A5“úĨ25“úÄGC(Next) A5“úĨ75“úÄGC(Next)A25“úĨ75“úÄGC(Next)BÎB
E“ú‘Ŧ(_1/_4)F5“ú•―‹Ï_802.00A25“ú•―‹Ï_940.80A75“ú•―‹Ï1083.17A200“ú•―‹Ï1488.48
E“ú‘Ŧ(_4/_5)F5“ú•―‹Ï1522.20A25“ú•―‹Ï1331.60A75“ú•―‹Ï1153.52A200“ú•―‹Ï1256.93
E“ú‘Ŧ(_7/_5)F5“ú•―‹Ï2363.20A25“ú•―‹Ï2172.52A75“ú•―‹Ï1765.69A200“ú•―‹Ï1367.07
E“ú‘Ŧ(10/_4)F5“ú•―‹Ï2435.60A25“ú•―‹Ï2342.44A75“ú•―‹Ï2407.73A200“ú•―‹Ï1749.46
E“ú‘Ŧ(12/30)F5“ú•―‹Ï2232.40A25“ú•―‹Ï2241.00A75“ú•―‹Ï2324.77A200“ú•―‹Ï2111.20
E“ú‘Ŧ(_1/10)F5“ú•―‹Ï2081.60A25“ú•―‹Ï2203.60A75“ú•―‹Ï2312.40A200“ú•―‹Ï2133.80

15ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:47:18.48ID:rjzKPc/a0
ĶT‘ŦF13TĨ52TGC(5/13)A26TĨ52TGC(6/10)B9TĨ13TÄGC(Next)A9TĨ26TÄGC(Next)A13TĨ26TÄGC(Next)BÎB
ET‘Ŧ(_1/_4)F9T•―‹Ï_972.66A13T•―‹Ï_978.92A26T•―‹Ï1208.38A52T•―‹Ï1676.03
ET‘Ŧ(_4/_5)F9T•―‹Ï1264.66A13T•―‹Ï1231.38A26T•―‹Ï1105.15A52T•―‹Ï1356.57
ET‘Ŧ(_7/_5)F9T•―‹Ï2019.22A13T•―‹Ï1852.15A26T•―‹Ï1513.73A52T•―‹Ï1371.11
ET‘Ŧ(10/_4)F9T•―‹Ï2405.88A13T•―‹Ï2425.15A26T•―‹Ï2138.65A52T•―‹Ï1614.26
ET‘Ŧ(12/30)F9T•―‹Ï2274.44A13T•―‹Ï2300.00A26T•―‹Ï2362.57A52T•―‹Ï1938.15
ET‘Ŧ(_1/10)F9T•―‹Ï2234.22A13T•―‹Ï2297.30A26T•―‹Ï2356.50A52T•―‹Ï1962.21

16ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:47:36.30ID:rjzKPc/a0
ĶŒŽ‘ŦF6ƒ–ŒŽĨ12ƒ–ŒŽGC(6/3)A6ƒ–ŒŽĨ24ƒ–ŒŽGC(8/1)A12ƒ–ŒŽĨ24ƒ–ŒŽGC(11/1) A6ƒ–ŒŽĨ60ƒ–ŒŽÄGC(Next)BÎB
EŒŽ‘Ŧ(_1/31)F6ƒ–ŒŽ•―‹Ï1144.50A12ƒ–ŒŽ•―‹Ï1532.25A24ƒ–ŒŽ•―‹Ï2152.79A60ƒ–ŒŽ•―‹Ï2180.18
EŒŽ‘Ŧ(_3/29)F6ƒ–ŒŽ•―‹Ï1090.33A12ƒ–ŒŽ•―‹Ï1376.04A24ƒ–ŒŽ•―‹Ï2017.50A60ƒ–ŒŽ•―‹Ï2203.32
EŒŽ‘Ŧ(_6/28)F6ƒ–ŒŽ•―‹Ï1600.00A12ƒ–ŒŽ•―‹Ï1404.16A24ƒ–ŒŽ•―‹Ï1896.31A60ƒ–ŒŽ•―‹Ï2265.95
EŒŽ‘Ŧ(_9/30)F6ƒ–ŒŽ•―‹Ï2182.00A12ƒ–ŒŽ•―‹Ï1636.16A24ƒ–ŒŽ•―‹Ï1885.50A60ƒ–ŒŽ•―‹Ï2330.32
EŒŽ‘Ŧ(12/30)F6ƒ–ŒŽ•―‹Ï2376.33A12ƒ–ŒŽ•―‹Ï1988.16A24ƒ–ŒŽ•―‹Ï1840.70A60ƒ–ŒŽ•―‹Ï2393.05
EŒŽ‘Ŧ(_1/10)F6ƒ–ŒŽ•―‹Ï2304.16A12ƒ–ŒŽ•―‹Ï2080.00A24ƒ–ŒŽ•―‹Ï1806.12A60ƒ–ŒŽ•―‹Ï2411.59

17ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:47:52.34ID:rjzKPc/a0
Ä‚Ņ‚ĖE‚Ēę(’ę’l)‚Đ‚į‚Ė…€’ųģ‚Í3”{Œ—ƒXƒe[ƒW‚ɂē‚ɐ„ˆÚBÎB—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋBÎB200“úü’ēŪBÎB
ŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—Š‚́A’…ŽĀ‚ČŠg[‚Æ‹Ī‚ɁA‡’ē‚ɐi“WBÎBX‚Ȃ鐎’·‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎB
Œo‰cí—Š‚Ė“]Š·‚É‚æ‚鍕Žš’č’…‰ŧBÎBĄ‰ņ‚Ėãļ‘Šę‚ā–Ę”’‚­‚Č‚čAˆŦ’n‡‚Ē‚ɂĐV”N‘Šę‚ŠŠJŽnBÎB

18ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 08:48:07.73ID:rjzKPc/a0
EEE

19ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 09:00:06.80ID:rjzKPc/a0
ŽŸ‚Č‚é”ō–ô‚ցB’…ŽĀ‚Ȑi’ŧ‚Æ‹Ī‚ɍX‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂĐU‚é‚Ēˆį‚ŋ‚ä‚­‘ŠęBT‚Ķ‚éÞ—ŋ‚Æ‹Ī‚ɐ…€’ųģBÎB
Ž’·ŠúB—\’č‚ģ‚ę‚Ä‚Ē‚―‹ÆŅ‚Ė‹}Ž’·‚Æ‹Ī‚ɍX‚Ȃ鐎’·í—Š‚Ši“WB‡’ē‚ČR&DEPL“™‚ĖŠg[EŠg‘å‚Ė‰Á‘ŽBÎB
EEE
ĶSosei HeptaresF‘n–ōuGPR52ė“Ū–ō‚É‚æ‚éƒh[ƒpƒ~ƒ“ė“ŪŒn‚Ļ‚æ‚ŅƒOƒ‹ƒ^ƒ~ƒ“Ž_‚Ė‹@”\’ēß‚Š“‡Žļ’ēĮ‚ðŠÜ‚ސļ_ŽūŠģ‚É‚Ļ‚Ŋ‚é—zŦĮó‚â”F’máŠQ‚ɑ΂·‚éV‹KŽĄ—Öō‚Æ‚ĩ‚Ä‚Ė—L—pŦ‚ÉŠņ—^vACNP2019‚É‚Ä”­•\B(12/12up)
ĶŽl‹G•ņFy•Žš’č’…zˆęŽž‹ā“™Žû“üãæ‚đB•Žš•‚ãB20”N12ŒŽŠú‚͐i’ŧƒ}ƒCƒ‹ƒXƒg[ƒ“A”Ė”„ƒƒCƒ„ƒ‹ƒeƒB‚ɐV‹K’ņŒg‚ĖˆęŽž‹ā“™Žû“ü‰Á‚í‚éBy”ŽÔzŽ–‹ÆŠJ”­‹­‰ŧ‚ĩ‚ĐϋɒņŒgí—Š‚ð‰Á‘ŽB‚Š‚ņ‘ΏÛ2ŽĄŒą‚Ėi’ŧ‡’ēB(12/13)
ĶSosei HeptaresF‘n–ōuSBDD‚ðŠˆ—p‚ĩ‚―A2ARhR–ōHTL1071/AZD4635‚Ė‘n–ōv‘æ24‰ņŒö‰vā’c–@l‚Š‚ņŒĪ‹†‰ï‘Û‚Š‚ņ‰ŧŠw—Ö@ƒVƒ“ƒ|ƒWƒEƒ€ New Drugs in Development in Japan, Europe and the USA‚É‚Ä”­•\B(12/13up)
ĶClinicalTrials(NCT03063086): Phase 2, Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma. (12/13update: Results up)
ĶAGING: "Protease-Activated Receptor 2 (PAR-2) Antagonist AZ3451 as a Novel Therapeutic Agent for Osteoarthritis." ttps://s3-us-west-1.amazonaws.com/paperchase-aging/pdf/P76c98pfHC5EHXY4Z.pdf (12/16 Published)
ĶSosei HeptaresF‘n–ōuPharmacological characterisation of the lipopolysaccharide challenge assay for conformation of target engagement of EP4 antagonists in human whole bloodvPharmacology 2019‚É‚Ä”­•\B(12/18up)
ĶSosei HeptaresF‘n–ōuDevelopment of Histamine H4 Receptor Target Engagement Assays in Immune Cell Populations Involved in Atopic Dermatitis PathophysiologyvPharmacology 2019‚É‚Ä”­•\B(12/18up)

20ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 09:00:16.68ID:rjzKPc/a0
Ķ‘Û“Á‹–oŠč(MiNA)F"Combination Therapies Comprising C/EBP Alpha saRNA" (Inventors: ETH Zurich, Imperial College London, NUST, MiNA Therapeutics). (12/19ŒöŠJ)
ĶSosei HeptaresFuƒ€ƒXƒJƒŠƒ“EƒvƒƒOƒ‰ƒ€v2019”N12ŒŽ‚Ü‚Å‚É‚Í‚Ļ’m‚į‚đ‚ðs‚Ī‚ą‚Æ‚Š‚Å‚Ŧ‚éŒĐž‚Ý‚Å‚ ‚é‚Æ”­•\‚ĩ‚Ä‚Ļ‚č‚Ü‚ĩ‚―‚ŠA’ņŒgæ‚É‚æ‚鍇ˆÓ‚Š“ū‚į‚ę‚―ę‡‚É‚Ė‚݉”\‚Æ‚Č‚é“_A‚ē—‰ð‰š‚ģ‚ĒB(12/20)
ĶClinicalTrials(NCT04206761): Phase 3, Investigating the Effects of QVM149 on MRI Ventilation Defects (XPERTT). EStudy Start: 2020/4/1. EStudy Completion: 2020/12/1. (12/20, "New Trial Record")
ĶJournal of Medicinal Chemistry: "Comparison of orexin 1 and orexin 2 ligand binding modes using X-ray crystallography and computational analysis" (12/20 Published)
ĶSosei HeptaresF‘n–ōuComparison of orexin 1 and orexin 2 ligand binding modes using X-ray crystallography and computational analysisvJournal of Medicinal ChemistryŽ‚Å”­•\B(12/23up)
ĶSosei HeptaresFuPfizerŽÐ‚Æ‚Ė•Ą”‚Ėƒ^[ƒQƒbƒg‚ð‘Ώۂɂĩ‚―ŒĪ‹†ŠJ”­’ņŒg‚É‚æ‚čŒĐ‚Ēo‚ģ‚ę‚―V–ōŠJ”­Œó•â•i‚Ė‰‚ß‚Ä‚Ė—Տ°ŽŽŒą‚ðŠJŽnv5•S–œ•Äƒhƒ‹(–ņ5‰­4700–œ‰~)‚Ėƒ}ƒCƒ‹ƒXƒgƒ“‚ðŽó—Ė‚·‚éB(12/23)
ĶSosei HeptaresFuPfizerŽÐ‚Æ‚Ė•Ą”‚Ėƒ^[ƒQƒbƒg‚ð‘Ώۂɂĩ‚―ŒĪ‹†ŠJ”­’ņŒg‚É‚Ļ‚Ē‚ÄŽO”Ô–Ú‚Ė—Տ°ŠJ”­Œó•â•ĻŽŋ‚ð‘novV‚―‚É3•S–œ•Äƒhƒ‹(–ņ3‰­2800–œ‰~)‚Ėƒ}ƒCƒ‹ƒXƒgƒ“‚ðŽó—Ė‚·‚éB(12/24)

21ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 09:00:36.45ID:rjzKPc/a0
ĶChemRxiv: "X-Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A2A Adenosine Receptor Antagonists." (12/24 Posted)
Ķ‰ĒB“Á‹–(Heptares)F"CGRP Receptor Antagonists"(European Patent EP3368526 B1). (12/25ŒöŠJ)
ĶSosei HeptaresFuƒTƒ“ƒtƒ‰ƒ“ƒVƒXƒR‚ÅŠJÃ‚Ė‘æ38‰ņ J.P.ƒ‚ƒ‹ƒKƒ“Eƒwƒ‹ƒXƒPƒAEƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚ÉŽQ‰Áv“–ŽÐCFOƒNƒŠƒXEƒJ[ƒMƒ‹‚ŠƒvƒŒƒ[ƒ“ƒe[ƒVƒ‡ƒ“(1/15 10:30)Bƒ‰ƒCƒu”zM‚ģ‚ę‚Ü‚·B(12/26)
Ķ•Ä‘“Á‹–oŠč(Heptares)F"Pharmaceutical Compounds"(US20190389849 A1). (12/26ŒöŠJ)
Ķ‘Û“Á‹–oŠč(Heptares)F"Oxadiazoles as Agonists of the Muscarinic M1 and/or M4 Receptor"(WO/2019/243850 A1). (12/26ŒöŠJ)
Ķ‘Û“Á‹–oŠč(Heptares)F"Bridged Compounds as Agonists of the Muscarinic M1 and/or M4 Receptor"(WO/2019/243851 A1). (12/26ŒöŠJ)
ĶClinicalTrials(NCT03980821): Phase 1, Study of AZD4635 in Japanese Patients with Advanced Solid Malignancies: Record Verification December 2019. (12/27update)
ĶSosei HeptaresFuV”N‚Ė‚ēˆĨŽA “c‘šáÁˆęv•ūŽÐ‚Å‚Í‘n–ō‚Ė‰Ī“đ‚ð—Í‹­‚­i‚Ý‚Č‚Š‚į‚āAŽaV‚ČŠvV“I‹Zp‚ðŒÕŽ‹ážX‚Æ‘_‚Á‚Ä‚Ē‚Ü‚·B2020”N‚ð‚ģ‚į‚Č‚é”ō–ô‚Ė”N‚É‚ĩ‚ÄŽQ‚č‚Ü‚·B(1/1)

22ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 09:01:03.80ID:rjzKPc/a0
ĶRCSB Protein Data Bank: "Crystal Structure of the Orexin-1 Receptor and Orexin-2 Receptor in Complex": 6TQ9, 6TQ7, 6TQ6, 6TQ4, 6TPN, 6TPJ, 6TPG, 6TP6, 6TP4, 6TP3, 6TOD, 6TO7. (1/1 Released)
Ķ•Ä‘“Á‹–oŠč(Heptares)F"Pharmaceutical Compounds"(US20200002328A1). (1/2ŒöŠJ)
ĶMiNA Therapeutics Publications: Molecular Therapy "Liver Activation of Hepatocellular Nuclear Factor-4a by Small Activating RNA Rescues Dyslipidemia and Improves Metabolic Profile". (1/4up)
ĶPsychopharmacology: "Lessons learned from using fMRI in the early clinical development of a mu-opioid receptor antagonist for disorders of compulsive consumption": Pradeep J. Nathan & Geor Bakker. (1/4 Published)
ĶClinicalTrials(NCT03381274): Phase 1b/2, Oleclumab(MEDI9447) EGFRm NSCLC Novel Combination Study. (MEDI9447 with Osimertinib or AZD4635, AZD4635 with MEDI9447): Record Verification January 2020. (1/6update)
ĶVectura: "Wefre looking forward to being in San Francisco for the 38th JPM Healthcare Conference Next Week"; Vectura CEO Presentation: 10:00 PST / 18:00 GMT on Thursday 16 January. (1/6)
ĶMiNA Therapeutics: "Announces Research Collaboration with AstraZeneca in Metabolic Diseases". Completion of these studies, AstraZeneca will have the option to negotiate a license agreement to further develop saRNA molecules. (1/7)
ĶRoche HP: Partnering: "Example Partnerships: "Heptares - research collaboration to discover and develop novel medicines that modulate G-protein-coupled receptor targets across a range of diseases." (1/10up, Add)
ĶSosei Heptares HPFEvents upuSosei Group 2019”N12ŒŽŠúŒˆŽZ”­•\ 2ŒŽ13“úv (1/10up)
EEE

23ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 09:02:17.68ID:rjzKPc/a0
Today EventsF
ĶJP Morgan Healthcare Conference:

E"Novartis" (1/13 Today 8:00 Presenting) Please check back in about 16 hours.
https://jpmorgan.metameetings.net/events/hc20/sessions/29835-novartis/webcast

E"Daiichi Sankyo" (1/13 Today 14:00 Presenting) Please check back in about 22 hours.
https://jpmorgan.metameetings.net/events/hc20/sessions/29666-daiichi-sankyo-co-ltd/webcast

EEE

24ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 11:04:28.79ID:I5aE5uydd
”s‘–‚ĩ‚―Šî’nŠO—ëŨƒXƒ}ƒzŒîHw

25ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 12:19:43.16ID:OKaqMlrJ0
5ch‚Å’N‚Đ‚É•ķ‹å‚ðŒū‚Ī‘O‚É
‡@ŽĐ•Š‚É‚Í‚ŧ‚ę‚ðŒĐ‚Č‚ĒŒ —˜‚Š‚ ‚Á‚―‚ЂȁH(‚Ų‚Ú•K‚ļ‚ ‚éB‚ ‚Á‚―‚į•ķ‹åŒū‚Ī‚Č)
‡A‚ą‚ĖŒū—t‚ÍŽĐ•Š‚ÉŒü‚Ŋ‚į‚ę‚―Œū—t‚ЂȁH(‚ū‚Ē‚―‚Ēˆá‚ĪBˆá‚Á‚―‚į•ķ‹åŒū‚Ī‚Č)
‡BŽĐ•Š‚Ė—‘z‚Ė‰Ÿ‚ĩ•t‚Ŋ‚ķ‚á‚Č‚Ē‚ЂȁH(‚Ų‚Æ‚ņ‚Į‚ŧ‚ĪB—‘z‰Ÿ‚ĩ•t‚ŊƒKƒbƒJƒŠƒNƒ\–ė˜Y‚É‚Č‚é‚Č)
‚ÆŽĐ–â‚ĩ‚Ä‚Ų‚ĩ‚Ē

26ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 13:04:57.50ID:/h2ILfTN0
–ū“ú‚Đ‚į‚Ü‚―‰Aü’n–

27ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 13:42:19.47ID:cLZACR5p0
‚ŋ‚å‚Ē‘Ō‚Á‚ĉš‚ģ‚Ē‚悧c

28ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 17:00:48.71ID:rjzKPc/a0
ĶSOSEI‚ĖŽ’·‘Šę‚Ė“ŪŒüF‘O‰ņ‚Ė‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē‚Å‚Ė’ēŪ‚ŠI‚čAÄ‚Ņ‚Ė’ę’l(2018/12/25:ÅˆĀ’l748)‚Đ‚į‚Ėãļ‘Šę‚͏‡’ē‚ɐ„ˆÚBÎB‹ÆŅ‘Šę‚Ö‚Ė“ŪˆÓ‘Ō‚ŋBÎB
2014/_4/25 (I’l_515) ”„Žc‚144800 ”ƒŽc‚_4212800 E(2014/_4/22ÅˆĀ’l_464) Ķ’†’·ŠúŒv‰æ”­•\(5/13Ķ)[E‚ĒęĶ][Ž’·‰ņŽûŠú‚Ė“üŒû]ƒXƒe[ƒW‚Ö
2015/_2/20 (I’l_945) ”„Žc‚_56800 ”ƒŽc‚_6123200 E(2015/_3/16ÅˆĀ’l_713) ĶHeptares(2/20Ķ)[ŽŒũ‚Ė˜ÍƒXƒe[ƒW]
2015/10/30 (I’l1080) ”„Žc‚_45600 ”ƒŽc‚_8871600 E(2015/_9/24ˆĀ’l_888) Ķ•Ä‘ģ”F[ŽŸ‚Č‚é”ō–ôƒXƒe[ƒW‚Ö]Ķ’ņŒg[ã”ē‚ŊŒ—‚Ö][’ęã‚°‘Šę]
2016/_4/25 (I’l5808) ”„Žc‚159200 ”ƒŽc‚13619600 E(2016_5/_9Å‚’l6545) Ķ“úXŒö•\Žw’č(3/7)ĶAllergan(4/7)[‹­‹C‘Šę]
2016/_6/24 (I’l3680) ”„Žc‚_42000 ”ƒŽc‚_9944400 E(2016/_6/24ˆĀ’l3240) Ķ“úXŒö•\‰ðœ(6/28)[‹­‹C‘Šę‰ðœ]Ķ[ŽžŠÔŽē‚Å‚Ė’ēŪ‹Į–Ę‚Ö]
2017/_3/31 (I’l2720) ”„Žc‚_22400 ”ƒŽc‚10487200 E2017/_9/_6ˆĀ’l2148) Ķ[ã”ē‚ŊŒ—‚Å‚ĖŽžŠÔŽē’ēŪ‚͏‡’ē‚ɐ„ˆÚ]Ķ[U‚é‚ĒęEE‚Ēę‚Ö]
2018/_1/26 (I’l3053) ”„Žc‚__3600 ”ƒŽc‚_5716400 E(2018/_1/22ˆĀ’l2740)ĶM—p”ƒŽcŒļ­[U‚é‚Ē‚ā‡’ē‚ɐ„ˆÚ]
2018/_3/_9 (I’l2378) ”„Žc‚_42000 ”ƒŽc‚_7177600 E(2018/_3/_5ˆĀ’l2195) ĶŽĐŽÐŠJ”­PLŠg[[ˆŦ’n‡‚Ē‚ɂčĂŅ‚ĖE‚Ēę‚Ö][ŽdŠ|‚Ŋ]
2018/_6/_8 (I’l1700) ”„Žc‚104800 ”ƒŽc‚_8714800 E(2018/_6/_7ˆĀ’l1618)Ķ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[(5/11ˆĀ’l1665, 6/5ˆĀ’l1695, 7/2ˆĀ’l1584, 7/3ˆĀ’l1414)
2018/_9/28 (I’l1371) ”„Žc‚__1500 ”ƒŽc‚_7687000 E(2018/_9/21ˆĀ’l1030)ĶM1—Տ°ŽĐŽå“I’†’f[ƒXƒgƒbƒvˆĀ”ä—á”z•Š(9/19ˆĀ’l1424, 9/20ˆĀ’l1124)]
2018/10/26 (I’l_878) ”„Žc‚___100 ”ƒŽc‚_8272800 E(2018/10/26ˆĀ’l_844) Ķ10/19:Cambridge R&D Facilities Steinmetz Building, Sosei HeptaresŽn“Ū
2018/12/28 (I’l_799) ”„Žc‚_26100 ”ƒŽc‚_6161600 E(2018/12/25ÅˆĀ’l_748) ĶSoseiHeptares–{ŠiŽn“Ū(12/1) [Ä‚Ņ‚ĖE‚ĒęĶ][‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē’ēŪ‚ŠI—đ]

29ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 17:01:10.24ID:rjzKPc/a0
2019/_1/18 (I’l1310) ”„Žc‚_22600 ”ƒŽc‚_5926200 E(2019/1/_4”N‰—ˆˆĀ’l_780) Ķ1/1:“c‘šCEO•œ‹AĶ1/7:AZD4635‘æ‡U‘Š(1/8ƒXƒgƒbƒv‚:I’l1078) [ãļƒgƒŒƒ“ƒh‚Ö“]Š·]
2019/_3/_1 (I’l1250) ”„Žc‚_67200 ”ƒŽc‚_5751800 E(1/30ˆĀ’l_985) Ķ2/4:ƒIƒ‰ƒrV”­”„Ķ2/12:2018”N12ŒŽŠúŒˆŽZĶ2/22:IRā–ū‰ïĒŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—ŠĢ
2019/_4/_5 (I’l1593) ”„Žc‚_62400 ”ƒŽc‚_6539800 E(3/11ˆĀ’l1105)Ķ3/27: Sosei GroupŠ”Žå‘‰ïĶ3/16:’†‘ãŽs(3/20ƒXƒgƒbƒv‚:1526)Ķ3/29:IRā–ū‰ï(–žŒÃ‰ŪE‘åã)Ķ(4/9:”N‰—ˆ‚’l1717)
2019/_5/17 (I’l1660) ”„Žc‚110300 ”ƒŽc‚_5488000 E(5/13ˆĀ’l1429) Ķ5/14:Pfizeri’ŧ(ˆę”Ô–Ú)Ķ5/14:‘æ1Žl”žŠúŒˆŽZĶ(5/15:‚’lXV:1743)
2019/_5/31 (I’l2012) ”„Žc‚170300 ”ƒŽc‚_6108300 E(5/21ˆĀ’l1591) Ķ5/22:QVM149P‡UŽŅĶ(5/22:‚’lXV:1834)(5/23:‚’lXV:2149) Ķ5/24:QVM149‰ĒB\ŋĶ(5/28:‚’lXV:2296)
2019/_6/28 (I’l2369) ”„Žc‚_36900 ”ƒŽc‚_5815600 E(6/_6ˆĀ’l1909) Ķ6/10:Pfizeri’ŧ(“ņ”Ô–Ú)Ķ6/18:IRā–ū‰ï(å‘ä)Ķ(6/24:‚’lXV:2377)(6/26:‚’lXV:2420)
2019/_7/19 (I’l2609) ”„Žc‚_15900 ”ƒŽc‚_7363700 E(7/_5ˆĀ’l2237) Ķ(7/_1:‚’lXV:2429)(7/_2:‚’lXV:2482)Ķ7/16:Genentech’ņŒgĶ(7/16ƒXƒgƒbƒv‚:‚’lXV:2773) Ķ7/18:APP13007i’ŧ
2019/_8/16 (I’l2413) ”„Žc‚_ 8600 ”ƒŽc‚_8270500 E(8/16ˆĀ’l2375) Ķ8/_5:•“c–ō•i’ņŒg Ķ8/_5:”N‰—ˆ‚’lXV:2794)Ķ8/13:‘æ2Žl”žŠúŒˆŽZ Ķ9/12: R&D Day [—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋ]
2019/10/11 (I’l2150) ”„Žc‚_ 5300 ”ƒŽc‚_7981900 E(9/17ˆĀ’l2088)Ķ9/28:MTL-CEBPA’PÜ‘æ‡T‘ŠÅIŒ‹‰ĘĶ9/30:QVM149‘æ‡V‘ŠIRIDIUMŒ‹‰ĘĶ10/9:Genentechi’ŧ
2019/11/29 (I’l2289) ”„Žc‚__2900 ”ƒŽc‚_8038400 E(10/15ˆĀ’l2139) Ķ11/12:‘æ3Žl”žŠúŒˆŽZĶ11/28: Ultibro’†‘NRDLŽûÚ
2019/12/27 (I’l2269) ”„Žc‚__7200 ”ƒŽc‚_7743600E(12/16ˆĀ’l2137) Ķ12/6:IRā–ū‰ï(L“‡)Ķ12/23:Pfizer‘æ‡T‘ŠŠJŽnĶ12/24:Pfizeri’ŧ(ŽO”Ô–Ú) Ķ12/30:‘å”[‰ï(I’l2171)
2020/_1/10 (I’l2115) 5“úü2081.60(+1.60“) 25“úü2203.64(-4.02“) 75“úü2312.40(-8.54“) 200“úü2133.80(-0.88“) E(1/8ˆĀ’l1977) Ķ1/6:‘å”­‰ï(Žn’l2150)Ķ1/7:MiNA Collaboration with AstraZeneca.

30ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 17:01:25.21ID:rjzKPc/a0
X‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂāA‘O‰ņ‚Ė‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē‚Å‚Ė’ēŪ‚ŠI‚čAÄ‚Ņ‚ĖE‚Ēę(’ę’l)‚Đ‚į‚Ė…€’ųģ‚́A3”{Œ—ƒXƒe[ƒW‚ɂē‚ɐ„ˆÚBÎB—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋBÎB
VķSoseiHeptaresAŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—Š‚ā‡’ē‚ɐi“WBÎB’…ŽĀ‚ČŠg[‚Æ‹Ī‚ɁAŒo‰cí—Š‚Ė“]Š·‚É‚æ‚鍕Žš’č’…‰ŧBÎBX‚Ȃ鐎’·‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎB
X‚Č‚éÄŽ’·ŠúA‹ÆŅ‘Šę‚ցBÎBŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎBĄ‰ņ(Ä‚Ņ)‚Ėãļ‘Šę‚ā–Ę”’‚­‚Č‚čAˆŦ’n‡‚Ē‚ɂĐV”N‘Šę‚ŠŠJŽnBÎB200“úü’ēŪBÎB

31ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 19:15:08.42ID:84dh90cZ0
1‰ģ

32ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/13(ŒŽ) 20:00:03.44ID:rjzKPc/a0
ĶVectura: Trading Update: "Pre-close trading update confirms 2019 trading in-line with expectations." (1/13)
Chippenham, UK - 13 January 2020.
Vectura Group plc. today announces an unaudited 2019 pre-close trading update.
The Group expects revenue and Adjusted EBITDA to be at least in line with Board expectations.
Vectura will report its preliminary results for the year ended 31 December 2019 on Tuesday 17th March 2020.
2020 Financial guidance:
EThe Group expects to see approval of QVM149 by its partners in H2 2020.
EVectura would earn $5m upon approval of QVM149 in Europe and would earn a low-single digit royalty on net sales of the product.
Attendance at 38th Annual J.P. Morgan Healthcare Conference:
EWill Downie, CEO, will give a presentation at 10.00 am PT on Thursday 16th January. The live presentation will be webcast.

33ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 05:34:41.11ID:scnB2ufG0
Novartis Presentation:
ĶJ.P. Morgan Healthcare Conference January 13, 2020 "Reimagining Medicine" Vas Narasimhan, CEO. (1/13 Presented)
2020 Catalysts Maintaining Long-Term Momentum:
EMajor approvals: "QVM / QMF 149: Asthma"
Focused on Launch Excellence for 15 Ongoing and Upcoming Major Launches:
E2020 Upcoming: "QVM / QMF 149: Asthma"
Novartis Pipeline in Registration:
E"QVM149 (Indacaterol Acetate +Mometasone Fuorate +Glycopyrrnium Bromide): Asthma"

34ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 07:00:49.26ID:scnB2ufG0
ŽŸ‚Č‚é”ō–ô‚ցB’…ŽĀ‚Ȑi’ŧ‚Æ‹Ī‚ɍX‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂĐU‚é‚Ēˆį‚ŋ‚ä‚­‘ŠęBT‚Ķ‚éÞ—ŋ‚Æ‹Ī‚ɐ…€’ųģBÎB
Ž’·ŠúB—\’č‚ģ‚ę‚Ä‚Ē‚―‹ÆŅ‚Ė‹}Ž’·‚Æ‹Ī‚ɍX‚Ȃ鐎’·í—Š‚Ši“WB‡’ē‚ČR&DEPL“™‚ĖŠg[EŠg‘å‚Ė‰Á‘ŽBÎB
EEE
ĶSOSEI‚ĖŽ’·‘Šę‚Ė“ŪŒüFÄ‚Ņ‚Ėãļ‘Šę‚͏‡’ē‚ɐ„ˆÚ(2018/12/25:ÅˆĀ’l748ĶA2019/1/4:ˆĀ’l_780A2019/8/5:Å‚’l:2794)BÎB‹ÆŅ‘Šę‚Ö‚Ė“ŪˆÓ‘Ō‚ŋBÎB
2018/12/28 (I’l_799) 25“úü_948.64(-15.77“) E(12/25ÅˆĀ’l_748) Ķ12/1:SoseiHeptares–{ŠiŽn“Ū[Ä‚Ņ‚ĖE‚ĒęĶ][‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē’ēŪ‚ŠI—đ]
2019/_1/_4 (I’l_864) 25“úü_940.80( -8.16“) E(_1/_4ˆĀ’l_780) Ķ1/1:“c‘šCEO•œ‹AĶ1/7:AZD4635‘æ‡U‘Š[1/8ƒXƒgƒbƒv‚:I’l1078] [ãļƒgƒŒƒ“ƒh‚Ö“]Š·]
2019/_2/_1 (I’l1021) 25“úü1051.28( -2.88“) E(_1/30ˆĀ’l_985) Ķ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[’ïG(1/21ˆĀ’l1164, 1/30ˆĀ’l985)Ķ(1/21:‚’lXV:1360)
2019/_3/_1 (I’l1250) 25“úü1133.28(+10.83“) E(_2/_4ˆĀ’l1021) Ķ2/14:ŒˆŽZ Ķ2/22:IRā–ū‰ï(ˆĒ”{–ė)ĒŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—ŠĢ
2019/_4/_5 (I’l1593) 25“úü1331.60(+19.63“) E(_3/11ˆĀ’l1105) Ķ3/16:’†‘ãŽs Ķ(3/20:‚’lXV:ƒXƒgƒbƒv‚:1526) Ķ3/29:IRā–ū‰ï(–žŒÃ‰ŪE‘åã)
2019/_5/10 (I’l1486) 25“úü1494.08( -0.54“) E(_4/22ˆĀ’l1372) Ķ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[’ïG(4/11ˆĀ’l1400) Ķ(4/9:‚’lXV:1717)Ķ(5/15:‚’lXV:1743)
2019/_6/_7 (I’l2014) 25“úü1800.28(+11.87“) E(_5/13ˆĀ’l1429) Ķ5/14:Pfizeri’ŧ;‘æ1Žl”žŠúŒˆŽZ Ķ5/24:QVM149\ŋ Ķ‚’lXV:(5/22:1834)(5/23:2149)(5/28:2296)
2019/_7/_5 (I’l2338) 25“úü2172.52( +7.62“) E(_6/12ˆĀ’l1969) Ķ6/10:Pfizeri’ŧĶ6/18:IRā–ū‰ï(å‘ä) Ķ‚’lXV:(6/24:2377)(6/26:2420)(7/1:2429)(7/2:2482)
2019/_8/_2 (I’l2544) 25“úü2448.12( +3.92“) E(_7/_9ˆĀ’l2216) Ķ7/16:Genentech’ņŒgĶ(7/16ƒXƒgƒbƒv‚:‚’lXV:2773) Ķ7/18:APP13007i’ŧ

35ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 07:00:56.63ID:scnB2ufG0
2019/_9/_6 (I’l2335) 25“úü2463.68( -5.22“) E(_8/30ˆĀ’l2179) Ķ8/5:•“c–ō•i’ņŒg Ķ8/5:‚’lXV:2794) Ķ8/13:‘æ2Žl”žŠúŒˆŽZ [—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋ]
2019/10/_4 (I’l2438) 25“úü2342.44(+4.08“) E(_9/17ˆĀ’l2088) Ķ9/12:ƒCƒ“ƒxƒXƒ^[R&D Day Ķ9/28:MTL-CEBPA’PÜ‘æ‡T‘ŠÅIŒ‹‰ĘĶ9/30:QVM149‘æ‡V‘ŠIRIDIUMŒ‹‰Ę
2019/11/_1 (I’l2570) 25“úü2385.96(+7.71“) E(10/11ˆĀ’l2130) Ķ10/9:Genentechi’ŧ
2019/12/_6 (I’l2317) 25“úü2346.72( -1.27“) E(11/15ˆĀ’l2185) Ķ11/12:‘æ3Žl”žŠúŒˆŽZĶ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[(11/13)Ķ11/28:’†‘NRDLŽûÚĶ12/6:IRā–ū‰ï(L“‡)
2019/12/30 (I’l2171) 25“úü2241.00( -3.12“) E(12/16ˆĀ’l2137) Ķ12/23:Pfizer‘æ‡T‘ŠŠJŽnĶ12/24:Pfizeri’ŧ(ŽO”Ô–Ú) Ķ2019”N‘å”[‰ï
2020/_1/_6 (I’l2117) 5“úü2211.40( -4.27“) 25“úü2235.12(-5.28“) 75“úü2322.30( -8.84“) 200“úü2115.53(+0.01“) (ˆĀ’l2110) Ķ2020”N‘å”­‰ï
2020/_1/_7 (I’l2117) 5“úü2189.20( -3.30“) 25“úü2229.88(-5.06“) 75“úü2319.32( -8.72“) 200“úü2120.30( -0.16“) (ˆĀ’l2115) Ķ1/7:MiNA Collaboration with AstraZeneca.
2020/_1/_8 (I’l2012) 5“úü2137.20( -5.86“) 25“úü2219.48(-9.35“) 75“úü2316.09(-13.13“) 200“úü2124.78( -5.31“) (ˆĀ’l1977)
2020/_1/_9 (I’l2047) 5“úü2092.80( -2.19“) 25“úü2209.80(-7.37“) 75“úü2313.70(-11.53“) 200“úü2129.23( -3.86“) (ˆĀ’l2030)
2020/_1/10 (I’l2115) 5“úü2081.60(+1.60“) 25“úü2203.64(-4.02“) 75“úü2312.40( -8.54“) 200“úü2133.80( -0.88“) (ˆĀ’l2038) E(1/8ˆĀ’l1977)

36ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 07:01:21.86ID:scnB2ufG0
Ä‚Ņ‚ĖE‚Ēę(’ę’l)‚Đ‚į‚Ė…€’ųģ‚Í3”{Œ—ƒXƒe[ƒW‚ɂē‚ɐ„ˆÚBÎB—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋBÎB200“úü’ēŪBÎB
ŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—Š‚́A’…ŽĀ‚ČŠg[‚Æ‹Ī‚ɁA‡’ē‚ɐi“WBÎBX‚Ȃ鐎’·‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎB
Œo‰cí—Š‚Ė“]Š·‚É‚æ‚鍕Žš’č’…‰ŧBÎBĄ‰ņ‚Ėãļ‘Šę‚ā–Ę”’‚­‚Č‚čAˆŦ’n‡‚Ē‚ɂĐV”N‘Šę‚ŠŠJŽnBÎB

37ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 07:03:36.22ID:9NXZK7/P0
‚ā‚Īƒ_ƒ‚ū

38ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 08:02:29.84ID:IeCjf95ba
‚ŋ‚å‚Ē‘Ō‚Á‚ĉš‚ģ‚Ē‚悧c

39ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 08:13:21.58ID:Vp8H5Xs9d
‚Ļ‚í‚―

40ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 08:30:56.74ID:kpuSUcgL0
OVER‚Í‚ą‚ņ‚Č‚É­‚Č‚Đ‚Á‚―‚Á‚ŊH

41ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 08:36:22.83ID:tB79WSoOd
618 –ž‘O:ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’† :2020/01/10(‹ā) 22:37:31.80 ID:2FgfH4Gap
‚ā‚Ī‚ŧ‚ę‚ĩ‚ĐŒū‚Ķ‚Č‚Ē‚ņ‚ū‚ȁB
ŒĐ‚đ”‚āŒ‹‹Į‚â‚į‚Č‚Ē‚ņ‚ū‚ëH
2150‚Å10000Š”ƒsƒRƒsƒR‚ĩ‚ĂȁB
‚Ļ‚Ü‚Ķ‚Š‚Ē‚­‚į‚É‚·‚é‚Đ•·‚Ē‚Ä‚Ŧ‚―‚ņ‚ū‚Đ‚į‚Čwww

42ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 08:50:47.56ID:buVxbrSGd
>>41
—v‹’Ę‚čo‚ĩ‚―‚ž

43ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 08:52:21.20ID:buVxbrSGd
Á‚·‚ž[

44ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 08:53:02.63ID:96FsTK2Ep
>>42 2150‰~‚ķ‚áŒĐ‚Ķ‚Č‚Ē‚íw2130‰~‚É‚ĩ‚Ä‚­‚ęI

45ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 08:53:45.64ID:buVxbrSGd
>>44
o‚ĩ‚―‚ž

46ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 08:54:41.31ID:buVxbrSGd
‚Ļ‚Ü‚Ŋ‚É2131‚É‚āo‚ĩ‚Ä‚â‚é

47ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 08:54:47.83ID:96FsTK2Ep
>>45 Šm”F‚ĩ‚―B

48ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 08:55:16.18ID:buVxbrSGd
‚ā‚Ī‚Ē‚Ē‚ȁHÁ‚·‚ž

49ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 08:57:19.37ID:96FsTK2Ep
>>48 —Į‚Ē‚žB

50ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 08:57:33.59ID:buVxbrSGd
ŽÓß•ķ‚Į‚Ī‚žw

51ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:01:51.61ID:96FsTK2Ep
‘‹–„‚߉ģI

52ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:02:16.08ID:cTCO8Yq+0
ƒ}ƒCƒeƒ“ƒbƒbƒbƒb[[[[[[[[I

53ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:04:05.17ID:cTCO8Yq+0
‚’lˆø‚Ŋ—zü‚ĖŽŸ‚Ė“ú‚̓}ƒCƒiƒX‰Aüˆø‚Ŋ‚ū‚Đ‚į‚Č

54ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:04:41.44ID:buVxbrSGd
‚Ü‚―ŽãŽŒîH‚ðŽa‚čŽĖ‚Ä‚Ä‚ĩ‚Ü‚Á‚―BBB
Œģ‚æ‚čŒĐ•Ô‚č‚ÍŠú‘Ō‚ĩ‚Ä‚Č‚Ēw

55ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:06:38.34ID:96FsTK2Ep
>>50 20000Š”ŒĐ‚đ”‚ĩ‚―Ž–ŽĀ‚ÍŠm”F‚ĩ‚―‚ŠAƒzƒ‹ƒ_[‚Å‚ ‚鎖ŽĀ‚Í‚Ē‚Đ‚æ‚Ī‚É‚ĩ‚ďؖū‚ĩ‚Ä‚­‚ę‚é‚Ė‚ū‚ë‚Ī‚ЁH

56ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:07:12.93ID:szdDZdMg0
ˆęu‚ÅŽŋ‚ĖˆŦ‚Ē•ûŒĐ•Š‚Ŋ‚―‚Ŋ‚Į‚Č

—ëŨ‚Í‚Č‚š‚Џã‚Đ‚į–ڐü

57ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:10:50.17ID:buVxbrSGd
>>55
”nŽ­‚Ė‘z’č“ā‚Ė•Ô“š‰ģ
‚ŧ‚Ė‚―‚ß‚ÉˆČ‰š‚ĖŒūŽŋ‚ð‚Æ‚Á‚Ä‚ ‚é

”„‚蔂ðo‚ĩ‚―‚įAŽÓß‚Æ‚Ļ‘O‚ā”„‚蔂ðo‚·Ž–B
Š
Œū‚Ē–ó‚·‚é‘O‚É‚â‚é‚ą‚Æ‚ ‚é‚ū‚ëHw



669 –ž‘O:ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’† :2020/01/11(“y) 19:12:56.94 ID:tJFzot9Zd
>>667
’rĀ‚Ƙb‚·‚Ė”æ‚ę‚é‚Čw


ŒJ‚č•Ô‚·‚Š

‰ī‚Š2150‰~‚ŏo‚ĩ‚―‚į
‚Ļ‘O‚Š
E”„‚č”o‚ĩ‚―‚įŽÓ‚鎖
E”„‚č”o‚ĩ‚―‚į‚Ļ‘O‚āo‚·Ž–

‚Æ‚Ē‚Ī‚ą‚Æ‚ÅŽó‚Ŋ‚―‚Æ‚Ē‚Ī‚ą‚Æ‚Å‚Ē‚Ē‚ЁH

670 –ž‘O:ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’† :2020/01/11(“y) 19:16:34.62 ID:Aw6VX4gmp
>>669‚ĩ‚Đ‚ÆŽó‚ŊŽ~‚ß‚―‚žII

58ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:15:55.77ID:szdDZdMg0
—ëŨ‚Č‚ņ‚Ä‚ą‚ņ‚Č‚ā‚ņ‚æ

‚Į‚Ī‚đ“Ķ‚°‚é

‘ŠŽč‚É‚·‚é‚ū‚ŊŽžŠÔ‚Ė–ģ‘Ę

ŽG‹›‚Š”„‚蔂ð”F‚ß‚―‚ū‚Ŋ‚Å‚ā‚ĪI‚í‚Á‚Ä‚ņ‚ū‚æ

59ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:18:28.04ID:96FsTK2Ep
‘z’č“ā‚Č‚įØ–ū‚ĩ‚Æ‚Ŋ‚æw

Žó‚ŊŽ~‚ß‚é‚ĖˆÓ–Ą•Š‚Đ‚Á‚Ä‚Č‚Ē‚Ė‚Đ‚Čwww

60ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:20:58.00ID:96FsTK2Ep
ƒvƒ‰“]—Į‚Ē‚æB

61ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:21:07.55ID:buVxbrSGd
‚ā‚Ī‚Ē‚Ē‚Á‚ÄwŒĐ‹ę‚ĩ‚Ēww

62ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:23:53.03ID:guRgk2Xrd
ID:96FsTK2Ep

ŽG‹›‚·‚Ž

63ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:24:32.30ID:96FsTK2Ep
Œ‹‹ĮA“ï•Č•t‚Ŋ‚―‚Đ‚Á‚―‚ū‚Ŋ‚Đwww

64ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:25:34.48ID:96FsTK2Ep
”„“Ø‚Ė‚΂ĩ‚Ē“õ‚Ē‚Š‚―‚Ü‚į‚ņ‚ˁB

65ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:25:36.70ID:4dsSq86Yd
‚ŧ[‚đ‚Ē‚Ä‚ą‚Ī‚Ē‚ĪƒRƒWƒL‚΂Ђč‚Č‚ĖH

66ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:28:57.22ID:5im35zNQd
Šį^‚ÁÔ‚Å–ģˆÓ–Ą‚ČƒŒƒX˜AŒÄ‚ĩ‚Ä‚ņ‚ū‚ë‚Ī‚Čww

‘åŒû—l‚ɑ΂·‚é‘Ô“x‚ķ‚á‚ˁ[‚íB

67ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:30:33.73ID:96FsTK2Ep
‚Č‚ņ‚Đ‚Ö‚ņ‚Č‚Ė‚Ē‚Á‚Ï‚Ē—N‚Ē‚Ä‚Ŧ‚―‚Čwww
‘åŒû‚Á‚ă‚ƒ‹ƒJƒX‚Ė‚ą‚Æ‚ĐH

68ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:34:31.56ID:5im35zNQd
•KŽ€ww

69ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:36:50.24ID:cTCO8Yq+0
ƒ}ƒCƒeƒ“ƒbƒbƒbƒb[[I

70ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:37:02.00ID:96FsTK2Ep
‘åŒû‚Á‚Ä’Nw“š‚Ķ‚į‚ę‚Č‚Ēwww

71ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:37:28.78ID:96FsTK2Ep
ƒvƒ‰“]—Į‚Ē‚æI

72ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:38:34.81ID:96FsTK2Ep
‹ts‚‚â‚Č‚Ē‚Đ‚ĒI

73ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:41:52.26ID:guYa4Dxp0
•‰‚ŊŒĒ‚ĖƒŒƒX”‚Í‘―‚Ē‚ŠA‚Ē‚‚ā”Ï‚ĒƒTƒ“ƒoƒCƒI–ė˜Y‚ÍŒŧ‚ę‚Č‚Ē

‚Č‚š‚ЁH

‚ ‚Æ‚Í•Š‚Đ‚é‚ȁH

74ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:42:30.94ID:5im35zNQd
įNŸT•a‚Ė‚æ‚Ī‚Č“Ū‚Ŧ‚ū‚Č

75ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:43:36.05ID:5im35zNQd
>>73
‹ó”„‚čƒKƒCƒW‚Đww
”„‚č”o‚đ‚é–ó‚Č‚Ē‚í‚Č

76ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:46:31.91ID:guYa4Dxp0
ƒTƒ“ƒoƒCƒI–ė˜Y



ģ‘Ė‚Î‚ę‚―Ą‚Ė‹C•Š‚Į‚ĪH

77ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:51:26.05ID:96FsTK2Ep
Ą“ú‚Í•Ï‚Č‚Ė‚Šƒƒ‰ƒƒ‰o‚Ä‚­‚é‚Čwww

78ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:52:44.16ID:5im35zNQd
‚Ļ‘O‚ū‚ëww

79ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:53:35.26ID:96FsTK2Ep
ˆęl‚яƒ‰ƒƒ‰‚Å‚Ŧ‚é‚ЁI

80ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:54:07.00ID:5im35zNQd
‚ŧ‚č‚áŠî’nŠO–ڐü‚ū‚ÆŽü‚č‚Ė‚â‚‘Sˆõ•Ï‚ÉŒĐ‚Ķ‚é‚ņ‚ū‚ë‚Ī‚Čww

81ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:55:31.10ID:96FsTK2Ep
‚Ē‚Ē‚æB‚Ē‚Ē‚æB

82ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:57:07.48ID:guYa4Dxp0
Ą“ú‚Í—§ęã@”„‚čø‚ę‚Č‚Ē•‰‚ŊŒĒƒƒƒ^

83ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 09:59:07.93ID:96FsTK2Ep
ŽY”p‰˜‚Ė˜b‚Í‚æ‚ŧ‚Å‚ĩ‚Ä‚­‚ę‚é‚ЂȁB
’ę‚Å”„‚Á‚ŋ‚á‚Á‚―ŽG‹›‚ЂȁH

84ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:02:00.43ID:FCcukTxCd
IRƒLƒ^

85ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:06:37.05ID:dwkbAMIha
‘å–\—Žw
‹ó”„‚čŠOŽ‘—l‚ðär‚ß‚ņ‚Č‚æ
–{•Ļ‚̓Tƒ“ƒoƒCƒI‚ū‚Ŋ

86ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:10:11.10ID:UJMBtVKs
ƒoƒJƒ‹ƒT‚ŠƒTƒ“ƒo‚Å‚Q“x‚ā‘å‘đ‚ĩ‚Ä‚ā‚Ē‚Ü‚ū‚ɃTƒ“ƒo‚Éãv‚闝—R‚—

——R‚PiƒoƒJƒ‹ƒT“I”ˆŦ‚ĖŠŒđ‚—j
ƒz[ƒ‹ƒh‚ĩ‚Ä‚Ļ‚Ŋ‚ΗĮ‚Đ‚Á‚―‚ŧ[‚đ‚Ē‚ð‘đØ‚Á‚ăTƒ“ƒo‚ɏæ‚芷‚Ķ”íŠQ‚ŠŠg‘åA’v–―‚—
‚ū‚Đ‚į‚ŧ[‚đ‚Ē‚ŠˆŦ‚Ē‚ÆŒū‚Ī—‹ü‚—

——R‚Q
ƒTƒ“ƒo‚ÍŒģX‚’l’Í‚Ý
‚ŧ‚Ė‹ð‚Đ‚ČƒgƒŒ[ƒh‚ð‚ŧ[‚đ‚Ē‚ð’@‚­ļ_Ÿ—˜–@‚Řc‹Č‚ĩ‚―‚Ė‚ŃTƒ“ƒo‚ɑ΂ĩ‚ĉ…”O‚Šķ‚Ü‚ę‚Č‚Đ‚Á‚―‚—

——R‚R
Šô“x‚ā‘å‘đ‚ĖŒ‹‰ĘAÅŒã‚ÉŽc‚Á‚―”ũX‚―‚é‹ā‚ŃTƒ“ƒo‚𔃂Á‚―‚Ė‚Å‘å‚ĩ‚―”íŠQ‚͐ķ‚ķ‚ļAƒTƒ“ƒo‚ɑ΂·‚éĶ‚݂͐ķ‚ķ‚Č‚Đ‚Á‚―‚—
‚ŧ‚ę‚æ‚č”ˆŦ‚ĖŠŒđ‚Å‚ ‚é‚ŧ[‚đ‚Ē‚Š‘ž‚Ē‚—

Œ‹‹Įu‚ŧ[‚đ‚Ē‚Š‘ž‚Ēv‚ÆŒū‚Ī—‹ü‚ɍs‚Ŧ’…‚­‚—

87ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:10:21.68ID:UJMBtVKs
ƒoƒJƒ‹ƒT[‚—

88ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:10:26.23ID:cTCO8Yq+0
ƒ}ƒCƒeƒ“‚Ļ‚ß‚Å‚Æ‚ĪI

89ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:10:37.44ID:cTCO8Yq+0
‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI

90ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:11:40.74ID:UJMBtVKs
ƒ‹ƒTƒ“ƒ`ƒƒ“ƒY‚Ė‹Đ‚Ņ‚—

‚ī‚Ü‚ ‚—

91ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:14:41.71ID:FCcukTxCd
ƒ}ƒU[ƒYŽã‚·‚Ž[

92ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:15:32.56ID:guYa4Dxp0
ƒLƒ`ƒKƒC”z‘—

93ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:17:07.28ID:96FsTK2Ep
”„“ØŒģ‹C‚Č‚Ē‚æ[w

94ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:17:43.06ID:cTCO8Yq+0
’˜‚ĩ‚Ēi’ŧ‚ÅŠ”‰ŋ‰š‚Š‚Á‚―IIIIIII

95ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:22:45.85ID:UJMBtVKs
ƒ‹ƒTƒ“ƒ`ƒƒ“ƒY‚Ėˆô‚Ņ‹ƒ‚Ŧ‚—

96ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:23:23.76ID:UJMBtVKs
ƒoƒJƒ‹ƒT[“c’†‚—

97ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:27:07.04ID:cTCO8Yq+0
‚ŧ[‚đ‚Ē‚Ļ‚ā‚ë

QVM‰ĒB\ŋ@Ļ@‰š‚Š‚é
ƒtƒ@ƒCƒU[Œó•â•i@Ļ@‰š‚Š‚é
ƒWƒFƒlƒeƒbƒN’ņŒg@Ļ@‰š‚Š‚é
Formosaƒ}ƒCƒ‹ƒXƒg[ƒ“@Ļ@‰š‚Š‚é
•“c–ō•i@’ņŒg@Ļ@‰š‚Š‚é
QVM P3—ĮD Ļ@‰š‚Š‚é
ƒEƒ‹ƒeƒBƒuƒ’†‘•ÛŒŊƒŠƒXƒg@Ļ@‰š‚Š‚é
ƒtƒ@ƒCƒU[‰—Տ°“ü‚č@Ļ@‰š‚Š‚é
ƒtƒ@ƒCƒU[Œó•â•i3‚–ځ@Ļ@‰š‚Š‚é

2020”N
‚lina’ņŒg@Ļ@‰š‚Š‚é
ƒXƒsƒ“ƒIƒt‰ïŽÐ’Į‰ÁoŽ‘Žó‚Ŋ‚é@Ļ‰š‚°”ZŒú

98ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:29:27.71ID:H4VN4Ypg0
‚܁[‚―ˆęl‚ōr‚į‚ĩ‚Ä‚é‚Ė‚Đ
’m“IáŠQŽ‚ŋ‚ЁH

99ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:30:41.59ID:UJMBtVKs
‚đ‚Á‚đ‚đ‚Á‚đ‚Æ‚ŧ[‚đ‚Ē‚ð’ē‚Ũ‚é‚Ė‚Šƒ‹ƒTƒ“ƒ`ƒƒ“ƒYiÎj

“ā—e‚ð˜c‹Č‚ĩ‚Đļ_Ÿ—˜–@‚ɐZ‚郋ƒTƒ“ƒ`ƒƒ“ƒY‚—

ƒzƒ‹ƒ_[‚æ‚čÚ‚ĩ‚Ē‚ŧ[‚đ‚Ēƒ‹ƒTƒ“ƒ`ƒƒ“ƒYiÎj

100ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:35:07.04ID:W94EVFZO0
ƒOƒj‚Ü‚ū[H

101ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 10:35:49.64ID:W94EVFZO0
Œë”šƒXƒ}ƒ\

102ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 11:19:04.99ID:Vp8H5Xs9d
‚ā‚Īƒ_ƒ‚ū

103ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 11:31:55.39ID:SNyCij4y0
Þ—ŋo‚ĩ‚―‚įŠé‹Æ‰ŋ’l‰š‚Š‚é

104ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 11:33:35.81ID:SNyCij4y0
“ŒØ‚Ė’pA‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI
“–•Šƒ}ƒU[ƒYŽc—ŊIRo‚ģ‚ę‚é‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI
”NŠņ‚č‚ĖˆÏˆõ‰ïÝ’u‚Å”nŽ­‘›‚Ž‚ĩ‚Ä‚éŽG‹›‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI
‡’ēƒf[ƒX‚ŠŒû•Č‚ĖŠOl‚É”N3‰­•Ĩ‚Á‚―ŽG‹›‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI
ƒJƒjƒNƒCƒUƒ‹‰ó‚ĩ‚Ü‚­‚éŽG‹›‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI
Š”‰ŋ–ˆ“ú‰š—Ž‚ĖŽG‹›‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI
M—p”ƒ‚Ē‚Æ‘ÝŠ”‹ā—˜‚ʼnš‚°•ú‘č‚ĖŽG‹›‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI
Š”‰ŋ‰š‚Š‚č‚·‚Ž‚Ä—L–]mina”ƒŽû‚Å‚Ŧ‚Č‚Đ‚Á‚―‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI
‘ž‚ĖƒoƒCƒIŠé‹Æ‚ðŒĐ‰š‚·ŽG‹›‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI
ŒˆŽZ‚ē‚Æ‚É‘å–\—Ž‚·‚éŽG‹›‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI
ƒtƒ@ƒCƒU[ˆÄŒƒ}ƒCƒ‹–á‚Á‚ÄŠ”‰ŋ‰š—Ž‚ĖŽG‹›‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI
•“cƒWƒFƒlƒ“ƒeƒbƒN‚Æ’ņŒg‚ĩ‚Ä‚āŠ”‰ŋ‰š—ŽŽG‹›‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI
M1Žļ”s‚Č‚įŠŪ‘SŽ€–S‚·‚éƒpƒCƒvƒ‰ƒCƒ“‚Ė”–‚ģ‚ĖŽG‹›‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI
–ˆ”NƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚ɍs‚Á‚Ä‹ó”„‚č‚Ė‘Ώۂɂģ‚ę‚éŽG‹›‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI
SMBC‚Ė“c’†‚ÉŠ”‰ŋ2000‰~‚‚Ŋ‚į‚ę‚ăuƒ`ƒMƒŒ‚·‚éŽG‹›‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI
‚ŧ‚Ė2000‰~‚āŠ„‚ę‚ÄŽG‹›‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪI
‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ŽĐŽE‚Ļ‚ß‚Å‚Æ‚ĪIIIIIIIIAIIIIIIII

105ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 11:35:03.83ID:guYa4Dxp0
•‰‚ŊŒĒŒîH‚Š‰Î•a”­•a‚ĩ‚―‚Č

106ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 11:35:27.74ID:UJMBtVKs
ƒoƒJƒ‹ƒT‚Ė”­‹ķiÎj

107ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 11:36:26.90ID:dwkbAMIha
>>103
ƒ‚ƒ‹ƒKƒ“—l‚ðär‚ß‚ņ‚Č‚æ

108ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 12:08:34.61ID:tCyy6tSVr
“c‘šŽŦ‚ß‚ë

109ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 12:16:14.29ID:Kfkb/LutM
“c’†ŽŦ‚ß‚ë

110ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 12:18:43.13ID:FCcukTxCd
“c“‡ŽŦ‚ß‚ë

111ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 12:20:58.88ID:5S5mHoMF0
Œ‹‹Į‹x‚Ý‚ĖŠÔ‚Ė‘ˆ‚Ē‚Í‚ŋ‚á‚ņ‚Ɣo‚ĩ‚āA“ï•Č‚‚Ŋ‚Ä‚―•û‚Š•‰‚Ŋ‚―‚ņ‚ū‚Čw

112ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 12:34:43.50ID:FCcukTxCd
>>111
‚ŧ[‚đ‚ĒƒXƒŒ‚̓Lƒ`ƒKƒC‚΂Ђč‚ū‚Đ‚įŽd•û‚Č‚Ē‚ū‚ë

113ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 12:36:23.42ID:5S5mHoMF0
>>112
‚΂Ђč‚ÆŒū‚Ī‚Đ”S’…ŒÃŽ–‹L1l‚ū‚Ŋ‚ū‚ëw

114ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 12:44:27.45ID:guYa4Dxp0
”o‚đ‚Č‚Ē•‰‚ŊŒĒ–Á•ŋ

115ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 12:44:57.38ID:H4VN4Ypg0
”“ú‚É‚í‚―‚éŽĐ‰‰˜A“Š‚É‘ōŽR‚Ė”―‰ž‚Š‚ ‚Á‚Ä–u‹N‚ĩ‚Č‚Š‚įƒˆƒ_ƒŒ‚‚į‚ĩ‚Ä‚é‚ū‚ë‚Ī‚Ë

116ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 12:46:48.55ID:FCcukTxCd
Œãę‚Đ‚į—ˆ‚é‚ÆŽv‚Á‚―‚Ė‚É

117ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 12:49:30.35ID:MxflYe+nF
”o‚đ‚Č‚Ē•ûŽS‚ß‚·‚Ž‚ďo‚Ä—ˆ‚ę‚Č‚ĒH

118ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 12:53:37.48ID:FCcukTxCd
ID•Ï‚Ķ‚ďo‚ę‚Č‚Ē‚ū‚Ŋ‚Đ‚Æ

119ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 12:54:48.03ID:FCcukTxCd
ƒ}ƒU[ƒYã‚°‚Ä‚Ŧ‚―‚Đ‚į‚Í‚â‚­

120ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 12:55:21.11ID:Vp8H5Xs9d
‚ā‚Īƒ_ƒ‚ū

121ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 13:05:54.35ID:IeCjf95ba
‚ŋ‚å‚Ē‘Ō‚Á‚ĉš‚ģ‚Ē‚悧c

122ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 13:20:52.62ID:96FsTK2Ep
>>111 “ï•Č•t‚Ŋ‚Đ‚Ķ‚é‚Č‚æwww

123ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 13:28:43.23ID:dwkbAMIha
ƒ‚ƒ‹ƒKƒ“—lA“c’†—l‚ðär‚ß‚ņ‚Č‚æ
–{•Ļ‚̓Tƒ“ƒoƒCƒI‚ū‚Ŋ

124ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 13:30:02.16ID:FCcukTxCd
>>122
‚­‚â‚ĩ‚Ē‚Ė‚Īwwwww

‚­‚â‚ĩ‚Ē‚Ė‚Īwwwww

125ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 13:32:42.18ID:guYa4Dxp0
‹ƒ‚Ē‚Ä‚é‚ņ‚ū‚Đ‚į—D‚ĩ‚­‚ĩ‚Ä‚â‚ę

126ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 13:52:54.99ID:8lL77eK70
‚ą‚Ė‚Æ‚ą‚ëGU‚ÅŽn‚Ü‚é‚Ɖš‚°AGD‚ÅŽn‚Ü‚é‚Əグ‚ĖƒAƒ‹ƒS‚Š“ü‚Á‚Ä‚é‚ą‚Æ‚Š‘―‚Ē

127ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 14:08:47.93ID:96FsTK2Ep
>>116 ‰ũ‚ĩ‚Ē‚Ė‚Ļwwwwww

128ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 14:11:23.01ID:cTCO8Yq+0
‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[Ž€‚ņ‚ūH

129ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 14:12:23.16ID:cTCO8Yq+0
‚’l—züˆø‚Ŋ‚ĖŽŸ‚Ė“ú‚Í•E‚Č‚ĩ‰Aü‚Ė–@‘Ĩ‚Å‚ŧ[‚đ‚ĒŽ€–S

130ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 14:14:46.68ID:Vp8H5Xs9d
ƒIƒƒ^

131ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 14:18:04.39ID:cTCO8Yq+0
‚ŧ[‚đ‚Ē‚Ļ‚ā‚ë

QVM‰ĒB\ŋ@Ļ@‰š‚Š‚é
ƒtƒ@ƒCƒU[Œó•â•i@Ļ@‰š‚Š‚é
ƒWƒFƒlƒeƒbƒN’ņŒg@Ļ@‰š‚Š‚é
Formosaƒ}ƒCƒ‹ƒXƒg[ƒ“@Ļ@‰š‚Š‚é
•“c–ō•i@’ņŒg@Ļ@‰š‚Š‚é
QVM P3—ĮD Ļ@‰š‚Š‚é
ƒEƒ‹ƒeƒBƒuƒ’†‘•ÛŒŊƒŠƒXƒg@Ļ@‰š‚Š‚é
ƒtƒ@ƒCƒU[‰—Տ°“ü‚č@Ļ@‰š‚Š‚é
ƒtƒ@ƒCƒU[Œó•â•i3‚–ځ@Ļ@‰š‚Š‚é

2020”N
‚lina’ņŒg@Ļ@‰š‚Š‚é
ƒXƒsƒ“ƒIƒt‰ïŽÐ’Į‰ÁoŽ‘Žó‚Ŋ‚é@Ļ‰š‚Š‚é

132ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 14:25:40.37ID:cTCO8Yq+0
‚ ‚Æ2‰~‚ōňĀ’l
‚Ī‚í[[[[[[[‚ŸIIIIII

133ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 14:25:57.93ID:cTCO8Yq+0
ÅˆĀ’l‚Ļ‚ß‚Å‚Æ‚ĪIIIIIII

134ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 14:26:39.83ID:cTCO8Yq+0
DÞ—ŋ‚ū‚ĩ‚ĉš—Ž‚Ļ‚ß‚Å‚Æ‚ĪI

135ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 14:27:54.64ID:cTCO8Yq+0
‚ā‚ĪI‚í‚č‚ū

136ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 14:28:36.40ID:cTCO8Yq+0
–ˆ“ú–O‚Ŧ‚ļ‚ɉEŒĻ‰š‚Š‚č‚ĖƒNƒ\ƒ`ƒƒ[ƒg‚Ļ‚ß‚Å‚Æ‚ĪI

137ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 14:34:18.16ID:96FsTK2Ep
20000Š”“Š‚°‚―”nŽ­www

138ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 14:40:44.84ID:96FsTK2Ep
>>136 ‚Į‚ąŠÏ‚Ä‚ņ‚ū‚æwˆęð“ú‚Đ‚įØ‚čƒAƒQƒAƒQ‚ķ‚á‚ˁ[‚Đwww

139ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 14:59:10.57ID:FCcukTxCd
‚Ī‚ē‚Đ‚ņ‚Ė‚Ī

140ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 15:00:07.22ID:scnB2ufG0
ĶSosei Heptares Twitter 6ŽžŠÔ‘OF(1/14)
"Sosei Group Corporation announces that significant scientific progress at its spin-off companies Orexia and Inexia has triggered the next tranche of funding from venture capital firm medicxi under its €40 million commitment."

ĶSosei HeptaresFuOrexiaŽÐ‚Ļ‚æ‚Ņ InexiaŽÐ‚É‚æ‚éƒIƒŒƒLƒVƒ“Žó—e‘Ėė“Ū–ōƒvƒƒOƒ‰ƒ€‚Ė’˜‚ĩ‚Ēi’ŧ‚É‚æ‚čMedicxiŽÐ‚ŠŽŸ‚Ȃ鎑‹ā’ņ‹Ÿ‚ðŽĀsv(1/14)
EƒXƒsƒ“ƒIƒt‚É‚æ‚čÝ—§‚ģ‚ę‚― OrexiaŽÐ‚Æ InexiaŽÐ‚ð’Ę‚ķŠJ”­‚Šs‚í‚ęAMedicxiŽÐ‚É‚æ‚č 40•S–œƒ†[ƒ‚Ė“ŠŽ‘‚Šs‚í‚ę‚é_ŒoŒnŽūŠģ‚ð‘ΏۂƂĩ‚―ƒIƒŒƒLƒVƒ“Žó—e‘Ė‚ÉŠÖ‚·‚éƒvƒƒOƒ‰ƒ€B
EOrexiaŽÐ‚Æ InexiaŽÐ‚͈Ā’č‰ŧ‚ģ‚ę‚―ƒIƒŒƒLƒVƒ“Žó—e‘Ė(StaR)ƒAƒSƒjƒXƒgŒ‹‡Œ^”zĀ‚ðŠˆ—p‚ĩAƒIƒŒƒLƒVƒ“Žó—e‘Ėƒ‚ƒWƒ…ƒŒ[ƒ^[‚ÉŠÖ‚·‚é“ÆŽĐ‚Ė‘n–ō‚Ļ‚æ‚ŅÝŒvƒGƒ“ƒWƒ“‚ð\’zB
E“–ŽÐƒOƒ‹[ƒv“ÆŽĐ‚Ė\‘Ēƒx[ƒX‘n–ō(SBDD)ƒAƒvƒ[ƒ`‚Š‘n–ō‚Ļ‚æ‚ŅV‹KŠˆŦŒ^•ŠŽq‚ÉŠÖ‚·‚éd—v‚Č–ðŠ„‚ð‰Ę‚―‚ĩ‚―B
“–ŽÐƒOƒ‹[ƒv‚́AƒXƒsƒ“ƒIƒtŠé‹Æ‚Å‚ ‚éOrexia Limited‚Ļ‚æ‚ŅInexia Limited‚É‚æ‚é’˜‚ĩ‚Ēi’ŧ‚É‚æ‚čA
40•S–œƒ†[ƒ(–ņ4,868•S–œ‰~)‚ĖƒRƒ~ƒbƒgƒƒ“ƒg‚Ė‰š‚ŁAƒxƒ“ƒ`ƒƒ[ƒLƒƒƒsƒ^ƒ‹‚Å‚ ‚é MedicxiŽÐ‚Đ‚įŽŸ‚Ȃ鎑‹ā’ņ‹Ÿ‚ŠŽĀs‚ģ‚ę‚Ü‚ĩ‚―‚Ė‚ŁA‚Ļ’m‚į‚đ‚Ē‚―‚ĩ‚Ü‚·B
“–ŽÐƒOƒ‹[ƒv‚Ļ‚æ‚Ņd—v‚ČƒAƒZƒbƒg‚É“Á‰ŧ‚ĩ‚―Šé‹Æ‚Ö‚ĖŽ‘‹ā’ņ‹Ÿ‚ðę–å‚Æ‚·‚éMedicxiŽÐ‚́AGƒ^ƒ“ƒpƒNŽŋ‹Ī–ðŽó—e‘Ė(GPCR)‚Å‚ ‚éƒIƒŒƒLƒVƒ“Žó—e‘ĖOX1‚Ļ‚æ‚ŅOX2‚Ėƒ|ƒWƒeƒBƒuƒ‚ƒWƒ…ƒŒ[ƒ^[‚ðŠî‘b‚Æ‚·‚éA
ƒiƒ‹ƒRƒŒƒvƒV[‚ðŠÜ‚ސ_ŒoŒnŽūŠģ‚ɑ΂·‚éV‹KŽĄ—Ö@‚ĖŠJ”­‚ð–ÚŽw‚ĩA2019”N‚ÉOrexiaŽÐ‚ÆInexiaŽÐ‚ðÝ—§‚ĩ‚Ü‚ĩ‚―B

141ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 15:00:16.20ID:scnB2ufG0
OrexiaŽÐ‚Ļ‚æ‚ŅInexiaŽÐCEO‚Å‚ ‚éMario Alberto AccardiŽm‚ÍŽŸ‚Ė‚æ‚Ī‚ɏq‚Ũ‚Ä‚Ē‚Ü‚·B
uSosei Heptares‚ĖSBDD‚Ļ‚æ‚ŅGPCR‹Zp‚ÉŠî‚ÂŦAOrexiaŽÐ‚Æ InexiaŽÐ‚É‚Ļ‚Ē‚Ä“ÆŽĐ‚Ė‘n–ō‚Ļ‚æ‚ŅÝŒvƒGƒ“ƒWƒ“‚ð\’z‚ĩ‚Ü‚ĩ‚―B
ˆĀ’č‰ŧ‚ģ‚ę‚―ƒIƒŒƒLƒVƒ“Žó—e‘Ė(StaR)ƒAƒSƒjƒXƒg“‡Œ^”zĀ‚É‚æ‚čAÚŨ‚ȍ\‘Ē“I“īŽ@‚ð“ū‚é‚Æ‚Æ‚ā‚ɁA‚ą‚ę‚Ü‚Å‚É‚Č‚Ē‘n–ōƒAƒvƒ[ƒ`‚ðĖ—p‚·‚é‚ą‚ƂŁAŒoŒû‚Ļ‚æ‚Ņ•@o“ā“Š—^‚Ė‰Â”\Ŧ‚ðŽ‚ÂA‘I‘ðŦ‚Š‚‚­‹­—Í‚Č•ŠŽq‚Ė‘nŧ‚Š‰Â”\‚É‚Č‚č‚Ü‚·B
‚ą‚Ėd—v‚ЂŠė‚΂ĩ‚Ēi’ŧ‚É‚æ‚čAMedicxiŽÐ‚Đ‚į‚ĖƒRƒ~ƒbƒg‚𔚂ĪŽŸ‚Ȃ鎑‹ā’ņ‹Ÿ‚ð‰Â”\‚É‚ģ‚đA‚ą‚ę‚į‚Ė”ņí‚É—L–]‚Č•ŠŽq‚ðv‘Ž‚ɗՏ°ŽŽŒą‚ւƐi‚ß‚Ä‚Ē‚­‚―‚ß‚ÉŽg‚í‚ę‚Ü‚·Bv
“–ŽÐŽ·s–𕛎В·Research and Early Development‚Å‚ ‚éƒ}ƒ‹ƒRƒ€EƒEƒBƒA[‚ÍŽŸ‚Ė‚æ‚Ī‚ɏq‚Ũ‚Ä‚Ē‚Ü‚·B
uOrexiaŽÐ‚Ļ‚æ‚ŅInexiaŽÐ‚Æ‚Ė‹Ķ—Í‚Ļ‚æ‚ŅMedicxiŽÐ‚Đ‚į‚ĖŽx‰‡‚ÆŽ‘‹ā’ņ‹Ÿ‚É‚æ‚éAƒIƒŒƒLƒVƒ“Žó—e‘Ėė“Ū–ōƒvƒƒOƒ‰ƒ€‚Ėi“W‚ð”ņí‚ÉŠė‚΂ĩ‚­Žv‚Á‚Ä‚Ē‚Ü‚·B
‚ą‚ĖƒvƒƒOƒ‰ƒ€‚É‚æ‚čAˆŲ‚Č‚é_ŒoŒnŽūŠģ‚Ɛ_Œo“`’B‚É“K‚ĩ‚―A•L‚Ē–ō—Šw“Iƒvƒƒtƒ@ƒCƒ‹‚ð”õ‚Ķ‚―‹ŧ–Ą[‚ĒV‹K•ŠŽq‚ðŠų‚É‘nŧ‚ĩ‚Ä‚Ļ‚čA‚ą‚ę‚Í OrexiaŽÐ‚Æ InexiaŽÐ‚ĖĄŒã‚ĖŽŒũ‚Ö‚Ė—Į‚Ē‘O’›‚Å‚ ‚é‚ÆŒū‚Ķ‚Ü‚·Bv

EEE

142ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 15:00:29.86ID:McNgPgJy0
‘åˆø‚Ŋ‚Ļ‚Â

143ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 15:00:38.90ID:scnB2ufG0
ŽŸ‚Č‚é”ō–ô‚ցB’…ŽĀ‚Ȑi’ŧ‚Æ‹Ī‚ɍX‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂĐU‚é‚Ēˆį‚ŋ‚ä‚­‘ŠęBT‚Ķ‚éÞ—ŋ‚Æ‹Ī‚ɐ…€’ųģBÎB
Ž’·ŠúB—\’č‚ģ‚ę‚Ä‚Ē‚―‹ÆŅ‚Ė‹}Ž’·‚Æ‹Ī‚ɍX‚Ȃ鐎’·í—Š‚Ši“WB‡’ē‚ČR&DEPL“™‚ĖŠg[EŠg‘å‚Ė‰Á‘ŽBÎB
EEE
ĶSOSEI‚ĖŽ’·‘Šę‚Ė“ŪŒüFÄ‚Ņ‚Ėãļ‘Šę‚͏‡’ē‚ɐ„ˆÚ(2018/12/25:ÅˆĀ’l748ĶA2019/8/5:Å‚’l:2794)BÎB‹ÆŅ‘Šę‚Ö‚Ė“ŪˆÓ‘Ō‚ŋBÎB
2018/12/28 (I’l_799) E(12/25ÅˆĀ’l_748) Ķ12/1:SoseiHeptares–{ŠiŽn“Ū[Ä‚Ņ‚ĖE‚ĒęĶ][‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē’ēŪ‚ŠI—đ]
2019/_1/_4 (I’l_864) E(_1/_4ˆĀ’l_780) Ķ1/1:“c‘šCEO•œ‹AĶ1/7:AZD4635‘æ‡U‘Š[1/8ƒXƒgƒbƒv‚:I’l1078] [ãļƒgƒŒƒ“ƒh‚Ö“]Š·]
2019/_2/_1 (I’l1021) E(_1/30ˆĀ’l_985) Ķ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[’ïG(1/21ˆĀ’l1164, 1/30ˆĀ’l985)Ķ(1/21:‚’lXV:1360)
2019/_3/_1 (I’l1250) E(_2/_4ˆĀ’l1021) Ķ2/4:ƒIƒ‰ƒr”­”„ Ķ2/14:ŒˆŽZ Ķ2/22:IRā–ū‰ï(ˆĒ”{–ė)ĒŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—ŠĢ
2019/_4/_5 (I’l1593) E(_3/11ˆĀ’l1105) Ķ3/16:’†‘ãŽs Ķ(3/20:‚’lXV:ƒXƒgƒbƒv‚:1526) Ķ3/29:IRā–ū‰ï(–žŒÃ‰ŪE‘åã)
2019/_5/10 (I’l1486) E(_4/22ˆĀ’l1372) Ķ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[’ïG(4/11ˆĀ’l1400) Ķ(4/9:‚’lXV:1717)Ķ(5/15:‚’lXV:1743)
2019/_6/_7 (I’l2014) E(_5/13ˆĀ’l1429) Ķ5/14:Pfizeri’ŧ;‘æ1Žl”žŠúŒˆŽZ Ķ5/24:QVM149\ŋ Ķ‚’lXV:(5/22:1834)(5/23:2149)(5/28:2296)

144ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 15:00:59.29ID:scnB2ufG0
2019/_7/_5 (I’l2338) E(_6/12ˆĀ’l1969) Ķ6/10:Pfizeri’ŧĶ6/18:IRā–ū‰ï(å‘ä) Ķ‚’lXV:(6/24:2377)(6/26:2420)(7/1:2429)(7/2:2482)
2019/_8/_2 (I’l2544) E(_7/_9ˆĀ’l2216) Ķ7/16:Genentech’ņŒgĶ(7/16ƒXƒgƒbƒv‚:‚’lXV:2773) Ķ7/18:APP13007i’ŧ
2019/_9/_6 (I’l2335) E(_8/30ˆĀ’l2179) Ķ8/5:•“c–ō•i’ņŒg Ķ8/5:Å‚’lXV:2794) Ķ8/13:‘æ2Žl”žŠúŒˆŽZ [—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋ]
2019/10/_4 (I’l2438) E(_9/17ˆĀ’l2088) Ķ9/12:ƒCƒ“ƒxƒXƒ^[R&D Day Ķ9/28:MTL-CEBPA’PÜ‘æ‡T‘ŠÅIŒ‹‰ĘĶ9/30:QVM149‘æ‡V‘ŠIRIDIUMŒ‹‰Ę
2019/11/_1 (I’l2570) E(10/11ˆĀ’l2130) Ķ10/9:Genentechi’ŧ
2019/12/_6 (I’l2317) E(11/15ˆĀ’l2185) Ķ11/12:‘æ3Žl”žŠúŒˆŽZĶ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[(11/13)Ķ11/28:’†‘NRDLŽûÚĶ12/6:IRā–ū‰ï(L“‡)
2019/12/30 (I’l2171) E(12/16ˆĀ’l2137) Ķ12/23:Pfizer‘æ‡T‘ŠŠJŽnĶ12/24:Pfizeri’ŧ(ŽO”Ô–Ú) Ķ12/30: 2019”N‘å”[‰ïI’l2171
2020/_1/10 (I’l2115) E(1/8ˆĀ’l1977) Ķ1/6: 2020”N‘å”­‰ïŽn’l2150 Ķ1/7:MiNA Collaboration with AstraZeneca.
2020/_1/14 (I’l2104) (ˆĀ’l2092) Ķ1/14:Orexia&Inexiai’ŧ

145ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 15:01:43.62ID:scnB2ufG0
X‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂāAÄ‚Ņ‚ĖE‚Ēę(’ę’l)‚Đ‚į‚Ė…€’ųģ‚Í3”{Œ—ƒXƒe[ƒW‚ɂē‚ɐ„ˆÚBÎB—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋBÎB
•Žš“]Š·AŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—Š‚͏‡’ē‚ɐi“WBÎB’…ŽĀ‚Ȑi’ŧ‚Æ‹Ī‚ɁAX‚Ȃ鐎’·‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎB
Ą‰ņ‚Ėãļ‘Šę‚ā–Ę”’‚­‚Č‚č‚Ü‚ĩ‚―BÎBŒo‰cí—Š‚Ė“]Š·‚É‚æ‚鍕Žš’č’…‰ŧBÎBˆŦ’n‡‚Ē‚ɂĐV”N‘Šę‚ŠŠJŽnBÎB

146ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 15:07:22.95ID:guYa4Dxp0
”o‚ĩ‘ÎŒˆ‚É”s‘–‚ĩ‚―•‰‚ŊŒĒŒîH‚ĖƒTƒ“ƒoƒCƒI‚ā‰š‚Š‚Á‚Ä‚é‚Č

147ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 15:15:14.88ID:on/W57FOp
ŒĐ‚đ”Â‚Å’Ę•ņ‚â‚Č

148ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 15:16:47.07ID:96FsTK2Ep
>>147 ‚Ų‚ņ‚Æ”nŽ­‚ū‚æ‚Č‚ w

149ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 15:23:50.64ID:FCcukTxCd
‚­‚â‚ĩ‚­‚ĈęķŒœ–―‚Ē‚Ē‚í‚Ŋl‚Ķ‚―‚ņ‚ū‚ë‚Ī‚Čwwwww

‚­‚â‚ĩ‚Ē‚Ė‚Īwwwww

‚­‚â‚ĩ‚Ē‚Ė‚Īwwwww

150ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 15:25:56.45ID:96FsTK2Ep
>>149 ‚ĶH‚Č‚ņ‚Å•”ŠOŽŌ‚Š‘›‚Ū‚Ėwww

151ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 15:27:02.53ID:H4VN4Ypg0
IDÔ‚­‚Č‚éƒƒ“ƒo[4”{‚­‚į‚Ē‚É‘‚Ķ‚Ä‚Ä‘

‚ņ‚Č‚í‚Ŋ‚ ‚é‚Đ‚ĒI

152ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 15:29:04.23ID:guYa4Dxp0
”o‚ĩ‘ÎŒˆ‚É”s‘–‚ĩ‚―•‰‚ŊŒĒŒîH

ƒTƒ“ƒoƒCƒI‚Ė‚ą‚Ɣےč‚ĩ‚Č‚Ē

“ŠˆŦ‚Ē‚Đ‚į”F‚ß‚ŋ‚á‚Á‚Ä‚ņ‚Ë

153ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 15:30:40.36ID:FCcukTxCd
>>150
ˆęķŒœ–―l‚Ķ‚―‚ĖH



‚­‚â‚ĩ‚Ē‚Ė‚Īwwwww

‚­‚â‚ĩ‚Ē‚Ė‚Īwwwww

154ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 15:37:29.51ID:5dOPGrwLd
‘ÎŒˆ‚É•‰‚Ŋ‚―•û‚ū‚Ŋ‹Ā‚Á‚Ä‚ņ‚Ë

155ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 15:48:48.98ID:rmkxwKpv
ƒ‹ƒTƒ“ƒ`ƒƒ“ƒY‚—

156ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 17:20:34.74ID:guYa4Dxp0
æ•Ļ–\—Ž

157ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 17:44:11.37ID:9CtRBJBk0
ˆĀ’lŠo‚Ķ‚Đ‚į‚ŧ‚ë‚ŧ‚ë‘ē‹Æ‚ĩ‚Ä‚Ē‚ĒŽžŠú‚ū‚ˁB

158ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 18:20:17.17ID:96FsTK2Ep
‚Č‚ņ‚ōĄ“ú‚̓SƒLƒuƒŠ‚Šƒƒ‰ƒƒ‰—N‚Ē‚Ä‚­‚é‚ņ‚ūw

159ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 18:21:27.36ID:/HsqqgCq0
‚ą‚Ė”“‚·‚Ž‚é‚Đ‚įŒxŽ@‚É’Ę•ņ‚ĩ‚―‚Ų‚Ī‚Š‚Ē‚Ē

160ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 18:29:09.93ID:FCcukTxCd
>>158
•n–Rl

‚­‚â‚ĩ‚Ē‚Ė‚Īwwwww

‚­‚â‚ĩ‚Ē‚Ė‚Īwwwww

161ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 18:40:49.80ID:96FsTK2Ep
>>160 ‚Æ‚ą‚ë‚Å‚Č‚ņ‚Å10Žž‚ÉIRƒLƒ^‚Č‚Ėwww

162ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 19:05:42.81ID:FCcukTxCd
>>161
•n–Rl

‚­‚â‚ĩ‚Ē‚Ė‚Īwwwww

‚­‚â‚ĩ‚Ē‚Ė‚Īwwwww

163ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 19:09:48.07ID:jgSpFor4d
‚ŧ[‚đ‚Ē‚Őg‚Ėä‚ɍ‡‚í‚Č‚Ē”į–œ‰~ŠÜ‚Ý‘đ‚ ‚Á‚―Žž‚Å‚ā‚ą‚ą‚܂Ől‚Æ‚ĩ‚Ä—Ž‚ŋ‚Ô‚ę‚Č‚Đ‚Á‚―‚Ŋ‚Į‚Į‚ņ‚Ȑķ‚Ŧ‚Ä‚Ŧ‚―‚ņ‚ū‚æ
ƒSƒ~ƒJƒX‰ß‚Ž‚é‚ū‚ë

164ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 19:17:16.67ID:+T5PwDigd
30Žü”N‹L”O”z“–‚Ė‰Â”\Ŧ‚́H

165ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 19:18:02.70ID:jgSpFor4d
2017 ‚Ėr‚ę‹ï‡‚ðŽv‚Ēo‚·‚í‚æ

166ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 19:29:29.36ID:szdDZdMg0
>>164
‚ ‚é‚Ŋ‚ĮŠ”‰ŋ‚É‚ ‚Ü‚č‰e‹ŋ‚ĩ‚Č‚ģ‚ŧ

167ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 19:32:21.25ID:szdDZdMg0
100Š””ƒ‚Ķ‚é‚Đ‚Į‚Ī‚Đ‚Ė—ëŨ‚Šr‚į‚ĩ‚Ä‚é‚ū‚Ŋ‚ū‚ë

168ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 20:01:55.30ID:NA/eAPuj0
>>164
‚ŧ‚Ė—‚”N‚É”z“–‚Š–ģ‚Đ‚Á‚―ę‡AŽl‹G•ņ‚Š‰―‚Ė’Žß‚ā‚Č‚ĩ‚Ɂu–ģ”z“]—Žv‚Á‚ď‘‚Ŧ‚â‚Š‚é‚Ė‚ÅŒp‘ą“I‚ɏo‚đ‚éŒĐž‚Ý‚Š‚Č‚ĒŒĀ‚č‹L”O“I‚Č”z“–‚Í–ģ‚­‚Ä‚Ē‚Ē”h‚Å‚·

169ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 20:39:48.47ID:9NXZK7/P0
‚ā‚Īƒ_ƒ‚ū

170ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 20:58:17.62ID:KGgTSywg0
‚ĶAär‚ß‚ņ‚Č‚æ‚Ļ‚ķ‚ģ‚ņ‚Á‚Ä’P‚Č‚éŽãŽŒÂl‚ū‚Á‚―‚ĖH

171ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 21:44:11.73ID:gFfRABYA0
”z“–‚æ‚芔Žå—D‘Ō‚ū‚ëƒ}ƒOƒJƒbƒv‚ƃ{[ƒ‹ƒyƒ“•œŠˆ‚Å‚Ķ‚Ķ‚æ

172ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/14(‰Î) 22:36:00.28ID:PX3HoGvaM
‰ïŽÐ‚ĖŽ‘–{‚ðƒhƒu‚ÉŽĖ‚Ä‚é‚æ‚Ī‚ȍsˆŨ‚ū

173ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 00:30:03.64ID:pHvkJEwq0
ŽŸ‚Č‚é”ō–ô‚ցB’…ŽĀ‚Ȑi’ŧ‚Æ‹Ī‚ɍX‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂĐU‚é‚Ēˆį‚ŋ‚ä‚­‘ŠęBT‚Ķ‚éÞ—ŋ‚Æ‹Ī‚ɐ…€’ųģBÎB
Ž’·ŠúB—\’č‚ģ‚ę‚Ä‚Ē‚―‹ÆŅ‚Ė‹}Ž’·‚Æ‹Ī‚ɍX‚Ȃ鐎’·í—Š‚Ši“WB‡’ē‚ČR&DEPL“™‚ĖŠg[EŠg‘å‚Ė‰Á‘ŽBÎB
EEE
ĶSosei HeptaresF‘n–ōuGPCRˆĀ’č‰ŧ‹Zp‚ð—p‚Ē‚―‘n–ōvƒŒƒNƒ`ƒƒ[ƒJƒ“ƒtƒ@ƒŒƒ“ƒXw‰ŧŠwŽŌ‚Š’m‚Á‚Ä‚Ļ‚­‚Ũ‚Ŧķ•ĻŠw‚Ė’mŽŊ1F ķ‘ĖŠO‚É‚Ļ‚Ŋ‚éķ•ĻŠwx‚ɂču‹`B(11/21up)
ĶSosei HeptaresF‘n–ōu\‘Ēƒx[ƒX‘n–ō(SBDD)‚Ļ‚æ‚Ņƒqƒbƒg‰ŧ‡•Ļ’Tõ‚É‚Ļ‚Ŋ‚éSosei Heptares‚ĖGPCR StaRƒvƒ‰ƒbƒgƒtƒH[ƒ€‚Ė‰ž—pvDrug Discovery 2019‚É‚Ä”­•\B(11/26up)
ĶSosei HeptaresFuCOPDŽĄ—ÖōƒEƒ‹ƒeƒBƒuƒ‚Ė’†‘‚Å‚Ė‘‰Æˆã—ÕیŊžŠŌˆã–ō•iƒŠƒXƒg(NRDL)‚Ö‚ĖŽûÚvNRDL‚́A‘ÎÛ‚Æ‚Č‚éŠģŽŌ‚ɑ΂ĩ‚āA‘SŠz‚ā‚ĩ‚­‚Íˆę•”‚ŠŒö“I•ÛŒŊ‚ŏžŠŌ‚ģ‚ę‚éˆã–ō•iƒŠƒXƒgB2019”N3ŒŽ‚É’†‘”Ė”„ŠJŽnÏB(11/28)
ĶClinicalTrials(NCT03244228: HTL0016878-101): Phase 1, A Two Part Study to Assess Safety, PK, PD, and Food Effect of Oral HTL0016878: Actual Study Completion: "2019/9/23". ("Completed", 11/28update)
ĶNovartis R&D Day: "Novartis Expects to Sustain Long-Term Growth with a Robust Pipeline of 25+ Potential Blockbusters Highlighted. "Significant Progress in 2019: Submissions: "Asthma" QVM149 / QMF149 (EU/JP)". (12/5)
ĶSosei Heptares Official BlogFuL“‡‚ɂȐl“ŠŽ‘‰ÆŒü‚Ŋ‰ïŽÐā–ū‰ï‚ð(12/6)ŠJÃvŽ·s–𕛎В· Å‚ā–ąÓ”CŽŌ CFO ƒNƒŠƒXEƒJ[ƒMƒ‹‚æ‚čA“–ŽÐƒOƒ‹[ƒv‚Ė‰ˆŠvAŽ–‹Æ“ā—eA‚ŧ‚ĩ‚čĄŒã‚ĖŽ’·í—Š‚ɂ‚Ē‚Ä‚Ļ˜b‚ĩ‚ĩ‚Ü‚ĩ‚―B–ņ130–ž‚ĖŽQ‰ÁB(12/9up)
ĶSosei HeptaresFuŽ–ŒãŒð•tŒ^Š”ŽŪ•ņV(ƒŠƒXƒgƒŠƒNƒeƒbƒhEƒXƒgƒbƒNEƒ†ƒjƒbƒg(RSU))§“x‚ÉŠî‚­VŠ”ŽŪ”­sv–{§“x‚ÉŠî‚­•ņV‚Ėˆę•”‚Æ‚ĩ‚āA–ðEˆõ‚Šˆę’č‚ĖŠúŠÔ‚É‚Ļ‚Ē‚Ä–ðEˆõ‚Ė’nˆĘ‚É‚ ‚Á‚―‚ą‚Æ‚ððŒ‚Æ‚ĩ‚čs‚í‚ę‚éB(12/11)

174ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 00:30:24.04ID:pHvkJEwq0
ĶSosei HeptaresF‘n–ōuGPR52ė“Ū–ō‚É‚æ‚éƒh[ƒpƒ~ƒ“ė“ŪŒn‚Ļ‚æ‚ŅƒOƒ‹ƒ^ƒ~ƒ“Ž_‚Ė‹@”\’ēß‚Š“‡Žļ’ēĮ‚ðŠÜ‚ސļ_ŽūŠģ‚É‚Ļ‚Ŋ‚é—zŦĮó‚â”F’máŠQ‚ɑ΂·‚éV‹KŽĄ—Öō‚Æ‚ĩ‚Ä‚Ė—L—pŦ‚ÉŠņ—^vACNP2019‚É‚Ä”­•\B(12/12up)
ĶŽl‹G•ņFy•Žš’č’…zˆęŽž‹ā“™Žû“üãæ‚đB•Žš•‚ãB20”N12ŒŽŠú‚͐i’ŧƒ}ƒCƒ‹ƒXƒg[ƒ“A”Ė”„ƒƒCƒ„ƒ‹ƒeƒB‚ɐV‹K’ņŒg‚ĖˆęŽž‹ā“™Žû“ü‰Á‚í‚éBy”ŽÔzŽ–‹ÆŠJ”­‹­‰ŧ‚ĩ‚ĐϋɒņŒgí—Š‚ð‰Á‘ŽB‚Š‚ņ‘ΏÛ2ŽĄŒą‚Ėi’ŧ‡’ēB(12/13)
ĶSosei HeptaresF‘n–ōuSBDD‚ðŠˆ—p‚ĩ‚―A2ARhR–ōHTL1071/AZD4635‚Ė‘n–ōv‘æ24‰ņŒö‰vā’c–@l‚Š‚ņŒĪ‹†‰ï‘Û‚Š‚ņ‰ŧŠw—Ö@ƒVƒ“ƒ|ƒWƒEƒ€ New Drugs in Development in Japan, Europe and the USA‚É‚Ä”­•\B(12/13up)
ĶClinicalTrials(NCT03063086): Phase 2, Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma. (12/13update: Results up)
ĶAGING: "Protease-Activated Receptor 2 (PAR-2) Antagonist AZ3451 as a Novel Therapeutic Agent for Osteoarthritis." ttps://s3-us-west-1.amazonaws.com/paperchase-aging/pdf/P76c98pfHC5EHXY4Z.pdf (12/16 Published)
ĶSosei HeptaresF‘n–ōuPharmacological characterisation of the lipopolysaccharide challenge assay for conformation of target engagement of EP4 antagonists in human whole bloodvPharmacology 2019‚É‚Ä”­•\B(12/18up)
ĶSosei HeptaresF‘n–ōuDevelopment of Histamine H4 Receptor Target Engagement Assays in Immune Cell Populations Involved in Atopic Dermatitis PathophysiologyvPharmacology 2019‚É‚Ä”­•\B(12/18up)

175ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 00:30:43.77ID:pHvkJEwq0
Ķ‘Û“Á‹–oŠč(MiNA)F"Combination Therapies Comprising C/EBP Alpha saRNA" (Inventors: ETH Zurich, Imperial College London, NUST, MiNA Therapeutics). (12/19ŒöŠJ)
ĶSosei HeptaresFuƒ€ƒXƒJƒŠƒ“EƒvƒƒOƒ‰ƒ€v2019”N12ŒŽ‚Ü‚Å‚É‚Í‚Ļ’m‚į‚đ‚ðs‚Ī‚ą‚Æ‚Š‚Å‚Ŧ‚éŒĐž‚Ý‚Å‚ ‚é‚Æ”­•\‚ĩ‚Ä‚Ļ‚č‚Ü‚ĩ‚―‚ŠA’ņŒgæ‚É‚æ‚鍇ˆÓ‚Š“ū‚į‚ę‚―ę‡‚É‚Ė‚݉”\‚Æ‚Č‚é“_A‚ē—‰ð‰š‚ģ‚ĒB(12/20)
ĶClinicalTrials(NCT04206761): Phase 3, Investigating the Effects of QVM149 on MRI Ventilation Defects (XPERTT). EStudy Start: 2020/4/1. EStudy Completion: 2020/12/1. (12/20, "New Trial Record")
ĶJournal of Medicinal Chemistry: "Comparison of orexin 1 and orexin 2 ligand binding modes using X-ray crystallography and computational analysis" (12/20 Published)
ĶSosei HeptaresF‘n–ōuComparison of orexin 1 and orexin 2 ligand binding modes using X-ray crystallography and computational analysisvJournal of Medicinal ChemistryŽ‚Å”­•\B(12/23up)
ĶSosei HeptaresFuPfizerŽÐ‚Æ‚Ė•Ą”‚Ėƒ^[ƒQƒbƒg‚ð‘Ώۂɂĩ‚―ŒĪ‹†ŠJ”­’ņŒg‚É‚æ‚čŒĐ‚Ēo‚ģ‚ę‚―V–ōŠJ”­Œó•â•i‚Ė‰‚ß‚Ä‚Ė—Տ°ŽŽŒą‚ðŠJŽnv5•S–œ•Äƒhƒ‹(–ņ5‰­4700–œ‰~)‚Ėƒ}ƒCƒ‹ƒXƒgƒ“‚ðŽó—Ė‚·‚éB(12/23)
ĶSosei HeptaresFuPfizerŽÐ‚Æ‚Ė•Ą”‚Ėƒ^[ƒQƒbƒg‚ð‘Ώۂɂĩ‚―ŒĪ‹†ŠJ”­’ņŒg‚É‚Ļ‚Ē‚ÄŽO”Ô–Ú‚Ė—Տ°ŠJ”­Œó•â•ĻŽŋ‚ð‘novV‚―‚É3•S–œ•Äƒhƒ‹(–ņ3‰­2800–œ‰~)‚Ėƒ}ƒCƒ‹ƒXƒgƒ“‚ðŽó—Ė‚·‚éB(12/24)

176ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 00:31:02.54ID:pHvkJEwq0
ĶChemRxiv: "X-Ray Crystallography and Free Energy Calculations Reveal the Binding Mechanism of A2A Adenosine Receptor Antagonists." (12/24 Posted)
Ķ‰ĒB“Á‹–(Heptares)F"CGRP Receptor Antagonists"(European Patent EP3368526 B1). (12/25ŒöŠJ)
ĶSosei HeptaresFuƒTƒ“ƒtƒ‰ƒ“ƒVƒXƒR‚ÅŠJÃ‚Ė‘æ38‰ņ J.P.ƒ‚ƒ‹ƒKƒ“Eƒwƒ‹ƒXƒPƒAEƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚ÉŽQ‰Áv“–ŽÐCFOƒNƒŠƒXEƒJ[ƒMƒ‹‚ŠƒvƒŒƒ[ƒ“ƒe[ƒVƒ‡ƒ“(1/15 10:30)Bƒ‰ƒCƒu”zM‚ģ‚ę‚Ü‚·B(12/26)
Ķ•Ä‘“Á‹–oŠč(Heptares)F"Pharmaceutical Compounds"(US20190389849 A1). (12/26ŒöŠJ)
Ķ‘Û“Á‹–oŠč(Heptares)F"Oxadiazoles as Agonists of the Muscarinic M1 and/or M4 Receptor"(WO/2019/243850 A1). (12/26ŒöŠJ)
Ķ‘Û“Á‹–oŠč(Heptares)F"Bridged Compounds as Agonists of the Muscarinic M1 and/or M4 Receptor"(WO/2019/243851 A1). (12/26ŒöŠJ)
ĶClinicalTrials(NCT03980821): Phase 1, Study of AZD4635 in Japanese Patients with Advanced Solid Malignancies: Record Verification December 2019. (12/27update)

177ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 00:31:24.20ID:pHvkJEwq0
ĶSosei HeptaresFuV”N‚Ė‚ēˆĨŽA “c‘šáÁˆęv•ūŽÐ‚Å‚Í‘n–ō‚Ė‰Ī“đ‚ð—Í‹­‚­i‚Ý‚Č‚Š‚į‚āAŽaV‚ČŠvV“I‹Zp‚ðŒÕŽ‹ážX‚Æ‘_‚Á‚Ä‚Ē‚Ü‚·B2020”N‚ð‚ģ‚į‚Č‚é”ō–ô‚Ė”N‚É‚ĩ‚ÄŽQ‚č‚Ü‚·B(1/1)
ĶRCSB Protein Data Bank: "Crystal Structure of the Orexin-1 Receptor and Orexin-2 Receptor in Complex": 6TQ9, 6TQ7, 6TQ6, 6TQ4, 6TPN, 6TPJ, 6TPG, 6TP6, 6TP4, 6TP3, 6TOD, 6TO7. (1/1 Released)
Ķ•Ä‘“Á‹–oŠč(Heptares)F"Pharmaceutical Compounds"(US20200002328A1). (1/2ŒöŠJ)
ĶMiNA Therapeutics Publications: Molecular Therapy "Liver Activation of Hepatocellular Nuclear Factor-4a by Small Activating RNA Rescues Dyslipidemia and Improves Metabolic Profile". (1/4up)
ĶPsychopharmacology: "Lessons learned from using fMRI in the early clinical development of a mu-opioid receptor antagonist for disorders of compulsive consumption": Pradeep J. Nathan & Geor Bakker. (1/4 Published)
ĶClinicalTrials(NCT03381274): Phase 1b/2, Oleclumab(MEDI9447) EGFRm NSCLC Novel Combination Study. (MEDI9447 with Osimertinib or AZD4635, AZD4635 with MEDI9447): Record Verification January 2020. (1/6update)
ĶVectura: "Wefre looking forward to being in San Francisco for the 38th JPM Healthcare Conference Next Week"; Vectura CEO Presentation: 10:00 PST / 18:00 GMT on Thursday 16 January. (1/6)

178ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 00:31:50.32ID:pHvkJEwq0
ĶMiNA Therapeutics: "Announces Research Collaboration with AstraZeneca in Metabolic Diseases". Completion of these studies, AstraZeneca will have the option to negotiate a license agreement to further develop saRNA molecules. (1/7)
ĶRoche HP: Partnering: "Example Partnerships: "Heptares - research collaboration to discover and develop novel medicines that modulate G-protein-coupled receptor targets across a range of diseases." (1/10up, Add)
ĶSosei Heptares HPFEvents upuSosei Group 2019”N12ŒŽŠúŒˆŽZ”­•\ 2ŒŽ13“úv (1/10up)
ĶVectura Group Trading Update: "2020 Financial Guidance: Vectura Would Earn $5m Upon Approval of QVM149 in Europe and Would Earn a Low-Single Digit Royalty on Net Sales of the Product." (1/13)
ĶJ.P. Morgan Healthcare Conference: Novartis Presentation: "2020 Catalysts Maintaining Long-Term Momentum: Major Approvals: QVM / QMF 149: Asthma". (1/13 Presented)
ĶSosei HeptaresFuOrexiaŽÐ‚Ļ‚æ‚Ņ InexiaŽÐ‚É‚æ‚éƒIƒŒƒLƒVƒ“Žó—e‘Ėė“Ū–ōƒvƒƒOƒ‰ƒ€‚Ė’˜‚ĩ‚Ēi’ŧ‚É‚æ‚čMedicxiŽÐ‚Š40•S–œƒ†[ƒ(–ņ48‰­6800–œ‰~)‚ĖƒRƒ~ƒbƒgƒƒ“ƒg‚Ė‰š‚ŁAŽŸ‚Ȃ鎑‹ā’ņ‹Ÿ‚ðŽĀsv(1/14)
EEE

179ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 06:03:40.13ID:pHvkJEwq0
Today EventsF

ĶJP Morgan Healthcare Conference:
E"Sosei Group Corporation" (1/15 10:30 Presenting) Please check back in about 21 hours.
ESpeaker: "Chris Cargill, Chief Financial Officer, Sosei Group Corporation".
EWebcast: https://jpmorgan.metameetings.net/events/hc20/sessions/29872-sosei-group-corporation/webcast
Description:
We are an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR technology and structure-based drug design platform capabilities.
We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications.
We have established partnerships with some of the worldfs leading pharmaceutical companies, including Allergan, AstraZeneca, Daiichi-Sankyo, Genentech (Roche), Novartis, Pfizer and Takeda;
and with innovative biotechnology companies, including Kymab, MorphoSys and PeptiDream.
Sosei Heptares is headquartered in Tokyo, Japan with R&D facilities in Cambridge, UK.
gSosei Heptaresh is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).
Speaker Featuring:
Chris has over a decade of experience in the global financial services sector and brings an extensive range of healthcare knowledge, financial acumen and market perspective from his previous roles.
Prior to joining Sosei Heptares, Chris worked at J.P. Morgan and focused on UK life sciences advisory.

EEE

180ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 06:30:32.17ID:pHvkJEwq0
ĶSOSEI‚ĖŽ’·‘Šę‚Ė“ŪŒüFÄ‚Ņ‚Ėãļ‘Šę‚͏‡’ē‚ɐ„ˆÚ(2018/12/25:ÅˆĀ’l748ĶA2019/1/4:ˆĀ’l_780A2019/8/5:Å‚’l:2794)BÎB‹ÆŅ‘Šę‚Ö‚Ė“ŪˆÓ‘Ō‚ŋBÎB
2018/12/28 (I’l_799) 25“úü_948.64(-15.77“) E(12/25ÅˆĀ’l_748) Ķ12/1:SoseiHeptares–{ŠiŽn“Ū[Ä‚Ņ‚ĖE‚ĒęĶ][‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē’ēŪ‚ŠI—đ]
2019/_1/_4 (I’l_864) 25“úü_940.80( -8.16“) E(_1/_4ˆĀ’l_780) Ķ1/1:“c‘šCEO•œ‹AĶ1/7:AZD4635‘æ‡U‘Š[1/8ƒXƒgƒbƒv‚:I’l1078] [ãļƒgƒŒƒ“ƒh‚Ö“]Š·]
2019/_2/_1 (I’l1021) 25“úü1051.28( -2.88“) E(_1/30ˆĀ’l_985) Ķ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[’ïG(1/21ˆĀ’l1164, 1/30ˆĀ’l985)Ķ(1/21:‚’lXV:1360)
2019/_3/_1 (I’l1250) 25“úü1133.28(+10.83“) E(_2/_4ˆĀ’l1021) Ķ2/14:ŒˆŽZ Ķ2/22:IRā–ū‰ï(ˆĒ”{–ė)ĒŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—ŠĢ
2019/_4/_5 (I’l1593) 25“úü1331.60(+19.63“) E(_3/11ˆĀ’l1105) Ķ3/16:’†‘ãŽs Ķ(3/20:‚’lXV:ƒXƒgƒbƒv‚:1526) Ķ3/29:IRā–ū‰ï(–žŒÃ‰ŪE‘åã)
2019/_5/10 (I’l1486) 25“úü1494.08( -0.54“) E(_4/22ˆĀ’l1372) Ķ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[’ïG(4/11ˆĀ’l1400) Ķ(4/9:‚’lXV:1717)Ķ(5/15:‚’lXV:1743)
2019/_6/_7 (I’l2014) 25“úü1800.28(+11.87“) E(_5/13ˆĀ’l1429) Ķ5/14:Pfizeri’ŧ;‘æ1Žl”žŠúŒˆŽZ Ķ5/24:QVM149\ŋ Ķ‚’lXV:(5/22:1834)(5/23:2149)(5/28:2296)
2019/_7/_5 (I’l2338) 25“úü2172.52( +7.62“) E(_6/12ˆĀ’l1969) Ķ6/10:Pfizeri’ŧĶ6/18:IRā–ū‰ï(å‘ä) Ķ‚’lXV:(6/24:2377)(6/26:2420)(7/1:2429)(7/2:2482)
2019/_8/_2 (I’l2544) 25“úü2448.12( +3.92“) E(_7/_9ˆĀ’l2216) Ķ7/16:Genentech’ņŒgĶ(7/16ƒXƒgƒbƒv‚:‚’lXV:2773) Ķ7/18:APP13007i’ŧ
2019/_9/_6 (I’l2335) 25“úü2463.68( -5.22“) E(_8/30ˆĀ’l2179) Ķ8/5:•“c–ō•i’ņŒg Ķ8/5:‚’lXV:2794) Ķ8/13:‘æ2Žl”žŠúŒˆŽZ [—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋ]

181ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 06:30:40.76ID:pHvkJEwq0
2019/10/_4 (I’l2438) 25“úü2342.44(+4.08“) E(_9/17ˆĀ’l2088) Ķ9/12:ƒCƒ“ƒxƒXƒ^[R&D Day Ķ9/28:MTL-CEBPA’PÜ‘æ‡T‘ŠÅIŒ‹‰ĘĶ9/30:QVM149‘æ‡V‘ŠIRIDIUMŒ‹‰Ę
2019/11/_1 (I’l2570) 25“úü2385.96(+7.71“) E(10/11ˆĀ’l2130) Ķ10/9:Genentechi’ŧ
2019/12/_6 (I’l2317) 25“úü2346.72( -1.27“) E(11/15ˆĀ’l2185) Ķ11/12:‘æ3Žl”žŠúŒˆŽZĶ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[(11/13)Ķ11/28:’†‘NRDLŽûÚĶ12/6:IRā–ū‰ï(L“‡)
2019/12/30 (I’l2171) 25“úü2241.00( -3.12“) E(12/16ˆĀ’l2137) Ķ12/23:Pfizer‘æ‡T‘ŠŠJŽnĶ12/24:Pfizeri’ŧ(ŽO”Ô–Ú) Ķ2019”N‘å”[‰ï
2020/_1/_6 (I’l2117) 5“úü2211.40( -4.27“) 25“úü2235.12(-5.28“) 75“úü2322.30( -8.84“) 200“úü2115.53(+0.01“) (ˆĀ’l2110) Ķ2020”N‘å”­‰ï
2020/_1/_7 (I’l2117) 5“úü2189.20( -3.30“) 25“úü2229.88(-5.06“) 75“úü2319.32( -8.72“) 200“úü2120.30( -0.16“) (ˆĀ’l2115) Ķ1/7:MiNA Collaboration with AstraZeneca.
2020/_1/_8 (I’l2012) 5“úü2137.20( -5.86“) 25“úü2219.48(-9.35“) 75“úü2316.09(-13.13“) 200“úü2124.78( -5.31“) (ˆĀ’l1977)
2020/_1/_9 (I’l2047) 5“úü2092.80( -2.19“) 25“úü2209.80(-7.37“) 75“úü2313.70(-11.53“) 200“úü2129.23( -3.86“) (ˆĀ’l2030)
2020/_1/10 (I’l2115) 5“úü2081.60(+1.60“) 25“úü2203.64(-4.02“) 75“úü2312.40( -8.54“) 200“úü2133.80( -0.88“) (ˆĀ’l2038) E(1/8ˆĀ’l1977)
2020/_1/14 (I’l2104) 5“úü2079.00(+1.20“) 25“úü2195.48(-4.17“) 75“úü2310.85( -8.95“) 200“úü2138.24( -1.60“) (ˆĀ’l2092) Ķ1/14:Orexia&Inexiai’ŧ

182ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 06:31:07.90ID:pHvkJEwq0
X‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂāA‘O‰ņ‚Ė‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē‚Å‚Ė’ēŪ‚ŠI‚čAÄ‚Ņ‚ĖE‚Ēę(’ę’l)‚Đ‚į‚Ė…€’ųģ‚́A3”{Œ—ƒXƒe[ƒW‚ɂē‚ɐ„ˆÚBÎB—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋBÎB
VķSoseiHeptaresAŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—Š‚ā‡’ē‚ɐi“WBÎB’…ŽĀ‚ČŠg[‚Æ‹Ī‚ɁAŒo‰cí—Š‚Ė“]Š·‚É‚æ‚鍕Žš’č’…‰ŧBÎBX‚Ȃ鐎’·‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎB
X‚Č‚éÄŽ’·ŠúA‹ÆŅ‘Šę‚ցBÎBŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎBĄ‰ņ(Ä‚Ņ)‚Ėãļ‘Šę‚ā–Ę”’‚­‚Č‚čAˆŦ’n‡‚Ē‚ɂĐV”N‘Šę‚ŠŠJŽnBÎB200“úü’ēŪBÎB

183ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 07:14:03.59ID:+w+5PWjTd
ŽãŽŒîH‚͍Ą“ú‚ā100Š”ˆŽ‚č‚ĩ‚߂ăXƒŒr‚į‚·‚Ė‚Đ

184ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 08:00:15.78ID:NJtDNHLoa
‹C”z‘å–\—Žw
‹ó”„‚čŠOŽ‘—l‚ðär‚ß‚ņ‚Č‚æ

185ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 08:55:00.74ID:cmGC7JXm0
‚Ü‚―ƒJƒ“ƒtƒ@ƒŒƒ“ƒXŒã‹ó”„‚č‚Ŧ‚ŧ‚Ī

186ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 08:57:45.89ID:cmGC7JXm0
ƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚Å‹ó”„‚č‘ÎÛ‚É‚Č‚é‚Č‚į‚Ē‚­‚Č‚æ

187ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 09:05:28.40ID:fQCSNC+yp
’ę‚Å”„‚Á‚―“zwww

188ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 09:08:43.84ID:6JPo31B/0
‚ā‚Īƒ_ƒ‚ū

189ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 09:38:08.89ID:rSTWrFvGd
‚ą‚ĖƒXƒŒ‰­ƒgƒŒŒ‹\‚Ē‚é‚ņ‚ū‚Č

190ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 09:39:24.56ID:zAN2euUE0
‚Å‚ā100Š”—ëŨ‚Ė•û‚ŠƒŒƒX‚Š‘―‚Ē‚Æ‚Ē‚Ī“ä

191ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 09:52:35.53ID:cmGC7JXm0
Å‰‚Ė30•Š‚ū‚Ŋ‚Ėƒ`ƒƒ[ƒgcƒIƒƒ^c

192ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 10:03:25.22ID:cmGC7JXm0
‚ŧ‚ë‚ŧ‚뉚‚­‚é

193ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 10:05:26.94ID:cmGC7JXm0
‰š‚Ŧ‚―‚ ‚ ‚ ‚ ‚ ‚ 
Ž€‚ņ‚ū[[[[IŽ€–S‚Ļ‚ß‚Å‚Æ‚ĪIIIIŽ€–S‚Ļ‚ß‚Å‚Æ‚ĪIIII

194ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 10:06:36.41ID:cmGC7JXm0
3•Š‚Å15‰~—Ž‚ŋ‚Ļ‚ß‚Å‚Æ‚ĪIIIIII‚Ļ‚ß‚Å‚Æ‚ĪI

195ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 10:07:43.29ID:6JPo31B/0
‚ā‚Īƒ_ƒ‚ūƒIƒƒ^

196ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 10:18:11.76ID:/xCyur8s0
‚‚ę[
ŽG‹›‚ĖŒŽ‹‹•Š‚Š‚PƒeƒBƒbƒN‚Å“Ū‚­‚í[
‚‚ę[

197ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 10:18:57.48ID:cmGC7JXm0
ƒ}ƒCƒeƒ“‚Ü‚Å‚ ‚Æ13‰~

198ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 10:48:43.36ID:NJtDNHLoa
‹ó”„‚čŠOŽ‘—l‚ðär‚ß‚ņ‚Č‚æ

199ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 10:52:16.91ID:5P2udNLy0
>>197
Ąƒ}ƒCƒeƒ“‚Ü‚Å‚ ‚Æ‚Ē‚­‚įH

200ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 11:14:51.23ID:cmGC7JXm0
ƒ}ƒCƒ‹‚ā‚į‚Á‚Ä250‰~‰š—Ž‚ĩ‚Ä150‰~ƒŠƒo‚é‚Æ‘åŠė‚Ņ

201ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 11:31:34.63ID:rb/C5hy2d
ƒSƒ~’Ž‚É‚Ü‚Æ‚ā‚ɃŒƒX‚ĩ‚Ä‚ā–ģ‘Ę‚ū‚æ
—ëŨŽG‹›‚Æ‚ĐƒTƒ“ƒoƒCƒIƒLƒ`ƒKƒC‚Æ‚Đ

202ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 11:37:56.40ID:fQCSNC+yp
>>193 ‚Į‚ąŠÏ‚Ä‚ņ‚ū‚æw

203ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 12:32:53.06ID:mORMNlEZd
‚ā‚Īƒ_ƒ‚ū

204ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 13:07:04.84ID:eWvv/ylo0
‚ŋ‚å‚Ē‘Ō‚Á‚ĉš‚ģ‚Ē‚悧c

205ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 14:30:27.41ID:cmGC7JXm0
‚ą‚ęˆČã‚ą‚Ė”r‚į‚·‚â‚‚͕ŲŒėŽm‚É’Ę•ņ‚·‚é‚Đ‚į

206ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 14:44:32.64ID:n1QITZPSd
’Þ‚į‚ę‚é‚Č‚æ

207ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 15:01:42.05ID:pHvkJEwq0
ĶProtein Expression and Purification: "Production of membrane proteins in industry: The example of GPCRs". (1/14 Published)
EJames C.Erreya, CedricFiez-Vandalb. Sosei Heptares, Steinmetz Building, Granta Park, Cambridge, UK.
Highlights:
EIn this review, the authors survey the state-of-the-art gene design, expression and purification strategies, and protein thermostabilisation methods used within a modern drug discovery program, with a focus on G protein-coupled receptors.
Abstract:
Whereas membrane proteins make up ∼23% of the human proteome, it is estimated that membrane proteins constitute more than 60% of current drug targets.
With membrane proteins forming such a high percentage of drug targets relative to their abundance within the proteome, it is little wonder that drug companies need to rapidly access high quality membrane proteins for their drug discovery process.
Newly devised technologies, such as rapid low-cost gene synthesis, novel detergents, and protein thermostabilisation strategies allow conventionally gundruggableh membrane proteins to be drugged.
In this review, we survey the state-of-the-art gene design, expression and purification strategies, and protein thermostabilisation methods used within a modern drug discovery program, with a focus on G protein-coupled receptors.

EEE

208ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 15:01:55.95ID:pHvkJEwq0
ŽŸ‚Č‚é”ō–ô‚ցB’…ŽĀ‚Ȑi’ŧ‚Æ‹Ī‚ɍX‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂĐU‚é‚Ēˆį‚ŋ‚ä‚­‘ŠęBT‚Ķ‚éÞ—ŋ‚Æ‹Ī‚ɐ…€’ųģBÎB
Ž’·ŠúB—\’č‚ģ‚ę‚Ä‚Ē‚―‹ÆŅ‚Ė‹}Ž’·‚Æ‹Ī‚ɍX‚Ȃ鐎’·í—Š‚Ši“WB‡’ē‚ČR&DEPL“™‚ĖŠg[EŠg‘å‚Ė‰Á‘ŽBÎB
EEE
ĶSOSEI‚ĖŽ’·‘Šę‚Ė“ŪŒüF‘O‰ņ‚Ė‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē’ēŪ‚ŠI‚čAÄ‚Ņ‚Ėãļ(…€’ųģ)‘Šę‚͏‡’ē‚ɐ„ˆÚBÎB‹ÆŅ‘Šę‚Ö‚Ė“ŪˆÓ‘Ō‚ŋBÎB
2010/12/30 (I’l_338) E(2010/10/15ĶÅˆĀ’l_163A2010/12/27Å‚’l_437) ĶQVA149‘æ‡V‘ŠŠJŽn
2011/12/30 (I’l_318) E(2011/_3/15ĶÅˆĀ’l_173A2011/_6/30Å‚’l_420) Ķƒmƒ‹ƒŒƒ{ģ”F(2/23Ķ)
2012/12/28 (I’l_522) E(2012/_6/_6ĶÅˆĀ’l_238A2012/_9/_7Å‚’l_742) ĶSeebri‰ĒBĨ“ú–{ģ”F
2013/12/30 (I’l1079) E(2013/_1/_4ĶÅˆĀ’l_513A2013/_5/_7Å‚’l1525) ĶUltibro‰ĒBĨ“ú–{ģ”F
2014/12/30 (I’l1093) E(2014/_4/12ĶÅˆĀ’l_464A2014/_9/_8Å‚’l1500) Ķ’†’·ŠúŒv‰æ”­•\(5/13Ķ)[E‚ĒęĶ][Ž’·‰ņŽûŠú‚Ė“üŒû]

209ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 15:02:21.44ID:pHvkJEwq0
2015/12/30 (I’l2488) E(2015/_3/16ĶÅˆĀ’l_713A2015/12/14Å‚’l2645) ĶHeptares(2/20Ķ)[ŽŒũ‚Ė˜Í]ĻĶ•Ä‘ģ”F(10/30Ķ)[ŽŸ‚Č‚é”ō–ô‚Ö]
2016/12/30 (I’l3363) E(2016/_1/18ĶÅˆĀ’l2270A2016/_5/_9Å‚’l6545) ĶAllergan(4/7)[‹­‹C‘Šę]ĻĶ“úXŒö•\‰ðœ(6/28)[‹­‹C‘Šę‰ðœ]
2017/12/29 (I’l2735) E(2017/_9/_6ĶÅˆĀ’l2148A2017/_1/_6Å‚’l3645) Ķ[ã”ē‚ŊŒ—‚Å‚ĖŽžŠÔŽē’ēŪ‚͏‡’ē‚ɐ„ˆÚ]ĻĶ[U‚é‚ĒęEE‚Ēę‚Ö]
2018/12/28 (I’l_799) E(2018/12/25ĶÅˆĀ’l_748A2018/_1/25Å‚’l3195) ĶSoseiHeptaresŽn“Ū[Ä‚Ņ‚ĖE‚Ēę(’ę’l)Ķ][‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē’ēŪ‚ŠI—đ]
2019/12/30 (I’l2171) E(2019/_1/_4ĶÅˆĀ’l_780A2019/_8/_5Å‚’l2794) Ķ“c‘šCEO•œ‹AĶ[ãļƒgƒŒƒ“ƒh‚Ö“]Š·]ĶQVM149‰ĒB\ŋ(5/24) [—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋ]
2020/_1/15 (I’l2139) E(2020/_1/_8ĶÅˆĀ’l1977A2020/_1/_6Å‚’l2176) Ķ1/7:MiNA Collaboration with AstraZeneca Ķ1/14:Orexia&Inexiai’ŧ

210ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 15:02:38.88ID:pHvkJEwq0
Ä‚Ņ‚ĖE‚Ēę(’ę’l)‚Đ‚į‚Ė…€’ųģ‚Í3”{Œ—ƒXƒe[ƒW‚ɂē‚ɐ„ˆÚBÎB—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋBÎB200“úü’ēŪBÎB
ŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—Š‚́A’…ŽĀ‚ČŠg[‚Æ‹Ī‚ɁA‡’ē‚ɐi“WBÎBX‚Ȃ鐎’·‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎB
Œo‰cí—Š‚Ė“]Š·‚É‚æ‚鍕Žš’č’…‰ŧBÎBĄ‰ņ‚Ėãļ‘Šę‚ā–Ę”’‚­‚Č‚čAˆŦ’n‡‚Ē‚ɂĐV”N‘Šę‚ŠŠJŽnBÎB

211ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 15:20:33.55ID:cmGC7JXm0
‚‚Ē‚ɍĄ“ú‚Ė–éƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚Đ
–ū“úŽR‚Ų‚Į‹ó”„‚č‚ģ‚ę‚é‚ņ‚ū‚ë‚Ī‚Č

212ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 16:00:29.34ID:pHvkJEwq0
ĶƒtƒBƒXƒRFƒ}ƒU[ƒYæ•ĻŠT‹ĩF 3“ú‘ą—ŽAŽž‰ŋ‘ŠzãˆĘ–Á•ŋ‚Í‚Ü‚ŋ‚Ü‚ŋAŒˆŽZŽó‚Ŋ‚―Œ™‹C”„‚č‚ā–Ú—§‚“WŠJ‚ɁB(1/15 15:24)
15“ú‚Ėƒ}ƒU[ƒYæ•Ļ‚Í‘O“ú”ä5.0ptˆĀ‚Ė870.0pt‚Æ3“ú‘ą—Ž‚ĩ‚―B‚Č‚ĻA‚’l875.0ptAˆĀ’l‚Í870.0ptAŽæˆø‚‚Í1349–‡B
–{“ú‚Ėƒ}ƒU[ƒYæ•Ļ‚́AŽž‰ŋ‘ŠzãˆĘ–Á•ŋ‚Å–ūˆÃ‚Š•Š‚Đ‚ęA•ûŒüŠī‚É–R‚ĩ‚Ē“WŠJ‚Æ‚Č‚Á‚―B
‘O“ú‚Ė•Ä‘Žsę‚ł́A•Ä­Œ ‚Š”­“ŪÏ‚Ý‚Ė‘Î’†’Į‰ÁŠÖÅ‚ð‘哝—Ė‘IŒã‚܂ňێ‚·‚é‚Æ“`‚í‚Á‚―‚ą‚ƂŁA–fˆÕ‹Ķ‹c‚ɑ΂·‚éŠyŠÏ“I‚ČŒĐ•û‚ŠŒã‘Þ‚ĩAŽå—vŠ”‰ŋŽw”‚͍‚ˆĀ‚Ü‚ŋ‚Ü‚ŋ‚Æ‚Č‚Á‚―B
‚ą‚ę‚ðŽó‚Ŋ‚āA‹}ƒsƒbƒ`‚ʼnņ•œ‚ĩ‚Ä‚Ē‚―“úŒo•―‹ÏŠ”‰ŋ‚āð“ú‚É24000‰~‘ä‚ð‰ņ•œ‚ĩ‚―’BŽŠī‚Đ‚į—˜‰vŠm’蔄‚č‚Š—DĻ‚Æ‚Č‚Á‚―B
‚ą‚Ī‚ĩ‚―’†A–‹ŠÔŒq‚Ž“I‚ČŒ`‚ŁAƒ}ƒU[ƒYŽsę‚Å‚Í’ž‹ßIPO–Á•ŋ‚⌈ŽZ‚ðŽó‚Ŋ‚―ŒÂ•ĘŠ”•ĻF‚Š·‚ņ‚Æ‚Č‚Á‚―‚ŠA‚ą‚Ī‚ĩ‚―–Á•ŋ‚É‚ÍŽw”ƒCƒ“ƒpƒNƒg‚Š‚Č‚­A
ˆę•û‚ÅŽw”Šņ—^“x‚Ė‚‚Ē‚Æ‚ą‚ë‚ł́AŽå—Í‹‰–Á•ŋ‚Ė–ūˆÃ‚Š•Š‚Đ‚ę‚―‚―‚߁Aƒ}ƒU[ƒYæ•Ļ‚Í•ûŒüŠī‚Š’č‚Ü‚į‚ļ‚ɁAŒ‹‹ĮA3“ú‘ą—Ž‚Æ‚Č‚Á‚―B
”„”ƒ‘ã‹āãˆĘ‚ł́A‚ŧ[‚đ‚Ē‚âƒTƒ“ƒoƒCƒI‚Č‚Į‚ĖƒoƒCƒIŠÖ˜A‚͏ãļ‚ĩ‚―‚ŠAƒƒ‹ƒJƒŠ‚Ė‚Ų‚ЁAŒˆŽZ“ā—e‚ŠŒ™‹C‚ģ‚ę‚―TKP‚âUUUM‚ŠdÎ‚Æ‚Č‚Á‚―B

213ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 16:05:19.99ID:mORMNlEZd
‚ā‚Ī‚Ļ‚í‚―

214ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 16:33:36.57ID:pHvkJEwq0
M—pŽc update:
EEE
2019/_5/17 (I’l1660) ”„Žc‚110300 ”ƒŽc‚_5488000 E(5/13ˆĀ’l1429) Ķ5/14:‘æ1Žl”žŠúŒˆŽZ Ķ(5/15:‚’lXV:1743) Ķ5/22:QVM149P‡UŽŅ
2019/_5/24 (I’l2017) ”„Žc‚117700 ”ƒŽc‚_5993300 E(5/21ˆĀ’l1591) Ķ(5/22:‚’lXV:1834)(5/23:‚’lXV:2149) Ķ5/24:QVM149‰ĒB\ŋ
2019/_5/31 (I’l2012) ”„Žc‚170300 ”ƒŽc‚_6108300 E(5/27ˆĀ’l1977) Ķ(5/28:‚’lXV:2296)
2019/_6/_7 (I’l2014) ”„Žc‚_66900 ”ƒŽc‚_5748000 E(6/_6ˆĀ’l1909)
2019/_6/14 (I’l2102) ”„Žc‚_80200 ”ƒŽc‚_6196400 E(6/12ˆĀ’l1969) Ķ6/10:Pfizeri’ŧ(“ņ”Ô–Ú)
2019/_6/21 (I’l2175) ”„Žc‚_17500 ”ƒŽc‚_6136200 E(6/20ˆĀ’l2030) Ķ6/18:IRā–ū‰ï(å‘ä)ĒŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—ŠĢ
2019/_6/28 (I’l2369) ”„Žc‚_36900 ”ƒŽc‚_5815600 E(6/24ˆĀ’l2184) Ķ(6/24:‚’lXV:2377)(6/26:‚’lXV:2420)
2019/_7/_5 (I’l2338) ”„Žc‚_18600 ”ƒŽc‚_6649200 E(7/_5ˆĀ’l2237) Ķ(7/_1:‚’lXV:2429)(7/_2:‚’lXV:2482)
2019/_7/12 (I’l2273) ”„Žc‚_52600 ”ƒŽc‚_6529400 E(7/_9ˆĀ’l2216)

215ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 16:33:51.27ID:pHvkJEwq0
2019/_7/19 (I’l2609) ”„Žc‚_15900 ”ƒŽc‚_7363700 E(7/16ˆĀ’l2150) Ķ7/16:Genentech’ņŒgĶ(7/16ƒXƒgƒbƒv‚:‚’lXV:2773) Ķ7/18:APP13007i’ŧ
2019/_7/26 (I’l2448) ”„Žc‚118300 ”ƒŽc‚_7845300 E(7/24ˆĀ’l2410)
2019/_8/_2 (I’l2544) ”„Žc‚_70500 ”ƒŽc‚_7547100 E(7/29ˆĀ’l2466)
2019/_8/_9 (I’l2653) ”„Žc‚_17500 ”ƒŽc‚_7379100 E(8/_5ˆĀ’l2501) Ķ8/_5:•“c–ō•i’ņŒg Ķ8/_5:”N‰—ˆ‚’lXV:2794)
2019/_8/16 (I’l2413) ”„Žc‚_ 8600 ”ƒŽc‚_8270500 E(8/16ˆĀ’l2375) Ķ8/13:‘æ2Žl”žŠúŒˆŽZ
2019/_8/23 (I’l2512) ”„Žc‚_31400 ”ƒŽc‚_7709300 E(8/19ˆĀ’l2326)
2019/_8/30 (I’l2282) ”„Žc‚_41800 ”ƒŽc‚_7902200 E(8/30ˆĀ’l2179)
2019/_9/_6 (I’l2335) ”„Žc‚_64000 ”ƒŽc‚_7796800 E(9/_2ˆĀ’l2242)
2019/_9/13 (I’l2226) ”„Žc‚_11400 ”ƒŽc‚_8097700 E(9/13ˆĀ’l2207) Ķ9/12: R&D Day

216ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 16:34:05.94ID:pHvkJEwq0
2019/_9/20 (I’l2335) ”„Žc‚_12100 ”ƒŽc‚_7592600 E(9/17ˆĀ’l2088)
2019/_9/27 (I’l2459) ”„Žc‚_ 3000 ”ƒŽc‚_7458200 E(9/24ˆĀ’l2341) Ķ9/28:MTL-CEBPA’PÜ‘æ‡T‘ŠÅIŒ‹‰Ę
2019/10/_4 (I’l2430) ”„Žc‚_ 4400 ”ƒŽc‚_7542100 E(9/30ˆĀ’l2347) Ķ9/30:QVM149‘æ‡V‘ŠIRIDIUMŒ‹‰Ę
2019/10/11 (I’l2150) ”„Žc‚_ 5300 ”ƒŽc‚_7981900 E(10/11ˆĀ’l2130) Ķ10/9:Genentechi’ŧ
2019/10/18 (I’l2307) ”„Žc‚_17800 ”ƒŽc‚_7631200 E(10/15ˆĀ’l2139)
2019/10/25 (I’l2403) ”„Žc‚_19300 ”ƒŽc‚_7333100 E(10/21ˆĀ’l2276)
2019/11/_1 (I’l2570) ”„Žc‚_18500 ”ƒŽc‚_6321100 E(10/28ˆĀ’l2415)
2019/11/_8 (I’l2477) ”„Žc‚_10800 ”ƒŽc‚_6694700 E(11/_8ˆĀ’l2468)
2019/11/15 (I’l2240) ”„Žc‚___500 ”ƒŽc‚_7921300 E(11/15ˆĀ’l2185) Ķ11/12:‘æ3Žl”žŠúŒˆŽZ
2019/11/22 (I’l2337) ”„Žc‚__3600 ”ƒŽc‚_7675600 E(11/18ˆĀ’l2224)

217ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/15(…) 16:34:29.16ID:pHvkJEwq0
2019/11/29 (I’l2289) ”„Žc‚__2900 ”ƒŽc‚_8038400 E(11/27ˆĀ’l2230) Ķ11/28: Ultibro’†‘NRDLŽûÚ
2019/12/_6 (I’l2317) ”„Žc‚__6300 ”ƒŽc‚_7928100 E(12/_6ˆĀ’l2218) Ķ12/6:IRā–ū‰ï(L“‡)
2019/12/13 (I’l2205) ”„Žc‚__1600 ”ƒŽc‚_8433000 E(12/13ˆĀ’l2204)
2019/12/20 (I’l2165) ”„Žc‚__2400 ”ƒŽc‚_8335900 E(12/16ˆĀ’l2137)
2019/12/27 (I’l2269) ”„Žc‚__7200 ”ƒŽc‚_7743600 E(12/24ˆĀ’l2146) Ķ12/23:Pfizer‘æ‡T‘ŠŠJŽnĶ12/24:Pfizeri’ŧ(ŽO”Ô–Ú)
2019/12/30 (I’l2171) ”„Žc‚__7200 ”ƒŽc‚_7743600 E(12/30ˆĀ’l2162) Ķ2019”N‘å”[‰ï
2020/_1/10 (I’l2115) ”„Žc‚__7300 ”ƒŽc‚_7992900(+249300)Ķ1/15up E(1/8ˆĀ’l1977) Ķ1/6:‘å”­‰ïŽn’l2150 Ķ1/7:MiNA Collaboration with AstraZeneca
2020/_1/14 (I’l2104) 5“úü2079.00(+1.20“) 25“úü2195.48(-4.17“) 75“úü2310.85(-8.95“) 200“úü2138.24(-1.60“) (ˆĀ’l2092) Ķ1/14:Orexia&Inexiai’ŧ
2020/_1/15 (I’l2139) 5“úü2083.40(+2.67“) 25“úü2188.36(-2.26“) 75“úü2309.37(-7.38“) 200“úü2142.99(-0.19“) (ˆĀ’l2108)
EEE

218ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 00:30:00.59ID:+16rRsYS0
ŽŸ‚Č‚é”ō–ô‚ցB’…ŽĀ‚Ȑi’ŧ‚Æ‹Ī‚ɍX‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂĐU‚é‚Ēˆį‚ŋ‚ä‚­‘ŠęBT‚Ķ‚éÞ—ŋ‚Æ‹Ī‚ɐ…€’ųģBÎB
Ž’·ŠúB—\’č‚ģ‚ę‚Ä‚Ē‚―‹ÆŅ‚Ė‹}Ž’·‚Æ‹Ī‚ɍX‚Ȃ鐎’·í—Š‚Ši“WB‡’ē‚ČR&DEPL“™‚ĖŠg[EŠg‘å‚Ė‰Á‘ŽBÎB
EEE
ĶSosei HeptaresFuCOPDŽĄ—ÖōƒEƒ‹ƒeƒBƒuƒ‚Ė’†‘‚Å‚Ė‘‰Æˆã—ÕیŊžŠŌˆã–ō•iƒŠƒXƒg(NRDL)‚Ö‚ĖŽûÚvNRDL‚́A‘SŠz‚ā‚ĩ‚­‚Íˆę•”‚ŠŒö“I•ÛŒŊ‚ŏžŠŌ‚ģ‚ę‚éˆã–ō•iƒŠƒXƒgB2019”N3ŒŽ‚É’†‘”Ė”„ŠJŽnÏB(11/28)
ĶƒAƒCƒtƒBƒXŠ”—\•ņFƒVƒeƒBGA‚ŧ[‚đ‚ĒGƒŒ[ƒeƒBƒ“ƒO‚ð‹­‹C(”ƒ‚Ē(1))Œp‘ąB–Ú•WŠ”‰ŋ‚Í3,700‰~(8/23)Ļ3,600‰~(12/4)‚Ɉø‚Ŧ‰š‚°B–Ú•WŠ”‰ŋƒRƒ“ƒZƒ“ƒTƒX‚Í2,971‰~(8/26)Ļ2,957‰~(ƒAƒiƒŠƒXƒg”7l)B(12/5up)
ĶŽl‹G•ņ(“Œ—mŒoÏ)Fy4565F‚ŧ[‚đ‚ĒƒOƒ‹[ƒvzF(‹ÆŅ—\‘z11/21XVAæŽæ‚č12/3”zMAŽl‹G•ņ12/13XVE”­”„)
y•Žš’č’…zV‹K’ņŒg‚É‚æ‚éˆęŽž‹ā“™Žû“üãæ‚đBŒĪ‹†ŠJ”­ƒRƒXƒg—}§‚ō•Žš•‚ãB20”N12ŒŽŠú‚ÍŠų‘ķ’ņŒgi’ŧ‚Ėƒ}ƒCƒ‹ƒXƒg[ƒ“A”Ė”„ƒƒCƒ„ƒ‹ƒeƒB‚ɐV‹K’ņŒg‚ĖˆęŽž‹ā“™Žû“ü‰Á‚í‚éBŒĪ‹†ŠJ”­”ï“™ƒRƒXƒgˆģk—]’nkŽ‚āAŽ•‰c‹Æ‘‰vB
y”ŽÔzŽ–‹ÆŠJ”­‹­‰ŧ‚ĩ‚Ä‘O—Տ°’iŠK‚Đ‚į‚ĖÏ‹É’ņŒgí—Š‚ð‰Á‘ŽB’ņŒgæE‰pƒAƒXƒgƒ‰ƒ[ƒlƒJ‚Ė‚Š‚ņ‘ΏÛ2ŽĄŒą‚Ėi’ŧ‡’ēB
E2019”N12ŒŽŠú—\‘zF”„ã‚10,600•S–œ‰~A‰c‹Æ—˜‰v 1,600•S–œ‰~AŒoí—˜‰v1,600•S–œ‰~A“–Šú—˜‰v1,500•S–œ‰~A1Š”‰v 19.5‰~
E2020”N12ŒŽŠú—\‘zF”„ã‚10,800•S–œ‰~A‰c‹Æ—˜‰v 1,700•S–œ‰~AŒoí—˜‰v1,700•S–œ‰~A“–Šú—˜‰v1,550•S–œ‰~A1Š”‰v 20.1‰~

219ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 00:30:09.49ID:+16rRsYS0
ĶSosei HeptaresFuPfizerŽÐ‚Æ‚Ė•Ą”‚Ėƒ^[ƒQƒbƒg‚ð‘Ώۂɂĩ‚―ŒĪ‹†ŠJ”­’ņŒg‚É‚æ‚čŒĐ‚Ēo‚ģ‚ę‚―V–ōŠJ”­Œó•â•i‚Ė‰‚ß‚Ä‚Ė—Տ°ŽŽŒą‚ðŠJŽnv5•S–œ•Äƒhƒ‹(–ņ5‰­4700–œ‰~)‚Ėƒ}ƒCƒ‹ƒXƒgƒ“‚ðŽó—Ė‚·‚éB(12/23)
EPfizerŽÐ‚É‚æ‚čV–ōŠJ”­Œó•â•i‚ðƒqƒg‚֏‰“Š—^‚·‚é—Տ°ŽŽŒą‚ŠŠJŽnB–{V–ōŠJ”­Œó•â•i‚Í–ĒŒö•\‚ĖGPCRƒ^[ƒQƒbƒg‚ɍė—p‚·‚éŒoŒû’á•ŠŽqƒ‚ƒWƒ…ƒŒ[ƒ^[B
ĶƒAƒCƒtƒBƒXŠ”—\•ņFSMBC“ú‹ŧØŒ”A‚ŧ[‚đ‚ĒGƒŒ[ƒeƒBƒ“ƒO‚ð’†—§(2)Œp‘ąB–Ú•WŠ”‰ŋ‚Í2,400‰~(7/11)Ļ2,000‚Ɉø‚Ŧ‰š‚°B–Ú•WŠ”‰ŋƒRƒ“ƒZƒ“ƒTƒX‚Í2,957‰~(12/5)Ļ2,900‰~(ƒAƒiƒŠƒXƒg”7l)B(12/23)
ESMBC“ú‹ŧØŒ”‚ł́AuŠ”ŽŪŽsę‚Đ‚į•]‰ŋ‚ģ‚ę‚é‚É‚ÍHeptares‚ĖŠJ”­ƒpƒCƒvƒ‰ƒCƒ“‚Ši“W‚·‚é‚ą‚Æ‚Šd—v‚É‚Č‚évBAZD4635‚ĖPhase2ƒtƒ‹ƒf[ƒ^‚Å‚ĖˆĀ‘SŦE—LŒøŦ‚ĖŽĀØAHTL0018318‚ĖŽĄŒąÄŠJ‚ŠŠ”‰ŋãļ‚ĖŒ_‹@‚Æ‚Č‚é‚Æ‘z’čB
E–Ú•WŠ”‰ŋ2000‰~‚́AĄŒã10”NŠÔ‚Ė“ŊØŒ”‹ÆŅ—\‘z‚ðŠî‚É‚ĩ‚ÄDCFƒ‚ƒfƒ‹‚ÅŽZo‚ģ‚ę‚Ä‚Ē‚éBSMBC“ú‹ŧØŒ”‚ł́A‹ÆŅ—\‘z‚ðXVB
E2019”N12ŒŽŠú—\‘zF”„ã‚ 9,087•S–œ‰~A‰c‹Æ—˜‰v1,087•S–œ‰~AÅ‘O—˜‰v1,087•S–œ‰~A“–Šú—˜‰v ,924•S–œ‰~A1Š”‰v12.1‰~
E2020”N12ŒŽŠú—\‘zF”„ã‚ 8,661•S–œ‰~A‰c‹Æ—˜‰v ,689•S–œ‰~AÅ‘O—˜‰v ,586•S–œ‰~A“–Šú—˜‰v ,498•S–œ‰~A1Š”‰v6.8‰~
E2021”N12ŒŽŠú—\‘zF”„ã‚ 8,821•S–œ‰~A‰c‹Æ—˜‰v ,646•S–œ‰~AÅ‘O—˜‰v ,646•S–œ‰~A“–Šú—˜‰v ,549•S–œ‰~A1Š”‰v 7.5‰~

220ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 00:30:35.94ID:+16rRsYS0
ĶReutersFy4565FSosei Groupz2019-2021‹ÆŅ—\‘zƒRƒ“ƒZƒ“ƒTƒX(Number of Analysts 6; Average Target Price 2,950 JP)F(12/24update)
E2019”N12ŒŽŠú—\‘zF”„ã‚ 8,894•S–œ‰~AEBITDA 6,045•S–œ‰~A‰c‹Æ—˜‰v 1,851•S–œ‰~AÅ‘O—˜‰v 4,704•S–œ‰~A“–Šú—˜‰v 3,458•S–œ‰~A1Š”‰v 45.3‰~
E2020”N12ŒŽŠú—\‘zF”„ã‚11,444•S–œ‰~AEBITDA 6,887•S–œ‰~A‰c‹Æ—˜‰v 4,689•S–œ‰~AÅ‘O—˜‰v 5,225•S–œ‰~A“–Šú—˜‰v 4,313•S–œ‰~A1Š”‰v 56.5‰~
E2021”N12ŒŽŠú—\‘zF”„ã‚14,206•S–œ‰~AEBITDA 7,510•S–œ‰~A‰c‹Æ—˜‰v 6,802•S–œ‰~AÅ‘O—˜‰v 6,907•S–œ‰~A“–Šú—˜‰v 5,000•S–œ‰~A1Š”‰v 72.7‰~
ĶSosei HeptaresFuPfizerŽÐ‚Æ‚Ė•Ą”‚Ėƒ^[ƒQƒbƒg‚ð‘Ώۂɂĩ‚―ŒĪ‹†ŠJ”­’ņŒg‚É‚Ļ‚Ē‚ÄŽO”Ô–Ú‚Ė—Տ°ŠJ”­Œó•â•ĻŽŋ‚ð‘novV‚―‚É3•S–œ•Äƒhƒ‹(–ņ3‰­2800–œ‰~)‚Ėƒ}ƒCƒ‹ƒXƒgƒ“‚ðŽó—Ė‚·‚éB(12/24)
E–{V‹KŒó•â•ĻŽŋ‚́A‘ãŽÓŦŽūŠģ‚â‚ŧ‚Ė‘ž‚ĖŽūŠģ‚ÉŠÖŒW‚·‚éGPCR‚ð•W“I‚Æ‚·‚éŒoŒû’á•ŠŽq‚Å‚·BPfizerŽÐ‚Í2019”N’†‚ÉŽO‚‚ĖˆŲ‚Č‚é—Տ°ŠJ”­Œó•â•ĻŽŋ‚ð‘I’č‚ĩA‚Ī‚ŋˆę‚‚͍ŋ߁A‰‚ß‚Ä‚Ė—Տ°ŽŽŒą‚ðŠJŽn‚ĩ‚―B
E“–ŽÐƒOƒ‹[ƒv‚Š–{”N’†‚É PfizerŽÐ‚Đ‚įŽó—Ė‚·‚é‚ą‚Æ‚Æ‚Č‚Á‚―d—v‚Čƒ}ƒCƒ‹ƒXƒgƒ“‚Í–{Œ‚ðŠÜ‚ߍ‡Œv14•S–œ•Äƒhƒ‹‚É‚Č‚č‚Ü‚·B
ĶSosei HeptaresFuƒTƒ“ƒtƒ‰ƒ“ƒVƒXƒR‚ÅŠJÃ‚Ė‘æ38‰ņJ.P.ƒ‚ƒ‹ƒKƒ“Eƒwƒ‹ƒXƒPƒAEƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚ÉŽQ‰Áv2020”N1ŒŽ15“ú(•Ä‘ŽžŠÔ10:30)A“–ŽÐCFO‚ĖƒNƒŠƒXEƒJ[ƒMƒ‹‚ŠƒvƒŒƒ[ƒ“ƒe[ƒVƒ‡ƒ“‚ðs‚Ē‚Ü‚·Bƒ‰ƒCƒu”zM‚ģ‚ę‚Ü‚·B(12/26)
Ehttps://jpmorgan.metameetings.net/events/hc20/sessions/29872-sosei-group-corporation/webcast
E"The live webcast has not started yet. Please check back in about 3 hour".

221ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 00:31:44.01ID:+16rRsYS0
ĶSosei HeptaresFuV”N‚Ė‚ēˆĨŽA ‘ã•\Ž·s–ð‰ï’·Œ“ŽÐ’· CEO “c‘šáÁˆęv(1/1)
E•W“I‚ĖģŠm‚ȍ\‘Ē‚ðŒˆ’č‚ĩ‚―ã‚Å•ŠŽqÝŒv‚ðs‚Īãk–§‚Č‘n–ō‹Zp‚Š•K—v‚Å‚·‚ŠA•ūŽÐ‚É‚Í‚ŧ‚Ė”õ‚Ķ‚Š‚ ‚č‚Ü‚·BŒŧŽž“_‚Å‚ÍGPCR‚É“Á‰ŧ‚ĩ‚Ä‚Ē‚Ü‚·‚ŠA“Ŋ‚ķ‹Zp‚ð‚ŧ‚ęˆČŠO‚Ė–Œƒ^ƒ“ƒpƒNŽŋ‚Ė•W“I‚É‚ā“K—p‚Å‚Ŧ‚Ü‚·B
E•ūŽÐ‚Å‚Í‘n–ō‚Ė‰Ī“đ‚ð—Í‹­‚­i‚Ý‚Č‚Š‚į‚āAŽaV‚ČŠvV“I‹Zp‚ðŒÕŽ‹ážX‚Æ‘_‚Á‚Ä‚Ē‚Ü‚·B56”NU‚č‚Ė“Œ‹žƒIƒŠƒ“ƒsƒbƒN‚ðŒ}‚Ķ‚é2020”N‚ð‚ģ‚į‚Č‚é”ō–ô‚Ė”N‚É‚ĩ‚ÄŽQ‚č‚Ü‚·B
ĶMiNA Therapeutics Publications: Molecular Therapy, Nucleic Acids Vol. 19 March 2020: "Liver Activation of Hepatocellular Nuclear Factor-4a by Small Activating RNA Rescues Dyslipidemia and Improves Metabolic Profile". (1/4up)
ĶMiNA Therapeutics: "MiNA Therapeutics Announces Research Collaboration with AstraZeneca in Metabolic Diseases". (1/7)
EThe collaboration combines MiNA's leading expertise in the discovery and development of saRNA therapeutics with AstraZeneca's experience in identifying and bringing breakthrough treatments to patients with metabolic diseases.
EUnder the terms of the agreement MiNA and AstraZeneca will conduct in vitro and in vivo studies that may enable the future development of saRNA therapeutics to treat metabolic diseases through biological pathways not addressable by conventional treatment strategies.
EUpon completion of these studies, AstraZeneca will have the option to negotiate a license agreement to further develop saRNA molecules that activate an undisclosed gene target identified by AstraZeneca.

222ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 00:32:09.95ID:+16rRsYS0
ĶƒAƒCƒtƒBƒXŠ”—\•ņFy4565F‚ŧ[‚đ‚ĒƒOƒ‹[ƒvz2019-2021‹ÆŅ—\‘zƒRƒ“ƒZƒ“ƒTƒX(ƒAƒiƒŠƒXƒg”6l)F(Ķ1/9XV)
E2019”N12ŒŽŠú‹ÆŅ—\‘zF”„ã‚11,099•S–œ‰~A‰c‹Æ—˜‰v 2,745•S–œ‰~AŒoí—˜‰v 2,899•S–œ‰~A“–Šú—˜‰v 2,479•S–œ‰~
E2020”N12ŒŽŠú‹ÆŅ—\‘zF”„ã‚10,820•S–œ‰~A‰c‹Æ—˜‰v 2,598•S–œ‰~AŒoí—˜‰v 1,572•S–œ‰~A“–Šú—˜‰v 1,291•S–œ‰~
E‚ŧ[‚đ‚ĒƒOƒ‹[ƒv‚ĖŒoí—˜‰v—\‘zƒRƒ“ƒZƒ“ƒTƒX‚́A‘OT’l‚Ė1,912•S–œ‰~‚Đ‚į51.6%ãļ‚ĩA2,899•S–œ‰~‚Æ‚Č‚Á‚―Bˆö‚݂ɃŒ[ƒeƒBƒ“ƒOƒRƒ“ƒZƒ“ƒTƒX‚Í4.0‚Å•Ï‚í‚į‚ļ‚Ė‚܂܁B
ĶVectura Group Trading Update: "2020 Financial Guidance: Vectura Would Earn $5m Upon Approval of QVM149 in Europe and Would Earn a Low-Single Digit Royalty on Net Sales of the Product." (1/13)
ĶJ.P. Morgan Healthcare Conference: Novartis Presentation: "2020 Catalysts Maintaining Long-Term Momentum: Major Approvals: QVM / QMF 149: Asthma". (1/13 Presented)
ĶSosei HeptaresFuOrexiaŽÐ‚Ļ‚æ‚Ņ InexiaŽÐ‚É‚æ‚éƒIƒŒƒLƒVƒ“Žó—e‘Ėė“Ū–ōƒvƒƒOƒ‰ƒ€‚Ė’˜‚ĩ‚Ēi’ŧ‚É‚æ‚čMedicxiŽÐ‚Š40•S–œƒ†[ƒ(–ņ48‰­6800–œ‰~)‚ĖƒRƒ~ƒbƒgƒƒ“ƒg‚Ė‰š‚ŁAŽŸ‚Ȃ鎑‹ā’ņ‹Ÿ‚ðŽĀsv(1/14)
EˆĀ’č‰ŧ‚ģ‚ę‚―ƒIƒŒƒLƒVƒ“Žó—e‘Ė(StaR)ƒAƒSƒjƒXƒg“‡Œ^”zĀ‚É‚æ‚čAÚŨ‚ȍ\‘Ē“I“īŽ@‚ð“ū‚é‚Æ‚Æ‚ā‚ɁA‚ą‚ę‚Ü‚Å‚É‚Č‚Ē‘n–ōƒAƒvƒ[ƒ`‚ðĖ—p‚·‚é‚ą‚ƂŁAŒoŒû‚Ļ‚æ‚Ņ•@o“ā“Š—^‚Ė‰Â”\Ŧ‚ðŽ‚ÂA‘I‘ðŦ‚Š‚‚­‹­—Í‚Č•ŠŽq‚Ė‘nŧ‚Š‰Â”\‚É‚Č‚č‚Ü‚·B
E‚ą‚Ėd—v‚ЂŠė‚΂ĩ‚Ēi’ŧ‚É‚æ‚čAMedicxiŽÐ‚Đ‚į‚ĖƒRƒ~ƒbƒg‚𔚂ĪŽŸ‚Ȃ鎑‹ā’ņ‹Ÿ‚ð‰Â”\‚É‚ģ‚đA‚ą‚ę‚į‚Ė”ņí‚É—L–]‚Č•ŠŽq‚ðv‘Ž‚ɗՏ°ŽŽŒą‚ւƐi‚ß‚Ä‚Ē‚­‚―‚ß‚ÉŽg‚í‚ę‚Ü‚·B
EEE

223ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 01:11:11.73ID:lkjvMPqM0
>>222
Œļ‰v—\‘z‚Ёc‚â‚΂Ē‚ȁc

224ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 01:19:59.72ID:MQTeLKiD0
>>223
‚ą‚Ėæ‚Į‚ņ‚Č’ņŒg‚â“ąo‚Š‚ ‚é‚Đ‚í‚Đ‚į‚Č‚Ē’iŠK‚ŋɂ߂čT‚Ķ‚ß‚É—§‚Ä‚―‚Å‚ ‚ë‚Ī—ˆ”N“x‚Ė—\‘z‚ð‚ā‚Á‚ÄŒļ‰v—\‘z‚ÄŒū‚Ī‚ĖH

225ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 01:27:18.65ID:Y3qVVquUd
>>224
Šî’nŠOƒTƒ“ƒoƒCƒIƒ}ƒ“‚ɉ―Œū‚Á‚Ä‚ā–ģ‘Ę

226ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 01:33:47.24ID:MQTeLKiD0
>>225‚Ü‚ ‚Ë
‚Å‚ā2”N˜A‘ą‚Ė•Žš—\‘z‚É‚Í>>223‚āˆŲ˜_‚Í‚Č‚Ē‚Ý‚―‚Ē‚ū‚Ëw

227ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 01:39:41.86ID:Y3qVVquUd
>>226
1/9‚Å2019‚Ė—\‘z‚Š1.5”{‚É‚Č‚Á‚ŋ‚á‚Á‚―‚Đ‚į
2020‚Š­‚Č‚­ŒĐ‚Ķ‚ŋ‚á‚Á‚―‚ū‚Ŋ‚Č‚ņ‚æ‚Ë

—š—ðŒĐ‚ę‚ΕŠ‚Đ‚é

228ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 04:05:38.94ID:un/1S7rz0
I‚í‚Á‚―
‹C‚É‚Č‚Á‚―“_
ƒmƒ‹ƒEƒF[‚ƃuƒ‰ƒbƒNƒƒbƒN‚ŠŽ‚Á‚Ä‚Ē‚é
CGRP‚Ši‚Ý‚ŧ‚Ī

229ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 06:00:04.06ID:+16rRsYS0
Ķ‰ĒB“Á‹–oŠč(MiNA): "C/EBP Alpha Short Activating RNA Compositions and Methods of Use" (1/15ŒöŠJ)
EDocument Type and Number: European Patent Application EP3594348 A1
EPublication Date: 2020/01/15
EAssignee: MiNA Therapeutics Limited
Abstract:
The invention relates to saRNA targeting a C/EBPƒŋ transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.
http://www.freepatentsonline.com/EP3594348A1.pdf

ĶJ.P. Morgan Healthcare Conference: Sosei Group Presentation: Sosei Heptares "Drug Dscovery and Erly Dvelopment Trgeting GPCRs": Chris Cargil. (1/15 Presented)
Robust FY2020 Outlook: Expected Events in 2020:
ESeed Next Wave of Pre-Discovery Projects.
EContinued Delivery of Candidates In-House and for Partners.
EProgress Existing Partnered Programs.
ENew Collaborations and Partnerships with World Leaders.
https://jpmorgan.metameetings.net/events/hc20/sessions/29872-sosei-group-corporation/webcast

EEE

230ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 06:13:57.90ID:MbgWLEtN0
‚Ļ‚Ē“c’†I
‘æˆęŽO‹Ī’ņŒg‰ðÁƒŠƒXƒN‚Æ‚ĐŸŽč‚ÉŒū‚Á‚Ä‚â‚Š‚Á‚―‚Š‘ą‚Ē‚Ä‚é‚ķ‚á‚ņ‚Đ‚æI

231ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 06:29:59.87ID:+16rRsYS0
ĶSosei Group ‹ÆŅ‚Ė•Ï‘JF
E2010”N03ŒŽŠúŽĀŅF”„ã‚__ 919•S–œ‰~A‰c‹Æ—˜‰v-1,854•S–œ‰~AÅ‘O—˜‰v-1,781•S–œ‰~Aƒ—˜‰v-1,769•S–œ‰~A1Š”‰v-150.0‰~
E2011”N03ŒŽŠúŽĀŅF”„ã‚__ 716•S–œ‰~A‰c‹Æ—˜‰v-1,876•S–œ‰~AÅ‘O—˜‰v-1,962•S–œ‰~Aƒ—˜‰v-1,871•S–œ‰~A1Š”‰v-158.6‰~
E2012”N03ŒŽŠúŽĀŅF”„ã‚__ 862•S–œ‰~A‰c‹Æ—˜‰v-1,962•S–œ‰~AÅ‘O—˜‰v-1,950•S–œ‰~Aƒ—˜‰v-1,954•S–œ‰~A1Š”‰v-165.1‰~
E2013”N03ŒŽŠúŽĀŅF”„ã‚ 1,958•S–œ‰~A‰c‹Æ—˜‰v_ -953•S–œ‰~AÅ‘O—˜‰v_ -788•S–œ‰~Aƒ—˜‰v_ -646•S–œ‰~A1Š”‰v-54.5‰~
E2014”N03ŒŽŠúŽĀŅF”„ã‚ 2,069•S–œ‰~A‰c‹Æ—˜‰v-1,185•S–œ‰~AÅ‘O—˜‰v-1,065•S–œ‰~Aƒ—˜‰v_ -122•S–œ‰~A1Š”‰v -2.5‰~
E2015”N03ŒŽŠúŽĀŅF”„ã‚ 3,671•S–œ‰~A‰c‹Æ—˜‰v 1,108•S–œ‰~AÅ‘O—˜‰v 1,366•S–œ‰~Aƒ—˜‰v__ 568•S–œ‰~A1Š”‰v 10.3‰~
E2016”N03ŒŽŠúŽĀŅF”„ã‚ 8,151•S–œ‰~A‰c‹Æ—˜‰v 1,075•S–œ‰~AÅ‘O—˜‰v-3,297•S–œ‰~Aƒ—˜‰v-1,432•S–œ‰~A1Š”‰v-23.4‰~
E2017”N03ŒŽŠúŽĀŅF”„ã‚18,901•S–œ‰~A‰c‹Æ—˜‰v12,398•S–œ‰~AÅ‘O—˜‰v12,483•S–œ‰~Aƒ—˜‰v9,311•S–œ‰~A1Š”‰v137.8‰~
E2018”N03ŒŽŠúŽĀŅF”„ã‚ 6,955•S–œ‰~A‰c‹Æ—˜‰v-2,291•S–œ‰~AÅ‘O—˜‰v-3,702•S–œ‰~Aƒ—˜‰v-2,654•S–œ‰~A1Š”‰v-37.5‰~
E2018”N12ŒŽŠúŽĀŅF”„ã‚ 2,872•S–œ‰~A‰c‹Æ—˜‰v-5,734•S–œ‰~AÅ‘O—˜‰v-7,243•S–œ‰~Aƒ—˜‰v-5,977•S–œ‰~A1Š”‰v-78.4‰~
2019”N12ŒŽŠúF
E‘æ1Žl”žŠúŽĀŅ(_5/14)F”„ã‚3,136•S–œ‰~A‰c‹Æ—˜‰v1,061•S–œ‰~AÅ‘O—˜‰v929•S–œ‰~Aƒ—˜‰v1,018•S–œ‰~A1Š”‰v13.3‰~
E‘æ2Žl”žŠúŽĀŅ(_8/13)F”„ã‚5,056•S–œ‰~A‰c‹Æ—˜‰v ,731•S–œ‰~AÅ‘O—˜‰v ,292•S–œ‰~Aƒ—˜‰v ,395•S–œ‰~A1Š”‰v5.13‰~
E‘æ3Žl”žŠúŽĀŅ(11/12)F”„ã‚7,770•S–œ‰~A‰c‹Æ—˜‰v1,094•S–œ‰~AÅ‘O—˜‰v1,142•S–œ‰~Aƒ—˜‰v1,461•S–œ‰~A1Š”‰v18.9‰~
ĶSosei Group 2019”N12ŒŽŠúŒˆŽZ”­•\EŒˆŽZā–ū (2/13Ķ)
EEE

232ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 06:30:16.74ID:+16rRsYS0
ĶSOSEI‚ĖŽ’·‘Šę‚Ė“ŪŒüF‘O‰ņ‚Ė‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē‚Å‚Ė’ēŪ‚ŠI‚čAÄ‚Ņ‚Ė’ę’l(2018/12/25:ÅˆĀ’l748)‚Đ‚į‚Ėãļ‘Šę‚͏‡’ē‚ɐ„ˆÚBÎB‹ÆŅ‘Šę‚Ö‚Ė“ŪˆÓ‘Ō‚ŋBÎB
2014/_4/25 (I’l_515) ”„Žc‚144800 ”ƒŽc‚_4212800 E(2014/_4/22ÅˆĀ’l_464) Ķ’†’·ŠúŒv‰æ”­•\(5/13Ķ)[E‚ĒęĶ][Ž’·‰ņŽûŠú‚Ė“üŒû]ƒXƒe[ƒW‚Ö
2015/_2/20 (I’l_945) ”„Žc‚_56800 ”ƒŽc‚_6123200 E(2015/_3/16ÅˆĀ’l_713) ĶHeptares(2/20Ķ)[ŽŒũ‚Ė˜ÍƒXƒe[ƒW]
2015/10/30 (I’l1080) ”„Žc‚_45600 ”ƒŽc‚_8871600 E(2015/_9/24ˆĀ’l_888) Ķ•Ä‘ģ”F[ŽŸ‚Č‚é”ō–ôƒXƒe[ƒW‚Ö]Ķ’ņŒg[ã”ē‚ŊŒ—‚Ö][’ęã‚°‘Šę]
2016/_4/25 (I’l5808) ”„Žc‚159200 ”ƒŽc‚13619600 E(2016_5/_9Å‚’l6545) Ķ“úXŒö•\Žw’č(3/7)ĶAllergan(4/7)[‹­‹C‘Šę]
2016/_6/24 (I’l3680) ”„Žc‚_42000 ”ƒŽc‚_9944400 E(2016/_6/24ˆĀ’l3240) Ķ“úXŒö•\‰ðœ(6/28)[‹­‹C‘Šę‰ðœ]Ķ[ŽžŠÔŽē‚Å‚Ė’ēŪ‹Į–Ę‚Ö]
2017/_3/31 (I’l2720) ”„Žc‚_22400 ”ƒŽc‚10487200 E2017/_9/_6ˆĀ’l2148) Ķ[ã”ē‚ŊŒ—‚Å‚ĖŽžŠÔŽē’ēŪ‚͏‡’ē‚ɐ„ˆÚ]Ķ[U‚é‚ĒęEE‚Ēę‚Ö]
2018/_1/26 (I’l3053) ”„Žc‚__3600 ”ƒŽc‚_5716400 E(2018/_1/22ˆĀ’l2740)ĶM—p”ƒŽcŒļ­[U‚é‚Ē‚ā‡’ē‚ɐ„ˆÚ]
2018/_3/_9 (I’l2378) ”„Žc‚_42000 ”ƒŽc‚_7177600 E(2018/_3/_5ˆĀ’l2195) ĶŽĐŽÐŠJ”­PLŠg[[ˆŦ’n‡‚Ē‚ɂčĂŅ‚ĖE‚Ēę‚Ö][ŽdŠ|‚Ŋ]
2018/_6/_8 (I’l1700) ”„Žc‚104800 ”ƒŽc‚_8714800 E(2018/_6/_7ˆĀ’l1618)Ķ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[(5/11ˆĀ’l1665, 6/5ˆĀ’l1695, 7/2ˆĀ’l1584, 7/3ˆĀ’l1414)
2018/_9/28 (I’l1371) ”„Žc‚__1500 ”ƒŽc‚_7687000 E(2018/_9/21ˆĀ’l1030)ĶM1—Տ°ŽĐŽå“I’†’f[ƒXƒgƒbƒvˆĀ”ä—á”z•Š(9/19ˆĀ’l1424, 9/20ˆĀ’l1124)]
2018/10/26 (I’l_878) ”„Žc‚___100 ”ƒŽc‚_8272800 E(2018/10/26ˆĀ’l_844) Ķ10/19:Cambridge R&D Facilities Steinmetz Building, Sosei HeptaresŽn“Ū
2018/12/28 (I’l_799) ”„Žc‚_26100 ”ƒŽc‚_6161600 E(2018/12/25ÅˆĀ’l_748) ĶSoseiHeptares–{ŠiŽn“Ū(12/1) [Ä‚Ņ‚ĖE‚ĒęĶ][‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē’ēŪ‚ŠI—đ]

233ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 06:30:46.60ID:+16rRsYS0
2019/_1/18 (I’l1310) ”„Žc‚_22600 ”ƒŽc‚_5926200 E(2019/1/_4”N‰—ˆˆĀ’l_780) Ķ1/1:“c‘šCEO•œ‹AĶ1/7:AZD4635‘æ‡U‘Š(1/8ƒXƒgƒbƒv‚:I’l1078) [ãļƒgƒŒƒ“ƒh‚Ö“]Š·]
2019/_3/_1 (I’l1250) ”„Žc‚_67200 ”ƒŽc‚_5751800 E(1/30ˆĀ’l_985) Ķ2/4:ƒIƒ‰ƒrV”­”„Ķ2/12:2018”N12ŒŽŠúŒˆŽZĶ2/22:IRā–ū‰ïĒŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—ŠĢ
2019/_4/_5 (I’l1593) ”„Žc‚_62400 ”ƒŽc‚_6539800 E(3/11ˆĀ’l1105)Ķ3/27: Sosei GroupŠ”Žå‘‰ïĶ3/16:’†‘ãŽs(3/20ƒXƒgƒbƒv‚:1526)Ķ3/29:IRā–ū‰ï(–žŒÃ‰ŪE‘åã)Ķ(4/9:”N‰—ˆ‚’l1717)
2019/_5/17 (I’l1660) ”„Žc‚110300 ”ƒŽc‚_5488000 E(5/13ˆĀ’l1429) Ķ5/14:Pfizeri’ŧ(ˆę”Ô–Ú)Ķ5/14:‘æ1Žl”žŠúŒˆŽZĶ(5/15:‚’lXV:1743)
2019/_5/31 (I’l2012) ”„Žc‚170300 ”ƒŽc‚_6108300 E(5/21ˆĀ’l1591) Ķ5/22:QVM149P‡UŽŅĶ(5/22:‚’lXV:1834)(5/23:‚’lXV:2149) Ķ5/24:QVM149‰ĒB\ŋĶ(5/28:‚’lXV:2296)
2019/_6/28 (I’l2369) ”„Žc‚_36900 ”ƒŽc‚_5815600 E(6/_6ˆĀ’l1909) Ķ6/10:Pfizeri’ŧ(“ņ”Ô–Ú)Ķ6/18:IRā–ū‰ï(å‘ä)Ķ(6/24:‚’lXV:2377)(6/26:‚’lXV:2420)
2019/_7/19 (I’l2609) ”„Žc‚_15900 ”ƒŽc‚_7363700 E(7/_5ˆĀ’l2237) Ķ(7/_1:‚’lXV:2429)(7/_2:‚’lXV:2482)Ķ7/16:Genentech’ņŒgĶ(7/16ƒXƒgƒbƒv‚:‚’lXV:2773) Ķ7/18:APP13007i’ŧ
2019/_8/16 (I’l2413) ”„Žc‚_ 8600 ”ƒŽc‚_8270500 E(8/16ˆĀ’l2375) Ķ8/_5:•“c–ō•i’ņŒg Ķ8/_5:”N‰—ˆ‚’lXV:2794)Ķ8/13:‘æ2Žl”žŠúŒˆŽZ
2019/10/11 (I’l2150) ”„Žc‚_ 5300 ”ƒŽc‚_7981900 E(9/17ˆĀ’l2088) Ķ9/12: R&D DayĶ9/28:MTL-CEBPA’PÜ‘æ‡T‘ŠÅIŒ‹‰ĘĶ9/30:QVM149‘æ‡V‘ŠIRIDIUMŒ‹‰ĘĶ10/9:Genentechi’ŧ
2019/11/29 (I’l2289) ”„Žc‚__2900 ”ƒŽc‚_8038400 E(10/15ˆĀ’l2139) Ķ11/12:‘æ3Žl”žŠúŒˆŽZĶ11/28: Ultibro’†‘NRDLŽûÚ
2019/12/30 (I’l2171) ”„Žc‚__7200 ”ƒŽc‚_7743600E(12/16ˆĀ’l2137) Ķ12/6:IRā–ū‰ï(L“‡)Ķ12/23:Pfizer‘æ‡T‘ŠŠJŽnĶ12/24:Pfizeri’ŧ(ŽO”Ô–Ú)

234ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 06:31:21.69ID:+16rRsYS0
2020/_1/10 (I’l2115) ”„Žc‚__7300 ”ƒŽc‚_7992900(+249300)Ķ1/15up E(1/8ˆĀ’l1977) Ķ1/6:‘å”­‰ïŽn’l2150 Ķ1/7:MiNA Collaboration with AstraZeneca
2020/_1/14 (I’l2104) 5“úü2079.00(+1.20“) 25“úü2195.48(-4.17“) 75“úü2310.85(-8.95“) 200“úü2138.24(-1.60“) (ˆĀ’l2092) Ķ1/14:Orexia&Inexiai’ŧ
2020/_1/15 (I’l2139) 5“úü2083.40(+2.67“) 25“úü2188.36(-2.26“) 75“úü2309.37(-7.38“) 200“úü2142.99(-0.19“) (ˆĀ’l2108) Ķ1/15:J.P. Morgan Healthcare Conference

X‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂāA‘O‰ņ‚Ė‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē‚Å‚Ė’ēŪ‚ŠI‚čAÄ‚Ņ‚ĖE‚Ēę(’ę’l)‚Đ‚į‚Ė…€’ųģ‚́A3”{Œ—ƒXƒe[ƒW‚ɂē‚ɐ„ˆÚBÎB—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋBÎB
VķSoseiHeptaresAŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—Š‚ā‡’ē‚ɐi“WBÎB’…ŽĀ‚ČŠg[‚Æ‹Ī‚ɁAŒo‰cí—Š‚Ė“]Š·‚É‚æ‚鍕Žš’č’…‰ŧBÎBX‚Ȃ鐎’·‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎB
X‚Č‚éÄŽ’·ŠúA‹ÆŅ‘Šę‚ցBÎBŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎBĄ‰ņ(Ä‚Ņ)‚Ėãļ‘Šę‚ā–Ę”’‚­‚Č‚čAˆŦ’n‡‚Ē‚ɂĐV”N‘Šę‚ŠŠJŽnBÎB200“úü’ēŪBÎB

235ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 08:04:42.37ID:nJ9C1K4T0
‚ā‚Īƒ_ƒ‚ūŠŪ‘S‚É‚Ļ‚í‚―

236ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 08:26:17.72ID:7NjojUbod
ƒmƒ‹ƒEƒF[‚Í”N‹ā‚ū‚æ‚ˁAƒuƒ‰ƒbƒNƒƒbƒN‚āˆĀ’芔Žå‚ÆŒĐ‚Ä—Į‚Ē‚Ė‚ЁH

237ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 08:37:20.79ID:9f3n9NWc0
ƒuƒ‰ƒbƒNƒƒbƒN‚Í’·Šú‚ū‚æ
ĒŠEÅ‘å‚Ė“ŠŽ‘ƒtƒ@ƒ“ƒh

238ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 08:41:24.24ID:7NjojUbod
>>237
ƒeƒ“ƒLƒ…[

239ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 08:46:21.09ID:lkjvMPqM0
‹C”zI‚í‚Á‚Ä‚é‚Č

240ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 08:48:21.50ID:fzGy0Z6Ed
‚ ‚Ú‚ņŠŪ—đ

241ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 08:52:28.12ID:S1Kdzt7Id
262 97

242ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 08:59:53.53ID:CabOj+2ga
‚ŋ‚å‚Ē‘Ō‚Á‚ĉš‚ģ‚Ē‚悧c

243ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 09:13:09.57ID:lkjvMPqM0
ƒmƒ‹ƒEƒF[”N‹ā‚ƃuƒ‰ƒbƒNƒƒbƒN‚Ē‚―‚Æ‚ĩ‚Ä‚āA‹ó”„‚č‘Ī‚Éjpƒ‚ƒ‹ƒKƒ“‚ƃ‚ƒ‹ƒKƒ“‚ƃNƒŒƒfƒBEƒXƒCƒX‚ƃhƒCƒc‹âs‚Æ–ė‘š‚ÆAQR‚ÆGS‚Æ‚ŧ‚Ė‘ž‚Š“ü‚ę‘ã‚í‚č—§‚ŋ‘ã‚í‚č‚Ē‚é‚Ŋ‚Į‚Čw

244ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 09:14:29.43ID:9ELeuopv
ƒ‹ƒTƒ“ƒ`ƒƒ“ƒY‚—

’Đ‚Đ‚į”ӂ܂Ń‹ƒTƒ“ƒ`ƒƒ“ƒY‚—

245ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 09:28:58.23ID:/gGNs58Jd
‚ā‚Īƒ_ƒ‚ūƒIƒƒ^

246ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 09:35:28.98ID:lkjvMPqM0
ƒ}ƒCƒeƒ“‚­‚é‚ž

247ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 09:35:50.55ID:lkjvMPqM0
‚ ‚Ə­‚ĩ‚Ń}ƒCƒeƒ“

248ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 09:36:32.17ID:9ELeuopv
ƒ‹ƒTƒ“ƒ`ƒƒ“ƒY‚Š‚Č‚É‚ĐŒū‚Á‚Ä‚é‚ĢiÎj

249ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 09:42:32.88ID:foHA000Qp
>>243
’·Šú‰^—p‘Ī‚ɂ̓Lƒƒƒsƒ^ƒ‹ƒŠƒT[ƒ`‚âTAIYOFUND‚ā‚Ē‚é‚Ŋ‚Į‚Č
ƒuƒ‰ƒbƒNƒƒbƒN‚͉^—pŽ‘ŽYĒŠEˆę
‘žŽÐ‚Ɉģ“|“I‚ȍ·‚ð‚‚Ŋ‚Ä‚Ē‚é‚ņ‚ū‚Š‹ó”„‚č‘Ī‚Ė‰^—pŽ‘ŽY‡Œv‚Á‚Ä’·Šú‰^—p‘Ī‚Ė‚ŧ‚ę‚ð’ī‚Ķ‚Ä‚é‚ĖH
‚ŧ‚Ī‚ÍŒĐ‚Ķ‚ņ‚Š

250ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 09:50:57.31ID:PRrh+S8X0
ƒpƒCƒvƒ‰ƒCƒ“‚ŠXV‚ģ‚ę‚Ä‚é‚į‚ĩ‚Ē‚Ŋ‚Į
‚Į‚ą‚É‚ ‚é‚ĖHŒĐ‚‚Ђį‚Č‚Ē

251ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 09:59:42.39ID:CabOj+2ga
‚ŋ‚å‚Ē‘Ō‚Á‚ĉš‚ģ‚Ē‚悧c

252ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 10:16:48.60ID:eAnye0Tid
>>249
Šî’nŠO‚ɃŒƒX‚ĩ‚ŋ‚áƒ_ƒ

253ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 10:20:25.89ID:eAnye0Tid
CGRP‚Ŧ‚ŋ‚á‚Ī

254ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 10:29:20.33ID:eAnye0Tid
>>250
M4ACGRP‚Ši‚ņ‚łāAƒtƒ@ƒBƒU[2ŒÂ’Į‰Á
ƒ‚ƒ‹ƒtƒH‚Æ‘æˆęŽO‹ĪAƒJƒCƒ}ƒu‚ŧ‚Ė‚Ü‚Ü
‚Á‚ÄŠī‚ķ‚Đ‚Č

255ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 10:41:39.67ID:7NjojUbod
>>254
‚ą‚ę‚ōĄŠú‚ā100‰­‚Ē‚Ŋ‚é‚Đ‚Č‚Ÿ

256ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 10:47:27.38ID:eAnye0Tid
–{ŠÛa2a
ŽŸ“_CGRP
‘匊@’†‘‚ĖƒAƒŒ

257ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 10:50:23.36ID:un/1S7rz0
QVM 149‚āŽŒũ‘O’ņ‚Řb‚ĩ‚Ä‚Ē‚―‚æ‚Ī‚Č
‰pŒę‚ū‚Á‚―‚Đ‚įA‚æ‚­‚í‚Đ‚į‚ņ‚ŠB

258ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 10:55:20.70ID:wmR4MN1f0
Ž‘—ŋ‚Ė‰Đ—΂Ėƒ`ƒFƒbƒNƒ}[ƒN‚Á‚ĉ―‚Č‚ĖH‰―‚ĖˆÓ–Ą‚Š‚ ‚é‚Ė

259ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 10:58:07.10ID:JmFMC8FDM
‚ā‚Īƒ_ƒ‚ū

260ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 11:01:51.69ID:lkjvMPqM0
‚ŧ‚ë‚ŧ‚ëƒhƒXƒ“‚ƐĀ‚­‚ЁcH

261ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 11:15:02.19ID:rIV/X5VuM
Šú‘ŌŠO‚ę‚ĖƒJƒ“ƒtƒ@ƒŒƒ“ƒX

‚ŧ‚ā‘æˆęŽO‹Ī‚Ė‚Í‚Ų‚Ú’†Ž~‚ū‚ë

262ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 11:38:11.08ID:lkjvMPqM0
ŒßŒãƒ}ƒCƒeƒ“‚ĩ‚ŧ‚Ī‚Čƒ`ƒƒ[ƒg‚ŃIƒƒ^

263ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 11:41:29.10ID:CabOj+2ga
‚ŋ‚å‚Ē‘Ō‚Á‚ĉš‚ģ‚Ē‚悧c

264ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 11:42:39.44ID:9ELeuopv
ƒoƒJƒ‹ƒT[‚—

265ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 12:33:40.92ID:lkjvMPqM0
Ā‚Á‚―‚ ‚ ‚ ‚ ‚ ‚ ‚ ‚ 

266ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 12:34:09.89ID:lkjvMPqM0
ŠÔ‚ā‚Č‚­ƒ}ƒCƒeƒ“I
ŠÔ‚ā‚Č‚­ƒ}ƒCƒeƒ“‚Ļ‚ß‚Å‚Æ‚ĪI

267ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 12:36:16.12ID:lkjvMPqM0
ƒ}ƒCƒeƒ“—ˆ‚é‚žI

268ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 12:43:09.74ID:/gGNs58Jd
‚ā‚Ī‚Ļ‚í‚―

269ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 12:55:57.90ID:e2Ei50/Wp
ƒ}ƒCƒeƒ“‚Ü‚ū‚ H

270ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 13:19:44.52ID:5aRMr3BbM
ƒTƒ“ƒoƒCƒI‘å–\—Žw

271ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 13:28:43.83ID:lkjvMPqM0
ƒ}ƒCƒeƒ“‚Ü‚Å‚ ‚Ə­‚ĩ
k‚Ķ‚éƒzƒ‹ƒ_[

272ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 13:30:32.08ID:lkjvMPqM0
‚ ‚Æ5‰~‚Ń}ƒCƒeƒ“

273ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 13:30:39.15ID:eAnye0Tid
‚ą‚ą‚Ü‚Å‚Ü‚Æ‚ā‚ȏ‘‚Ŧž‚Ý–ģ‚ĩ

274ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 13:33:21.46ID:e2Ei50/Wp
ƒ}ƒCƒeƒ“‚Ü‚ū‚ H

275ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 13:35:53.63ID:lkjvMPqM0
ƒ}ƒCƒeƒ“ƒzƒ‹ƒ_[ƒVƒ‡ƒbƒNŽ€‚Ü‚Å‚ ‚Æ3‰~

276ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 13:50:01.76ID:e2Ei50/Wp
ƒ}ƒCƒeƒ“‚Ü‚ū‚ H

277ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 13:51:48.21ID:lSzlA3SX0
Ą”N‚Í7`10”{‚É‚Č‚é‚ÆŒū‚Á‚―‚æ‚Č

278ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 13:53:30.19ID:BHYw0NCt
ƒoƒJƒ‹ƒT‹Ī‚Šš“‚Á‚Ä‚é‚Č‚ŸiÎj

279ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 13:53:43.12ID:lkjvMPqM0
ƒ}ƒCƒeƒ“Šó–]ŽŌ‘ąXW‚Ü‚Á‚Ä‚é‚Čw
‚ą‚č‚áÅŒã‚Ƀ}ƒCƒeƒ“‚ЁHIw

280ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 13:55:50.18ID:BHYw0NCt
ƒ‹ƒTƒ“ƒ`ƒƒ“ƒY‘åW‡‚ЁHiÎj

281ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 14:08:41.38ID:2OzJ1E1J0
–ˆŒŽ15–œ‰~‚ðSBIØŒ”‚É“Ë‚Áž‚ņ‚Å‚é‚đ‚Ē‚ŐķŠˆ‚ŠŒĩ‚ĩ‚Ē

282ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 14:22:19.84ID:PRrh+S8X0
>>‚Ļ‚Ļ‚ ‚č‚Š‚Æ‚ĪI
ˆę——•\‚Ý‚―‚Ē‚Č‚Ė‚Š‚Č‚Ē‚ņ‚ū‚æ‚ˁB
ƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚ĖŽ‘—ŋ‚Šo‚―‚į‚Ė‚é‚Đ‚Č‚ B

283ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 14:27:57.04ID:0YAVSp7L0
100Š”—ëŨ‚ĩ‚Ȃˁ[‚Đ‚Č

284ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 14:43:51.36ID:Gjy4vT7E0
2014”N1ŒŽA2015”N2ŒŽA2016”N10ŒŽ‚ ‚―‚č‚Ėƒ`ƒƒ[ƒg‚ÉŽ—‚Ä‚é‹C‚Š‚·‚é

285ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 14:45:05.38ID:sFJxu0gr0
ĒŠE’†‚Ė‹@ŠÖ“ŠŽ‘‰Æ‚ŠW‚Ü‚éƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚Å‘å‚ĩ‚―Ž–Œū‚Á‚Ä‚Č‚Ē‚Đ‚įA‹@ŠÖ“ŠŽ‘‰ÆŒĐŒü‚Ŧ‚ā‚ĩ‚Č‚ĒB

286ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 14:45:44.75ID:sFJxu0gr0
>>284
‚ŧ‚ĖŽž‚͏り‚Á‚―H‰š‚Š‚Á‚―H

287ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 15:07:02.47ID:h/rExidLp
o—ˆ‚‚Š‚Ī‚ņ‚ą‚ū‚Č

288ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 15:09:11.16ID:/qelTiOAp
“ÆŽĐƒ‹[ƒ‹‚ňá‚Ī—V‚Ņ‚ð‚ĩ‚Ä‚é“z‚Š•ī‚ꍾ‚ņ‚Å‚é‚Č

289ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 16:00:19.34ID:w343tWx30
EEE
ĶVectura 2018 Preliminary ResultsFUltibro in-Market Sales $512m(2018); EU Market Share 46%(2018). (2019/3/26)
EQVM149 Filling H2 2019 (Submission Milestone $2.5m); QVM149 Launch 2020.
E[2024 Consensus Sales Estimates]: Ultibro: $632m, Seebri: $168m, QVM149: $238m.
ĶNovartis Q1 2019 Results: Ultibro Breezhaler Sales"$104m", Seebr Breezhaler Sales"$31m". (2019/4/24)
EExpected Pipeline Milestones 2019: "QVM149 Asthma ( EU / JP ) Submissions: H2 2019"; Potential Blockbuster Launches 2020: "QVM149 Asthma".
ĶVectura: hVectura receives $2.5m milestone payment for the European regulatory submission of QVM149h. (2019/5/24)
EFurther Milestone Payment of $5.0 million on European regulatory approval of the product and thereafter royalties on net sales from launch.
ĶNovartis Q2 2019 Results: Ultibro Breezhaler Sales"$112m", Seebr Breezhaler Sales"$34m". (2019/7/18)
E2019 Expected Pipeline Milestones: [Submissions: H2 2019]: QVM149 Asthma (EU / JP): Achieved (QVM149 Submitted in EU).

290ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 16:00:26.77ID:w343tWx30
ĶVectura 2019 Interim Results: Ultibro in-Market Sales: $510m (2Q19MAT): EU Market Share: 44% (2Q19MAT). [Potential Growth Catalysts]: China. (2019/9/10)
EQVM149(EU), Further Milestone of $5.0m on Approval with low single-digit royalties from Launch (2020).
E[2024 Consensus Sales Estimates]: Ultibro: $562m, Seebri: $122m, QVM149: $240m.
ĶNovartis Q3 2019 Results: Ultibro Breezhaler Sales"$97m", Seebr Breezhaler Sales"$28m". (2019/10/22)
EH2 2019 Major Expected Submissions: "QVM149 Asthma: EU(Q2 2019)/ Japan(Q3 2019); "Achieved".
E2020 Catalysts Expected : Key Approvals: "QVM149 Asthma".[In Registration]
ĶNovartis R&D Day: "Novartis Expects to Sustain Long-Term Growth with a Robust Pipeline of 25+ Potential Blockbusters Highlighted; (2019/12/5)
E"Significant Progress in 2019: Submissions: "Asthma" QVM149 / QMF149 (EU/JP)".

291ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 16:01:43.53ID:w343tWx30
ĶVectura: "Wefre looking forward to being in San Francisco for the 38th JPM Healthcare Conference Next Week"; Vectura CEO Presentation: 10:00 PST / 18:00 GMT on Thursday 16 January. (1/6)
ĶVectura Group Trading Update: "2020 Financial Guidance: Vectura Would Earn $5m Upon Approval of QVM149 in Europe and Would Earn a Low-Single Digit Royalty on Net Sales of the Product." (1/13)
ĶJ.P. Morgan Healthcare Conference: Novartis Presentation: "2020 Catalysts Maintaining Long-Term Momentum: Major Approvals: QVM / QMF 149: Asthma". (1/13 Presented)
Ŧ
Today EventsF
ĶJP Morgan Healthcare Conference: "Vectura" (1/16 Today 10:00 Presenting) Please check back in about 11 hours.
https://jpmorgan.metameetings.net/events/hc20/sessions/29892-vectura-group-plc/webcast

EEE

292ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 16:02:20.84ID:w343tWx30
ŽŸ‚Č‚é”ō–ô‚ցB’…ŽĀ‚Ȑi’ŧ‚Æ‹Ī‚ɍX‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂĐU‚é‚Ēˆį‚ŋ‚ä‚­‘ŠęBT‚Ķ‚éÞ—ŋ‚Æ‹Ī‚ɐ…€’ųģBÎB
Ž’·ŠúB—\’č‚ģ‚ę‚Ä‚Ē‚―‹ÆŅ‚Ė‹}Ž’·‚Æ‹Ī‚ɍX‚Ȃ鐎’·í—Š‚Ši“WB‡’ē‚ČR&DEPL“™‚ĖŠg[EŠg‘å‚Ė‰Á‘ŽBÎB
EEE
ĶSOSEI‚ĖŽ’·‘Šę‚Ė“ŪŒüF‘O‰ņ‚Ė‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē’ēŪ‚ŠI‚čAÄ‚Ņ‚Ėãļ(…€’ųģ)‘Šę‚͏‡’ē‚ɐ„ˆÚBÎB‹ÆŅ‘Šę‚Ö‚Ė“ŪˆÓ‘Ō‚ŋBÎB
2010/12/30 (I’l_338) E(2010/10/15ĶÅˆĀ’l_163A2010/12/27Å‚’l_437) ĶQVA149‘æ‡V‘ŠŠJŽn
2011/12/30 (I’l_318) E(2011/_3/15ĶÅˆĀ’l_173A2011/_6/30Å‚’l_420) Ķƒmƒ‹ƒŒƒ{ģ”F(2/23Ķ)
2012/12/28 (I’l_522) E(2012/_6/_6ĶÅˆĀ’l_238A2012/_9/_7Å‚’l_742) ĶSeebri‰ĒBĨ“ú–{ģ”F
2013/12/30 (I’l1079) E(2013/_1/_4ĶÅˆĀ’l_513A2013/_5/_7Å‚’l1525) ĶUltibro‰ĒBĨ“ú–{ģ”F
2014/12/30 (I’l1093) E(2014/_4/12ĶÅˆĀ’l_464A2014/_9/_8Å‚’l1500) Ķ’†’·ŠúŒv‰æ”­•\(5/13Ķ)[E‚ĒęĶ][Ž’·‰ņŽûŠú‚Ė“üŒû]

293ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 16:02:53.82ID:w343tWx30
2015/12/30 (I’l2488) E(2015/_3/16ĶÅˆĀ’l_713A2015/12/14Å‚’l2645) ĶHeptares(2/20Ķ)[ŽŒũ‚Ė˜Í]ĻĶ•Ä‘ģ”F(10/30Ķ)[ŽŸ‚Č‚é”ō–ô‚Ö]
2016/12/30 (I’l3363) E(2016/_1/18ĶÅˆĀ’l2270A2016/_5/_9Å‚’l6545) ĶAllergan(4/7)[‹­‹C‘Šę]ĻĶ“úXŒö•\‰ðœ(6/28)[‹­‹C‘Šę‰ðœ]
2017/12/29 (I’l2735) E(2017/_9/_6ĶÅˆĀ’l2148A2017/_1/_6Å‚’l3645) Ķ[ã”ē‚ŊŒ—‚Å‚ĖŽžŠÔŽē’ēŪ‚͏‡’ē‚ɐ„ˆÚ]ĻĶ[U‚é‚ĒęEE‚Ēę‚Ö]
2018/12/28 (I’l_799) E(2018/12/25ĶÅˆĀ’l_748A2018/_1/25Å‚’l3195) ĶSoseiHeptaresŽn“Ū[Ä‚Ņ‚ĖE‚Ēę(’ę’l)Ķ][‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē’ēŪ‚ŠI—đ]
2019/12/30 (I’l2171) E(2019/_1/_4ĶÅˆĀ’l_780A2019/_8/_5Å‚’l2794) Ķ“c‘šCEO•œ‹AĶ[ãļƒgƒŒƒ“ƒh‚Ö“]Š·]ĶQVM149‰ĒB\ŋ(5/24) [—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋ]
2020/_1/16 (I’l2150) E(2020/_1/_8ĶÅˆĀ’l1977A2020/_1/_6Å‚’l2176) Ķ1/7:MiNA Collabo with AstraZenecaĶ1/14:Orexia&Inexiai’ŧĶ1/15:Presentation
E5“úü2111.00(+1.85“) 25“úü2185.00(-1.60“) 75“úü2306.90(-6.80“) 200“úü2147.81(+0.10“) (1/16ˆĀ’l2115)

294ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 16:03:15.93ID:w343tWx30
Ä‚Ņ‚ĖE‚Ēę(’ę’l)‚Đ‚į‚Ė…€’ųģ‚Í3”{Œ—ƒXƒe[ƒW‚ɂē‚ɐ„ˆÚBÎB—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋBÎB200“úü’ēŪBÎB
ŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—Š‚́A’…ŽĀ‚ČŠg[‚Æ‹Ī‚ɁA‡’ē‚ɐi“WBÎBX‚Ȃ鐎’·‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎB
Œo‰cí—Š‚Ė“]Š·‚É‚æ‚鍕Žš’č’…‰ŧBÎBĄ‰ņ‚Ėãļ‘Šę‚ā–Ę”’‚­‚Č‚čAˆŦ’n‡‚Ē‚ɂĐV”N‘Šę‚ŠŠJŽnBÎB

295ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 16:29:59.15ID:w343tWx30
ĶSosei HeptaresFu‘æ38‰ņJ.P.ƒ‚ƒ‹ƒKƒ“Eƒwƒ‹ƒXƒPƒAEƒJƒ“ƒtƒ@ƒŒƒ“ƒX ƒvƒŒƒ[ƒ“ƒe[ƒVƒ‡ƒ“Ž‘—ŋi‰p•ķ‚Ė‚݁jv(1/16up)
https://ssl4.eir-parts.net/doc/4565/announcement/55455/00.pdf

296ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 16:34:13.79ID:GyGnlP7Y0
ˆę‰ž‚Ë
https://answers.ten-navi.com/pharmanews/17556/?yclid=YJAD.1579159434.5FbXX8Gdcq1ptkAj7xmCaI61tvpHD9WCvBGVwljDiuRRtVE5drJ43tKgLdMz1GG.IxXMdEReKTANaJQ-
ŒÄ‹zŠí—Ėˆæ‚ł́Aƒmƒoƒ‹ƒeƒBƒXƒtƒ@[ƒ}‚Š‹CŠĮŽxšb‘§ŽĄ—Öō2Ü‚ð”­”„‚·‚éŒĐž‚Ý‚Å‚·B
‚P‚–ڂ̓‚ƒƒ^ƒ]ƒ“ƒtƒ‰ƒ“ƒJƒ‹ƒ{ƒ“Ž_ƒGƒXƒeƒ‹/ƒCƒ“ƒ_ƒJƒeƒ[ƒ‹|Ž_‰–‚ŁA‹z“üƒXƒeƒƒCƒhiICSj‚Æ’·ŽžŠÔė—pŦƒĀ2ŽhŒƒ–ōiLABAj‚Ė”z‡ÜB
2‚–ڂ̓‚ƒƒ^ƒ]ƒ“ƒtƒ‰ƒ“ƒJƒ‹ƒ{ƒ“Ž_ƒGƒXƒeƒ‹/ƒCƒ“ƒ_ƒJƒeƒ[ƒ‹|Ž_‰–/ƒOƒŠƒRƒsƒƒjƒEƒ€L‰ŧ•Ļ‚ŁAICS‚ÆLABAA’·ŽžŠÔė—pŦRƒRƒŠƒ“–ōiLAMAj‚Ė3Ü”z‡Ü‚Å‚·B
‹CŠĮŽxšb‘§‚ł̓mƒoƒ‹ƒeƒBƒX‚Š‰‚Æ‚Č‚č‚Ü‚·B

297ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 16:51:35.24ID:EBH0b6AY0
‚ā‚Īƒ_ƒ‚ū

298ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 17:00:15.91ID:w343tWx30
ĶAnswersNewsFƒjƒ…[ƒX‰ðāFy2020”N‚É”­”„‚ŠŒĐž‚Ü‚ę‚éV–ō2z(1/16)
2020”N‚É”­”„‚Š—\‘z‚ģ‚ę‚éV–ō‚ð—Ėˆæ•Ę‚É2‰ņ‚É•Š‚Ŋ‚ďЉî‚ĩ‚Ü‚·B2‰ņ–ڂ́utvu“œ”A•avuŒÄ‹zŠívu”į•†vuŠá‰Čv‚Æ‚ŧ‚Ė‘ž‚Ė—Ėˆæ‚Å‚·B
EEE
ŒÄ‹zŠí—Ėˆæ‚ł́Aƒmƒoƒ‹ƒeƒBƒXƒtƒ@[ƒ}‚Š‹CŠĮŽxšb‘§ŽĄ—Öō2Ü‚ð”­”„‚·‚éŒĐž‚Ý‚Å‚·B
1‚–ڂ̓‚ƒƒ^ƒ]ƒ“ƒtƒ‰ƒ“ƒJƒ‹ƒ{ƒ“Ž_ƒGƒXƒeƒ‹/ƒCƒ“ƒ_ƒJƒeƒ[ƒ‹|Ž_‰–‚ŁA‹z“üƒXƒeƒƒCƒh(ICS)‚Æ’·ŽžŠÔė—pŦƒĀ2ŽhŒƒ–ō(LABA)‚Ė”z‡ÜB
2‚–ڂ̓‚ƒƒ^ƒ]ƒ“ƒtƒ‰ƒ“ƒJƒ‹ƒ{ƒ“Ž_ƒGƒXƒeƒ‹/ƒCƒ“ƒ_ƒJƒeƒ[ƒ‹|Ž_‰–/ƒOƒŠƒRƒsƒƒjƒEƒ€L‰ŧ•Ļ‚ŁAICS‚ÆLABAA’·ŽžŠÔė—pŦRƒRƒŠƒ“–ō(LAMA)‚Ė3Ü”z‡Ü‚Å‚·B
ICS/LABA/LAMA‚Ė3Ü”z‡Ü‚́Að”N5ŒŽ”­”„‚ĖuƒeƒŠƒ‹ƒW[v(ƒOƒ‰ƒNƒ\EƒXƒ~ƒXƒNƒ‰ƒCƒ“)‚Æ“Ŋ9ŒŽ”­”„‚ĖuƒrƒŒ[ƒYƒgƒŠv(ƒAƒXƒgƒ‰ƒ[ƒlƒJ)‚É‘ą‚Ē‚č‘“ā3•i–ږځB
‚ą‚ę‚į2ŧ•i‚Í‚Ē‚ļ‚ę‚ā–Ŧ•ÂĮŦ”xŽūŠģ(COPD)‚Š‘ΏۂŁA‹CŠĮŽxšb‘§‚ł̓mƒoƒ‹ƒeƒBƒX‚Š‰‚Æ‚Č‚č‚Ü‚·B
EEE

299ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 17:06:55.72ID:e2Ei50/Wp
5˜A“Ŧ‚ū‚ȁBƒ}ƒCƒeƒ“1‰ņ‚ā‚Å‚Ŧ‚ˁ[ŽG‹›w

300ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 17:08:49.81ID:3vVM8xSkd
—ëŨ‚Ī‚ī

301ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 17:38:53.61ID:1aTQPOan0
‚ŧ‚Ī‚ÍŒū‚Á‚Ä‚āŽŸ‚Í‚Į‚ą”ƒ‚Ē‚―‚Ē‚ņ‚â‚ë‚Ë
“c‘š‚ģ‚ņ

302ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 17:44:20.23ID:sFJxu0gr0
‚ŧ‚č‚áMina‚ū‚ëB

303ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 17:52:25.99ID:jkaB1bT20
4‰c‹Æ“ú‚Å250‰š‚Š‚Á‚Ä‚â‚Á‚Æ150–ß‚ĩ‚―‚É‚·‚Ž‚Č‚Ē

304ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 17:59:10.70ID:sFJxu0gr0
ƒ‚ƒ‹ƒKƒ“ƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚ŃAƒbƒrƒB‚ĖƒvƒŒƒ[ƒ“‚Å‚ĖM1”­Œū‚Č‚Đ‚Á‚―‚Ė‚ЁH

305ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 17:59:24.65ID:1aTQPOan0
>>302
Žļ”s‚ƐŽŒũ‚Ė‚ ‚Á‚―ƒ~ƒi‚ð‚Ü‚―”ƒ‚Ī‚Đ‚Č‚ 
•Š‚Đ‚į‚Č‚Ē

306ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 18:05:53.47ID:TudusPF00
‰ī‚ŠŽá‚­‚ĩ‚ănƒQ‹C–Ą‚Č‚Ė‚Í‚ŧ[‚đ‚Ē‚Ė‚đ‚Ē‚É‘ž‚Č‚į‚Č‚Ē
ŽžŠÔ‚Æ–Ņ‚ðIŽļ‚Á‚―‚ņ‚ū‚žI

307ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 18:10:59.67ID:w343tWx30
Heptares Patent update:
EEE
Ķ•Ä‘“Á‹–(Heptares)FMuscarinic Agonists (US Patent 10351545 B2). (7/16ŒöŠJ)
Ķ•Ä‘“Á‹–oŠč(Heptares)FCGRP Receptor Antagonists (US20190231773 A1). (8/1ŒöŠJ)
Ķ•Ä‘“Á‹–oŠč(Heptares)FMutant G-Protein Coupled Receptors and Methods for Screening Them (US20190241644 A1). (8/8ŒöŠJ)
Ķ•Ä‘“Á‹–(Heptares)FBicyclic AZA Compounds as Muscarnic M1 Receptor and/or M4 Receptor Antagonists (US Patent 10385039 B2). (8/20ŒöŠJ)
Ķ‰ĒB“Á‹–oŠč(Heptares)FHeterocyclic Compounds Having Activity as Modulators of Muscarinic M1 Receptor and/or M4 Receptors in the Treatment of CNS Diseases and Pains (EP3526207 A1). (8/21ŒöŠJ)
Ķ“ú–{“Á‹–(Heptares)Fu•ÏˆŲ‘Ėƒ^ƒ“ƒpƒNŽŋ‚Æ‚ŧ‚Ėŧ‘Ē•û–@v(“Á‹–‘æ6567291† B2) (8/9“o˜^A8/28ŒöŠJ)
Ķ•Ä‘“Á‹–oŠč(Heptares)FMuscarinic Agonists (US 20190270718 A1). (9/5ŒöŠJ)
Ķ•Ä‘“Á‹–oŠč(Heptares)FPharmaceutical Compounds (US 20190276437 A1). (9/12ŒöŠJ)
Ķ•Ä‘“Á‹–(Heptares)FMuscarinic M1 Receptor Agonists (US Patent 10413553 B2). (9/17ŒöŠJ)

308ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 18:11:20.14ID:w343tWx30
Ķ•Ä‘“Á‹–(Heptares)FMuscarinic Receptor Agonists (US Patent 10428088 B2). (10/1ŒöŠJ)
Ķ“ú–{“Á‹–oŠč(Heptares)FuCNSŽūŠģ‹y‚Ņáu’É‚ĖŽĄ—ÂɂĻ‚Ŋ‚郀ƒXƒJƒŠƒ“M1‹y‚Ņ^–”‚ÍM4Žó—e‘Ė‚Ė’ēßˆöŽq‚Æ‚ĩ‚ÄŠˆŦ‚ð—L‚·‚é•Ą‘fŠÂŽŪ‰ŧ‡•Ļ(“ÁŠJ2019-530725A)v(10/24ŒöŠJ)
Ķ•Ä‘“Á‹–(Heptares)FAssay for Assessing Conformational Stability of Membrane Protein (US Patent 10458993 B2). (10/29ŒöŠJ)
Ķ•Ä‘“Á‹–oŠč(Heptares)FBicyclic AZA Compounds as Muscarinic M1 Receptor and/or M4 Receptor (US 20190337925 A1). (11/7ŒöŠJ)
Ķ‰ĒB“Á‹–(Heptares)FCGRP Receptor Antagonists (European Patent EP3368526 B1). (12/25ŒöŠJ)
Ķ•Ä‘“Á‹–oŠč(Heptares)FPharmaceutical Compounds (US20190389849 A1). (12/26ŒöŠJ)
Ķ‘Û“Á‹–oŠč(Heptares)FOxadiazoles as Agonists of the Muscarinic M1 and/or M4 Receptor (WO/2019/243850 A1). (12/26ŒöŠJ)
Ķ‘Û“Á‹–oŠč(Heptares)FBridged Compounds as Agonists of the Muscarinic M1 and/or M4 Receptor (WO/2019/243851 A1). (12/26ŒöŠJ)
Ķ•Ä‘“Á‹–oŠč(Heptares)FPharmaceutical Compounds (US20200002328A1). (2020/1/2ŒöŠJ)

309ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 18:11:37.52ID:w343tWx30
Ŧ
Ķ•Ä‘“Á‹–oŠč(Heptares)F"Muscarinic Receptor Agonists". (1/16ŒöŠJ)
EDocument Type and Number: United States Patent Application 20200017530 A1
EPublication Date: 2020/01/16
EAssignee: Heptares Therapeutics Limited.
Abstract:
This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases.
Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.
Compounds provided are of formula where m, p, q, W, Z, Y, X1, X2, R1, R2, R3 and R4 are as defined herein.
http://www.freepatentsonline.com/20200017530.pdf

310ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 18:40:21.44ID:e2Ei50/Wp
>>306 ‚ŧ[‚đ‚Ē‚Č‚į“°–ō‚ā‚â‚Á‚Ä‚­‚ę‚é‚Í‚ļI

311ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 18:41:59.00ID:TudusPF00
Žž‚ā–ß‚ĩ‚Ä‚­‚ę
•s˜V•sŽ€‚Ė–ō‚ð‘n‚ę
“c‘š‚Š_‚É’§í‚·‚é‚Ė‚ū

312ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 18:59:02.72ID:M2U6zIf3
>>311
‚ ‚ņ‚―“°ƒLƒˆƒV‚ģ‚ņ‚ЁH

313ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 18:59:11.54ID:Gka7i1QV0
‚ŋ‚å‚Ē‘Ō‚Á‚ĉš‚ģ‚Ē‚悧c

314ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 19:12:29.35ID:nOqF82/e0
>>311
ė‚é‚Č‚įŽá•Ô‚č‚Ė–ō‚ū‚Č
•sŽ€‚Í‚Č‚ŸAŽ€‚É‚―‚ĒŽžŽ€‚Ë‚Č‚Ē‚Ė‚ā•|‚Ē‚í
’·‚­ķ‚Ŧ‚ę‚ΐķ‚Ŧ‚é‚Ų‚Į’ʏí‚Ėlķ‚Å‚Í‚ ‚č‚Ķ‚Č‚Ē‚æ‚Ī‚Č•sK‚â‹ę’É‚ÉŒĐ•‘‚í‚ę‚éŠm—Ķ‚ŠƒOƒ“‚Əり‚é
•s˜V‚ā‚Č‚ŸA˜V‚Ē‚É‚ā‚ŧ‚ę‚Č‚č‚Ė–Ģ—Í‚Í‚ ‚é‚ĩ
ŽĐ‘R‚ɘV‚Ē‚Ä–â‘čo‚―‚č–O‚Ŧ‚―‚įD‚Ŧ‚Č”N—î‚ÉŽá•Ô‚č‚Č‚į‚Ü‚ ‚Ē‚Ē‚Đ‚Č

315ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 19:59:15.77ID:nc9Y0R/Sd
‚ą‚ĖƒXƒŒchi‚ģ‚ņ‚ĩ‚ĐŒĐ‚é‰ŋ’l‚Č‚Ē‚ņ‚ū‚Š
‘ž‚Ė‚â‚‚ĖƒRƒƒ“ƒgŒĐ‚Č‚Ē•û–@’m‚č‚―‚Ē

316ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 20:07:55.17ID:EBH0b6AY0
‚ā‚Īƒ_ƒ‚ū

317ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 20:36:47.22ID:4c/TVoyi0
‰i‰“‚Ė2000‰~‘ä

318ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 21:52:27.41ID:s+i5bYUvd
ƒhƒ‰ƒSƒ“ƒ{[ƒ‹W‚ß‚č‚á‚Ķ‚Ķ‚â‚ņ

319ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 22:42:45.17ID:SQQbBZT60
ƒAƒz”‚ĖŠCƒJƒX‚Æfujiyanyan‚Š”„‚ę‚Î3,000‰~‚͉z‚Ķ‚é‚ū‚ë‚Ī

320ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 22:50:19.47ID:/qelTiOAp
Œü‚ą‚Ī‚Ė˜b‚ÍŒü‚ą‚Ī‚ÅŠŪŒ‹‚ģ‚đ‚ë
‚ą‚Á‚ŋ‚É‚Ü‚ÅŽ‚ŋž‚Þ‚Ė‚Í‚â‚ß‚ë

321ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/16(–Ø) 22:57:02.21ID:SQQbBZT60
‚q‚r‚t‚Ė2249‰~‚Ė‚ÔŒú‚Ē•Į‚͉z‚Ķ‚Č‚Ē‚ū‚ë‚Ī@@@

322ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 01:19:28.80ID:C5iGwMf+0
ƒ}ƒCƒeƒ“‚Ü‚Å‚ ‚Æ8ŽžŠÔ

323ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 05:31:23.95ID:sMdtSGI50
ŽŸ‚Č‚é”ō–ô‚ցB’…ŽĀ‚Ȑi’ŧ‚Æ‹Ī‚ɍX‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂĐU‚é‚Ēˆį‚ŋ‚ä‚­‘ŠęBT‚Ķ‚éÞ—ŋ‚Æ‹Ī‚ɐ…€’ųģBÎB
Ž’·ŠúB—\’č‚ģ‚ę‚Ä‚Ē‚―‹ÆŅ‚Ė‹}Ž’·‚Æ‹Ī‚ɍX‚Ȃ鐎’·í—Š‚Ši“WB‡’ē‚ČR&DEPL“™‚ĖŠg[EŠg‘å‚Ė‰Á‘ŽBÎB
EEE
ĶSosei HeptaresFuV”N‚Ė‚ēˆĨŽA “c‘šáÁˆęv•ūŽÐ‚Å‚Í‘n–ō‚Ė‰Ī“đ‚ð—Í‹­‚­i‚Ý‚Č‚Š‚į‚āAŽaV‚ČŠvV“I‹Zp‚ðŒÕŽ‹ážX‚Æ‘_‚Á‚Ä‚Ē‚Ü‚·B2020”N‚ð‚ģ‚į‚Č‚é”ō–ô‚Ė”N‚É‚ĩ‚ÄŽQ‚č‚Ü‚·B(1/1)
ĶRCSB Protein Data Bank: "Crystal Structure of the Orexin-1 Receptor and Orexin-2 Receptor in Complex": 6TQ9, 6TQ7, 6TQ6, 6TQ4, 6TPN, 6TPJ, 6TPG, 6TP6, 6TP4, 6TP3, 6TOD, 6TO7. (1/1 Released)
Ķ•Ä‘“Á‹–oŠč(Heptares)F"Pharmaceutical Compounds"(US20200002328A1). (1/2ŒöŠJ)
ĶMiNA Therapeutics Publications: Molecular Therapy "Liver Activation of Hepatocellular Nuclear Factor-4a by Small Activating RNA Rescues Dyslipidemia and Improves Metabolic Profile". (1/4up)
ĶPsychopharmacology: "Lessons learned from using fMRI in the early clinical development of a mu-opioid receptor antagonist for disorders of compulsive consumption": Pradeep J. Nathan & Geor Bakker. (1/4 Published)
ĶClinicalTrials(NCT03381274): Phase 1b/2, Oleclumab(MEDI9447) EGFRm NSCLC Novel Combination Study. (MEDI9447 with Osimertinib or AZD4635, AZD4635 with MEDI9447): Record Verification January 2020. (1/6update)
ĶMiNA Therapeutics: "Announces Research Collaboration with AstraZeneca in Metabolic Diseases". Completion of these studies, AstraZeneca will have the option to negotiate a license agreement to further develop saRNA molecules. (1/7)
ĶRoche HP: Partnering: "Example Partnerships: "Heptares - research collaboration to discover and develop novel medicines that modulate G-protein-coupled receptor targets across a range of diseases." (1/10up, Add)

324ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 05:31:49.50ID:sMdtSGI50
ĶVectura Group Trading Update: "2020 Financial Guidance: Vectura Would Earn $5m Upon Approval of QVM149 in Europe and Would Earn a Low-Single Digit Royalty on Net Sales of the Product." (1/13)
ĶJ.P. Morgan Healthcare Conference: Novartis Presentation: "2020 Catalysts Maintaining Long-Term Momentum: Major Approvals: QVM / QMF 149: Asthma". (1/13 Presented)
ĶSosei HeptaresFuOrexiaŽÐ‚Ļ‚æ‚Ņ InexiaŽÐ‚É‚æ‚éƒIƒŒƒLƒVƒ“Žó—e‘Ėė“Ū–ōƒvƒƒOƒ‰ƒ€‚Ė’˜‚ĩ‚Ēi’ŧ‚É‚æ‚čMedicxiŽÐ‚Š40•S–œƒ†[ƒ(–ņ48‰­6800–œ‰~)‚ĖƒRƒ~ƒbƒgƒƒ“ƒg‚Ė‰š‚ŁAŽŸ‚Ȃ鎑‹ā’ņ‹Ÿ‚ðŽĀsv(1/14)
Ķ‰ĒB“Á‹–oŠč(MiNA): "C/EBP Alpha Short Activating RNA Compositions and Methods of Use"(EP3594348 A1). (1/15ŒöŠJ)
ĶJ.P. Morgan Healthcare Conference: Sosei Group Presentation: "Drug Dscovery and Erly Dvelopment Trgeting GPCRs": Chris Cargil. (1/15 Presented)
ERobust FY2020 Outlook: Seed Next Wave of Pre-Discovery Projects; Continued Delivery of Candidates In-House and for Partners; Progress Existing Partnered Programs; New Collaborations and Partnerships with World Leaders.
ĶSosei HeptaresFu‘æ38‰ņJ.P.ƒ‚ƒ‹ƒKƒ“Eƒwƒ‹ƒXƒPƒAEƒJƒ“ƒtƒ@ƒŒƒ“ƒX ƒvƒŒƒ[ƒ“ƒe[ƒVƒ‡ƒ“Ž‘—ŋ(‰p•ķ‚Ė‚Ý) https://ssl4.eir-parts.net/doc/4565/announcement/55455/00.pdf v(1/16up)
Ķ•Ä‘“Á‹–oŠč(Heptares)F"Muscarinic Receptor Agonists" (US20200017530A1). (1/16ŒöŠJ)

325ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 05:32:21.49ID:sMdtSGI50
ĶJP Morgan Healthcare Conference 2020: Vectura Presentation: "Executing on Our Inhaled Specialist CDMO Strategy". (1/16 Presented)
The CDMO Opportunity Re-Shaping Our Business Profile:
EExisting Partnerships: Approvals in 2020 Expected for: QVM149 Triple (Novartis).
2020 Guidance:
E$5m Milestone on Approval of QVM149 with Low-Single Digit Royalty on Net Sales.
EEE

326ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 05:46:02.96ID:sMdtSGI50EQ
ĶASCO 2020: "First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)": Debashis Sarker. (1/24 12:00 Presenting)
ĶPfizer Quarterly Corporate Performance - Q4 2019 Results. (1/28)
ĶNovartis Q4 and Full Year Results 2019 and Annual Report 2019 Publication. (1/29)
ĶPatients as Partners Europe: "Patient Involvement in Regulatory Decisions: How Regulations are Incorporating the Patient Voice": Domenico Merante, MD, VP, Clinical Development, Sosei Heptares. (1/27 16:15-16:45 Presenting)
ĶR•DŽx‰‡ƒZƒ“ƒ^[ŽåÃƒyƒvƒ`ƒhƒZƒ~ƒi[uƒyƒvƒ`ƒhˆã–ō•iŒī–ō‚Ėŧ‘ĒƒvƒƒZƒXŠJ”­‚ƃXƒP[ƒ‹ƒAƒbƒv‚Ė—ŊˆÓ“_vJITSUBO ŒĪ‹†ŠJ”­•” •”’· ŽRúą‹MŽjB(1/31 12:30-16:30)
ĶSosei Group 2019”N12ŒŽŠúŒˆŽZ”­•\ (2/13Ķ)
ĶAstrazeneca Full-Year 2019 Results. (2/14)
ĶAllergan Q4 and Full-Year 2019 Results. (2/19 Projected)
ĶSMi RNA Therapeutics: "Small Activating RNAs(saRNAs) - A Novel Therapeutic Class of Oligonucleotides with Broad Therapeutic Potential": David Blakey, MiNA Therapeutics. (2/19 13:20-14:00 Presenting)
ĶICDD (International Conference on Drug Discovery) 2020: Speaker Dr. Jonathan Mason, Sosei Heptares. (2/29-3/2)
ĶŽl‹G•ņ2020”N2Wt†F(Žl‹G•ņæŽæ‚čF3ŒŽã{AŽl‹G•ņXVF3/16”­”„)
ĶVectura Group 2019 Preliminary results. (3/17)
ĶSosei Group ‘æ30‰ņ’莞Š”Žå‘‰ï (3ŒŽ‰š{)
EEE

327ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 06:00:31.77ID:sMdtSGI50
ĶSOSEI‚ĖŽ’·‘Šę‚Ė“ŪŒüFÄ‚Ņ‚Ėãļ‘Šę‚͏‡’ē‚ɐ„ˆÚ(2018/12/25:ÅˆĀ’l748ĶA2019/1/4:ˆĀ’l_780A2019/8/5:Å‚’l:2794)BÎB‹ÆŅ‘Šę‚Ö‚Ė“ŪˆÓ‘Ō‚ŋBÎB
2018/12/28 (I’l_799) 25“úü_948.64(-15.77“) E(12/25ÅˆĀ’l_748) Ķ12/1:SoseiHeptares–{ŠiŽn“Ū[Ä‚Ņ‚ĖE‚ĒęĶ][‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē’ēŪ‚ŠI—đ]
2019/_1/_4 (I’l_864) 25“úü_940.80( -8.16“) E(_1/_4ˆĀ’l_780) Ķ1/1:“c‘šCEO•œ‹AĶ1/7:AZD4635‘æ‡U‘Š[1/8ƒXƒgƒbƒv‚:I’l1078] [ãļƒgƒŒƒ“ƒh‚Ö“]Š·]
2019/_2/_1 (I’l1021) 25“úü1051.28( -2.88“) E(_1/30ˆĀ’l_985) Ķ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[’ïG(1/21ˆĀ’l1164, 1/30ˆĀ’l985)Ķ(1/21:‚’lXV:1360)
2019/_3/_1 (I’l1250) 25“úü1133.28(+10.83“) E(_2/_4ˆĀ’l1021) Ķ2/14:ŒˆŽZ Ķ2/22:IRā–ū‰ï(ˆĒ”{–ė)ĒŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—ŠĢ
2019/_4/_5 (I’l1593) 25“úü1331.60(+19.63“) E(_3/11ˆĀ’l1105) Ķ3/16:’†‘ãŽs Ķ(3/20:‚’lXV:ƒXƒgƒbƒv‚:1526) Ķ3/29:IRā–ū‰ï(–žŒÃ‰ŪE‘åã)
2019/_5/10 (I’l1486) 25“úü1494.08( -0.54“) E(_4/22ˆĀ’l1372) Ķ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[’ïG(4/11ˆĀ’l1400) Ķ(4/9:‚’lXV:1717)Ķ(5/15:‚’lXV:1743)
2019/_6/_7 (I’l2014) 25“úü1800.28(+11.87“) E(_5/13ˆĀ’l1429) Ķ5/14:Pfizeri’ŧ;‘æ1Žl”žŠúŒˆŽZ Ķ5/24:QVM149\ŋ Ķ‚’lXV:(5/22:1834)(5/23:2149)(5/28:2296)
2019/_7/_5 (I’l2338) 25“úü2172.52( +7.62“) E(_6/12ˆĀ’l1969) Ķ6/10:Pfizeri’ŧĶ6/18:IRā–ū‰ï(å‘ä) Ķ‚’lXV:(6/24:2377)(6/26:2420)(7/1:2429)(7/2:2482)
2019/_8/_2 (I’l2544) 25“úü2448.12( +3.92“) E(_7/_9ˆĀ’l2216) Ķ7/16:Genentech’ņŒgĶ(7/16ƒXƒgƒbƒv‚:‚’lXV:2773) Ķ7/18:APP13007i’ŧ

328ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 06:00:50.15ID:sMdtSGI50
2019/_9/_6 (I’l2335) 25“úü2463.68( -5.22“) E(_8/30ˆĀ’l2179) Ķ8/5:•“c–ō•i’ņŒg Ķ8/5:‚’lXV:2794) Ķ8/13:‘æ2Žl”žŠúŒˆŽZ [—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋ]
2019/10/_4 (I’l2438) 25“úü2342.44(+4.08“) E(_9/17ˆĀ’l2088) Ķ9/12:ƒCƒ“ƒxƒXƒ^[R&D Day Ķ9/28:MTL-CEBPA’PÜ‘æ‡T‘ŠÅIŒ‹‰ĘĶ9/30:QVM149‘æ‡V‘ŠIRIDIUMŒ‹‰Ę
2019/11/_1 (I’l2570) 25“úü2385.96(+7.71“) E(10/11ˆĀ’l2130) Ķ10/9:Genentechi’ŧ
2019/12/_6 (I’l2317) 25“úü2346.72( -1.27“) E(11/15ˆĀ’l2185) Ķ11/12:‘æ3Žl”žŠúŒˆŽZĶ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[(11/13)Ķ11/28:’†‘NRDLŽûÚĶ12/6:IRā–ū‰ï(L“‡)
2019/12/30 (I’l2171) 25“úü2241.00( -3.12“) E(12/16ˆĀ’l2137) Ķ12/23:Pfizer‘æ‡T‘ŠŠJŽnĶ12/24:Pfizeri’ŧ(ŽO”Ô–Ú) Ķ2019”N‘å”[‰ï
2020/_1/10 (I’l2115) 25“úü2203.64(-4.02“) E(1/8ˆĀ’l1977) Ķ1/6:‘å”­‰ïŽn’l2150 Ķ1/7:MiNA Collaboration with AstraZeneca
2020/_1/14 (I’l2104) 5“úü2079.00(+1.20“) 25“úü2195.48(-4.17“) 75“úü2310.85( -8.95“) 200“úü2138.24( -1.60“) (ˆĀ’l2092) Ķ1/14:Orexia&Inexiai’ŧ
2020/_1/15 (I’l2139) 5“úü2083.40(+2.67“) 25“úü2188.36(-2.26“) 75“úü2309.37( -7.38“) 200“úü2142.99( -0.19“) (ˆĀ’l2108) Ķ1/15:J.P. Morgan Healthcare Conference
2020/_1/16 (I’l2150) 5“úü2111.00(+1.85“) 25“úü2185.00(-1.60“) 75“úü2306.90( -6.80“) 200“úü2147.81(+0.10“) (1/16ˆĀ’l2115)

329ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 06:01:04.09ID:sMdtSGI50
X‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂāA‘O‰ņ‚Ė‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē‚Å‚Ė’ēŪ‚ŠI‚čAÄ‚Ņ‚ĖE‚Ēę(’ę’l)‚Đ‚į‚Ė…€’ųģ‚́A3”{Œ—ƒXƒe[ƒW‚ɂē‚ɐ„ˆÚBÎB—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋBÎB
VķSoseiHeptaresAŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—Š‚ā‡’ē‚ɐi“WBÎB’…ŽĀ‚ČŠg[‚Æ‹Ī‚ɁAŒo‰cí—Š‚Ė“]Š·‚É‚æ‚鍕Žš’č’…‰ŧBÎBX‚Ȃ鐎’·‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎB
X‚Č‚éÄŽ’·ŠúA‹ÆŅ‘Šę‚ցBÎBŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎBĄ‰ņ(Ä‚Ņ)‚Ėãļ‘Šę‚ā–Ę”’‚­‚Č‚čAˆŦ’n‡‚Ē‚ɂĐV”N‘Šę‚ŠŠJŽnBÎB200“úü’ēŪBÎB

330ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 06:27:41.82ID:pSG5cT/n0
2500‰~‚ð‰z‚Ķ‚é‚ƃ^ƒCƒˆƒEƒtƒ@ƒ“ƒh‚âƒuƒ‰ƒbƒNƒƒbƒN‚Č‚Į‚Ė”ƒ‚Ē‹@ŠÖ‚Š—˜‰vŠm’č‚Å”„‚Á‚Ä‚Ŧ‚āA
ƒ‚ƒ‹ƒKƒ“‚Č‚Į‚Ė‹ó”„‚č‹@ŠÖ‚Š”„‚Á‚Ä‚Ŧ‚āA850–œ‚Ė”ƒŽc‚Š~‚Á‚Ä‚Ŧ‚āA
3000‰~‚͉z‚Ķ‚é‚ą‚Æ‚Í‚Č‚Ē‚ū‚ë‚ĪB

331ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 06:44:18.80ID:+rGtBUftd
ƒo[ƒJ

332ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 07:21:52.65ID:pSG5cT/n0
‚Ē‚­‚į‚Å”ƒ‚Á‚āA‚Ē‚­‚į‚Å”„‚é‚ÆŒvŽZ‚Å‚Ŧ‚é‚Ų‚Į‘Šę‚͊­‚Í‚Č‚ĒB
‘厖‚Č‚Ė‚Í‚Ē‚”ƒ‚Á‚āA‚Ē‚”„‚é‚Đ‚Å‚ ‚éB
2000‰~‘ä‘O”ž‚ĖĄA”ƒ‚Á‚āA4`5”NŒã‚Ė‚`2‚‚ĖãŽs‚Å”„‚éB
‚ŧ‚ę‚Å‚āŠ”‰ŋ‚Í2000‰~‘äI

333ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 07:26:55.02ID:+rGtBUftd
ƒo[ƒJ

334ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 07:41:24.83ID:pSG5cT/n0
‚ŧ[‚đ‚Ēƒwƒvƒ^ƒŒƒX‚ĖŦ—ˆ‚ĖŠé‹Æ‰ŋ’l‚ðM‚ķ‚é‚ȁI
ŽĐ•Š‚Ė“ŠŽ‘ƒZƒ“ƒX‚Ė–ģ‚ģ‚ðM‚ķ‚ëI

335ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 08:07:47.15ID:UVBCl4mrd
‚ā‚Īƒ_ƒ‚ū

336ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 08:13:05.09ID:dHZEwfEZ0
ƒ^ƒCƒˆƒE‚Ƀmƒ‹ƒEƒF[’†‰›‹âs‚Ƀuƒ‰ƒbƒNƒƒbƒN‚Š‰Á‚í‚Á‚Ä
—Š‚ā‚ĩ‚ĒŒĀ‚č‚ū‚Č

337ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 08:18:53.18ID:Mkwpxlrrp
‹C”z—Į‚Ē‚ȁB

338ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 08:19:35.78ID:HW6xCtMSa
‚ŋ‚å‚Ē‘Ō‚Á‚ĉš‚ģ‚Ē‚悧c

339ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 08:24:13.34ID:XtXNBADkp
‹C”zˆŦ‚Ē‚Č

340ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 08:27:21.03ID:4XndTLksp
‚Ē‚‚ā‚Į‚Ļ‚č‚Ė–Ņķ‚Ķ

341ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 08:30:55.10ID:K56lSxxn
ƒJƒ“ƒtƒ@ƒŒƒ“ƒXŽ‘—ŋ‚ðn“Į‚ĩ‚―ƒ‹ƒTƒ“ƒ`ƒƒ“ƒY

•KŽ€‚Ė‰ÎÁ‚ĩiÎj

342ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 08:32:05.96ID:yaSdy37D0
“ŒØˆę•”‚ķ‚á‚Č‚Ē‚Æ‹@ŠÖ‚Š”ƒ‚í‚Č‚Ē‚Æ‚ĐŒū‚í‚ę‚Ä‚―‚Ė‚Ƀmƒ‹ƒEƒF[­•{‚âƒuƒ‰ƒbƒNƒƒbƒN‚Í”ƒ‚Á‚Ä‚Ŧ‚Ä‚é‚ņ‚ū‚æ‚Č
‚ŧ‚ĖŠ„‚ÉŠ”‰ŋ‚͏り‚é‚Į‚ą‚ë‚Љš‚Š‚Á‚Ä‚é‚Ŋ‚Į

343ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 08:36:30.47ID:K56lSxxn
Žđ“i‚≅”O‚Đ‚į‚ĖŽ‹ü‚Å“Į‚Ý‹™‚é‹P‚Đ‚ĩ‚ĒƒJƒ“ƒtƒ@ƒŒƒ“ƒXŽ‘—ŋ‚—

‚ŧ[‚đ‚Ēƒ‹ƒTƒ“ƒ`ƒƒ“ƒYi‘åÎ‚Ēj

344ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 08:41:46.97ID:C5iGwMf+0
>>342
‚ŧ‚č‚á1“‚ū‚ĩ

345ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 08:41:59.91ID:AvXD0wZZd
8ŒŽ‚’l‚ū‚Á‚―‚Đ‚į”ž”NŒã‚Ė—ˆŒŽŒˆŽZŽž‚Í”―Œ‚‚ĖD‹@‚Å‚Í‚ ‚é
‚ŧ‚ę‚Ü‚Å‚Ėh•ø‚ķ‚á‚æB

346ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 08:45:06.03ID:vUBk9qSod
341 109

347ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 08:55:54.39ID:ppL6FbTA0
‚ĩ‚å‚ÚƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚Å‚Ē‚‚ā‚Į‚Ī‚č‘å–\—Ž‚ū‚Č

348ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 08:59:39.27ID:vUBk9qSod
377 160

349ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 09:28:19.70ID:C5iGwMf+0
ˆęð“úð“úŠæ’Ģ‚Á‚ďグ‚―‚Ô‚ņ‘S–ß‚ĩ‚ĩ‚ŧ‚Ī

350ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 09:44:59.76ID:C5iGwMf+0
ƒJƒ“ƒtƒ@ƒŒƒ“ƒXŽļ”s–Á•ŋ

351ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 09:54:48.52ID:fFgs4EOId
lķŽļ”s‚Ļ‚ķ‚ģ‚ņ

352ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 09:59:38.31ID:T7R4ggfQ0
ƒnƒQƒ^ƒJƒ‚ƒ‹ƒKƒ“ƒwƒ‹ƒXƒPƒAŠÃƒtƒ@ƒ‰ƒ“ƒX

353ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 10:17:47.13ID:C5iGwMf+0
‚ŧ‚ë‚ŧ‚뉚‚ɃhƒXƒ“‚Ŧ‚ŧ‚Ī

354ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 10:28:27.53ID:ee95nksap
M1ŽŸ‘æ‚â‚ë‚Ë

355ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 10:39:31.26ID:C5iGwMf+0
—L–ž‹@ŠÖ‚É1“”ƒ‚í‚ę‚―‚ū‚Ŋ‚Ńhƒ„‚é‚ŧ[‚đ‚Ē

356ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 10:42:00.21ID:4d5rHuOTa
ƒ‚ƒ‹ƒKƒ“—l‚Č‚ß‚ņ‚Č‚æ

357ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 10:46:31.86ID:C5iGwMf+0
Ā‚Ŧ‚Ü‚ĩ‚―`

358ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 10:47:06.73ID:C5iGwMf+0
ƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚ÉŽQ‰Á‚ĩ‚Ä”„‚į‚ę‚é–Á•ŋ

359ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 10:47:40.82ID:C5iGwMf+0
‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ƒVƒ‡ƒbƒNŽ€

360ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 10:47:54.78ID:C5iGwMf+0
‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[‚Ė•æ‚Í‚ą‚ą‚Å‚·‚ЁH

361ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 10:51:48.08ID:C5iGwMf+0
ƒJƒ“ƒtƒ@ƒŒƒ“ƒXŽQ‰Á‚ĩ‚Ä’N‚ā”ƒ‚Á‚Ä‚­‚ę‚Č‚Đ‚Á‚―‚ŧ[‚đ‚Ēw

362ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 10:53:10.99ID:FydEJQhG0
‘Ï‚Ķ‚į‚ę‚Č‚Ē‚Č‚į‘đØ‚č‚ĩ‚Ä‘ž–Á•ŋ‚ʼnŌ‚Ž‚Ü‚ĩ‚å‚Ī

363ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 11:06:13.03ID:2hS70A56
‚ŧ[‚đ‚Ē‘đØ‚č‚ĩ‚ăTƒ“ƒo‚ɏæ‚芷‚Ķ‚—

ƒoƒJƒ‹ƒT[‚—

364ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 11:21:07.01ID:2hS70A56
ƒoƒJƒ‹ƒT‚ĖŠč‚Ē‹•‚ĩ‚­‚—

‚ŧ[‚đ‚Ēƒ‹ƒTƒ“ƒ`ƒƒ“ƒY‚—

365ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 11:33:08.99ID:HW6xCtMSa
‚ŋ‚å‚Ē‘Ō‚Á‚ĉš‚ģ‚Ē‚悧c

366ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 11:34:32.92ID:2hS70A56
‚ƁAƒoƒJƒ‹ƒT[“c’†‚—

367ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 11:39:01.11ID:fFgs4EOId
355‚Đ‚į366‚Š‘S•”‚ ‚ځ[‚ņ‚Č‚ņ‚ū‚Š
362ˆČŠO

368ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 11:42:09.68ID:UVBCl4mrd
‚ā‚Īƒ_ƒ‚ūƒIƒƒ^

369ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 12:26:05.54ID:arXP1kuqr
“c‘šX“R

370ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 12:58:02.76ID:4d5rHuOTa
‹ó”„‚čŠOŽ‘—l‚ðär‚ß‚ņ‚Č‚æ

371ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 13:12:55.06ID:C5iGwMf+0
ƒ}ƒCƒeƒ“‚Å‚ŧ[‚đ‚Ēƒzƒ‹ƒ_[ƒVƒ‡ƒbƒNŽ€

372ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 13:13:57.65ID:C5iGwMf+0
ƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚ÍŒo”ï‚Ė–ģ‘Ę‚ū‚Á‚―‚ĩ—ˆ”N‚Đ‚įs‚Đ‚Č‚Ē‚Ų‚Ī‚Š‚Ē‚Ē

373ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 13:25:50.61ID:2hS70A56
ƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚Å‚Ė‹P‚Đ‚ĩ‚Ē”­•\‚Ƀrƒr‚č‚Ü‚­‚é‚Ė‚Š‚ŧ[‚đ‚Ēƒ‹ƒTƒ“ƒ`ƒƒ“ƒY‚—

“c’†‚—

374ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 13:29:06.22ID:C5iGwMf+0
“c’†Š”‰ŋ‚Ü‚Å‚ ‚Æ140‰~w
3‰c‹Æ“ú‚ ‚ę‚Γž’B‚·‚é‹——Ģw

375ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 13:53:54.25ID:Mkwpxlrrp
ƒ}ƒCƒeƒ“‚Ü‚ū‚ H

376ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 14:02:13.41ID:C5iGwMf+0
ƒ}ƒCƒeƒ“‚Ļ‚ß‚Å‚Æ‚ĪI

377ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 14:08:11.49ID:vVSUR0Zj
ˆĢ‚ę‚ČƒoƒJƒ‹ƒT‚Ė‘Ŧ‘~‚Ŧ‚ð’­‚ß‚ÄŠy‚ĩ‚ÞƒXƒŒiÎj

378ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 14:11:08.29ID:4d5rHuOTa
“c’†—l‚ðär‚ß‚ņ‚Č‚æ

379ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 14:21:18.31ID:rYFtG5RT0
ƒvƒ‰ƒeƒ“ww

380ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 14:28:03.47ID:5REld39K0
ƒ^ƒiƒJI@ƒ^ƒiƒJI

381ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 14:36:48.65ID:C5iGwMf+0
5‰~ƒvƒ‰ƒX‚Å‹ķŠė—•‘‚Ėƒzƒ‹ƒ_[

382ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 14:36:49.66ID:ppL6FbTA0
‘Š•Ï‚í‚į‚ļ‚ą‚ą‚ĖƒXƒŒƒbƒh‚ĖƒŒƒ”ƒFƒ‹’á‚Ē‚Č

383ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 14:44:14.38ID:rYFtG5RT0
>>381
‚Ļ‚Ü‚ä‚Ī

384ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 14:45:41.72ID:C5iGwMf+0
ƒ}ƒCƒeƒ“‚Ü‚Å‚ ‚Æ1‰~

385ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 14:47:18.33ID:C5iGwMf+0
ƒ}ƒCƒeƒ““y•UÛ
ƒzƒ‹ƒ_[‹ó‘O‚Ė“”‰Î

386ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 14:53:25.48ID:vVSUR0Zj
“c’†‚æ

‚ā‚Á‚Æ‘Ŧ‘~‚Ŋ‚æ‚—

387ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 15:00:12.55ID:C5iGwMf+0
Ž€–S‚Ļ‚ß‚Å‚Æ‚ĪI

388ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 15:00:21.97ID:C5iGwMf+0
Ā‚Á‚―w

389ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 15:02:01.25ID:vVSUR0Zj
-2
ƒoƒJƒ‹ƒT‚Ė‘叟—˜‚ū‚Č‚—

390ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 15:03:06.50ID:rYFtG5RT0
2‰~ƒ}ƒCƒiƒX‚Å‹ķŠė—•‘‚Ė”„‚čø‚č
ŽĐ‚įƒu[ƒƒ‰ƒ““Š‚°‚Ü‚­‚éƒhƒAƒz

391ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 16:00:32.93ID:LkX29MH20
ŽŸ‚Č‚é”ō–ô‚ցB’…ŽĀ‚Ȑi’ŧ‚Æ‹Ī‚ɍX‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂĐU‚é‚Ēˆį‚ŋ‚ä‚­‘ŠęBT‚Ķ‚éÞ—ŋ‚Æ‹Ī‚ɐ…€’ųģBÎB
Ž’·ŠúB—\’č‚ģ‚ę‚Ä‚Ē‚―‹ÆŅ‚Ė‹}Ž’·‚Æ‹Ī‚ɍX‚Ȃ鐎’·í—Š‚Ši“WB‡’ē‚ČR&DEPL“™‚ĖŠg[EŠg‘å‚Ė‰Á‘ŽBÎB
EEE
ĶSOSEI‚ĖŽ’·‘Šę‚Ė“ŪŒüFÄ‚Ņ‚Ėãļ‘Šę‚͏‡’ē‚ɐ„ˆÚ(2018/12/25:ÅˆĀ’l748ĶA2019/1/4:ˆĀ’l_780A2019/8/5:Å‚’l:2794)BÎB‹ÆŅ‘Šę‚Ö‚Ė“ŪˆÓ‘Ō‚ŋBÎB
2018/12/28 (I’l_799) E(12/25ÅˆĀ’l_748) Ķ12/1:SoseiHeptares–{ŠiŽn“Ū[Ä‚Ņ‚ĖE‚ĒęĶ][‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē’ēŪ‚ŠI—đ]
2019/_1/_4 (I’l_864) E(_1/_4ˆĀ’l_780) Ķ1/1:“c‘šCEO•œ‹AĶ1/7:AZD4635‘æ‡U‘Š[1/8ƒXƒgƒbƒv‚:I’l1078] [ãļƒgƒŒƒ“ƒh‚Ö“]Š·]
2019/_2/_1 (I’l1021) E(_1/30ˆĀ’l_985) Ķ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[’ïG(1/21ˆĀ’l1164, 1/30ˆĀ’l985)Ķ(1/21:‚’lXV:1360)
2019/_3/_1 (I’l1250) E(_2/_4ˆĀ’l1021) Ķ2/14:ŒˆŽZ Ķ2/22:IRā–ū‰ï(ˆĒ”{–ė)ĒŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—ŠĢ
2019/_4/_5 (I’l1593) E(_3/11ˆĀ’l1105) Ķ3/16:’†‘ãŽs Ķ(3/20:‚’lXV:ƒXƒgƒbƒv‚:1526) Ķ3/29:IRā–ū‰ï(–žŒÃ‰ŪE‘åã)
2019/_5/10 (I’l1486) E(_4/22ˆĀ’l1372) Ķ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[’ïG(4/11ˆĀ’l1400) Ķ(4/9:‚’lXV:1717)Ķ(5/15:‚’lXV:1743)
2019/_6/_7 (I’l2014) E(_5/13ˆĀ’l1429) Ķ5/14:Pfizeri’ŧ;‘æ1Žl”žŠúŒˆŽZ Ķ5/24:QVM149\ŋ Ķ‚’lXV:(5/22:1834)(5/23:2149)(5/28:2296)
2019/_7/_5 (I’l2338) E(_6/12ˆĀ’l1969) Ķ6/10:Pfizeri’ŧĶ6/18:IRā–ū‰ï(å‘ä) Ķ‚’lXV:(6/24:2377)(6/26:2420)(7/1:2429)(7/2:2482)

392ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 16:00:49.08ID:LkX29MH20
2019/_8/_2 (I’l2544) E(_7/_9ˆĀ’l2216) Ķ7/16:Genentech’ņŒgĶ(7/16ƒXƒgƒbƒv‚:‚’lXV:2773) Ķ7/18:APP13007i’ŧ
2019/_9/_6 (I’l2335) E(_8/30ˆĀ’l2179) Ķ8/5:•“c–ō•i’ņŒg Ķ8/5:‚’lXV:2794) Ķ8/13:‘æ2Žl”žŠúŒˆŽZ [—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋ]
2019/10/_4 (I’l2438) E(_9/17ˆĀ’l2088) Ķ9/12:ƒCƒ“ƒxƒXƒ^[R&D Day Ķ9/28:MTL-CEBPA’PÜ‘æ‡T‘ŠÅIŒ‹‰ĘĶ9/30:QVM149‘æ‡V‘ŠIRIDIUMŒ‹‰Ę
2019/11/_1 (I’l2570) E(10/11ˆĀ’l2130) Ķ10/9:Genentechi’ŧ
2019/12/_6 (I’l2317) E(11/15ˆĀ’l2185) Ķ11/12:‘æ3Žl”žŠúŒˆŽZĶ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[(11/13)Ķ11/28:’†‘NRDLŽûÚĶ12/6:IRā–ū‰ï(L“‡)
2019/12/30 (I’l2171) E(12/16ˆĀ’l2137) Ķ12/23:Pfizer‘æ‡T‘ŠŠJŽnĶ12/24:Pfizeri’ŧ(ŽO”Ô–Ú) Ķ2019”N‘å”[‰ï
2020/_1/10 (I’l2115) E(_1/_8ˆĀ’l1977) Ķ1/6:‘å”­‰ïŽn’l2150 Ķ1/7:MiNA Collaboration with AstraZeneca
2020/_1/17 (I’l2148) E(_1/14ˆĀ’l2092) Ķ1/14:Orexia&Inexiai’ŧ Ķ1/15:J.P. Morgan Healthcare Conference
E5“úü2131.20(+0.79“) 25“úü2178.24(-1.39“) 75“úü2302.36(-6.70“) 200“úü2152.48(-0.21“) (1/17ˆĀ’l2135)

393ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 16:01:13.36ID:LkX29MH20
X‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂāA‘O‰ņ‚Ė‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē‚Å‚Ė’ēŪ‚ŠI‚čAÄ‚Ņ‚ĖE‚Ēę(’ę’l)‚Đ‚į‚Ė…€’ųģ‚́A3”{Œ—ƒXƒe[ƒW‚ɂē‚ɐ„ˆÚBÎB—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋBÎB
VķSoseiHeptaresAŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—Š‚ā‡’ē‚ɐi“WBÎB’…ŽĀ‚ČŠg[‚Æ‹Ī‚ɁAŒo‰cí—Š‚Ė“]Š·‚É‚æ‚鍕Žš’č’…‰ŧBÎBX‚Ȃ鐎’·‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎB
X‚Č‚éÄŽ’·ŠúA‹ÆŅ‘Šę‚ցBÎBŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎBĄ‰ņ(Ä‚Ņ)‚Ėãļ‘Šę‚ā–Ę”’‚­‚Č‚čAˆŦ’n‡‚Ē‚ɂĐV”N‘Šę‚ŠŠJŽnBÎB200“úü’ēŪBÎB

394ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 16:37:59.45ID:RIq2dLSBM
Œ‹‹Įð“ú‚ĖƒJƒ“ƒtƒ@ƒŒƒ“ƒX‚Å‚Ė”­ŒūA5‰­‚ĖŒ_–ņ‚Č‚ĖH500‰­‚Č‚ĖH

395ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 17:09:28.59ID:XtXNBADkp
500‰­ƒhƒ‹

396ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 17:18:35.82ID:UVBCl4mrd
‚ā‚Īƒ_ƒ‚ū‚Ļ‚í‚―

397ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 18:36:40.22ID:lULj+lUGd
5m$

398ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 18:56:05.69ID:H1+dN4qHd
ŽãŽŒîHĄ“ú‚Í”„‚čø‚č‚É“O‚ĩ‚ĘA“Š‚ĩ‚Ü‚­‚Á‚Ä‚ņ‚Ë

399ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 19:39:23.88ID:4d5rHuOTa
“c’†—l‚ðär‚ß‚ņ‚Č‚æ

400ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 20:45:44.86ID:mapLObpH0
PER 100%‚ÍŠú‘Ōæs‚ĩ‰ß‚ŽA
PER 20%‚Ė400‰~‘ä‚ÉŽû‘Đ‚ĩ‚Ä‚Ē‚­‚ū‚ë‚ĪB

401ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 21:36:44.23ID:H1+dN4qHd
‚Į‘fl‚ЁH

402ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 22:41:15.69ID:JYpCDr9XM
‚ą‚ą’ú‚߂ăIƒ“ƒR‚Å‚ā”ƒ‚Ļ‚Ī‚Đ‚Č‚—

403ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 23:42:36.45ID:s1+Q7oB20
M—p800–œŽã‚Đ
d‚―‚Ē‚ą‚Æ‚æ

404ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 23:52:26.79ID:FydEJQhG0
‰―‚Š‚ ‚Á‚Ä‚āˆęķã‚Š‚į‚Č‚ĒŽd‘g‚Ý‚Š­‚ĩ•Š‚Đ‚é‚í

405ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/17(‹ā) 23:53:33.36ID:Mkwpxlrrp
M—pŽc‚‚Č‚ņ‚Đ‚ļ‚Á‚Æ•Ï‚í‚į‚Č‚Ē‚ņ‚ū‚Đ‚įŠÖŒW‚Č‚ĒB

406ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 00:15:14.09ID:LV7LZC6D0
ˆę”­‚ð‘_‚Á‚―ŒîH‚Š”ƒ‚Ē‚Đ‚į“ü‚Á‚Ä‚­‚é‚Đ‚į‘_‚í‚ę‚é‚í‚Č
‚ĩ‚Đ‚āM—p‚ŃKƒ“ƒKƒ““ü‚Á‚Ä‚­‚é
‚ŧ‚ĩ‚Ä”„‚č‚Đ‚į“ü‚鎖‚Í‚Å‚Ŧ‚Č‚Ē

‹ó”„‚č‚Ė‚Å‚Ŧ‚é‹@ŠÖ‚Æ‚ĩ‚Ä‚Í”„‚ę‚Δ„‚é‚Ų‚Į–Ũ‚Đ‚é
‚Č‚Ė‚Å’n‡‚Ē‚Æ‚Đ‹ÆŅ‚ÍŠÖŒW–ģ‚­Ą‚͉š‚Š‚éó‘Ô‚Č‚Ė‚ū‚æ

407ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 03:12:53.68ID:ZG4i5U5Ka
—ĮÞ—ŋ‚ð‰Ÿ‚ģ‚Ķ‘ą‚Ŋ‚ÄŠé‹Æ‰ŋ’l‚Đ‚į”—Ģ‚ĩ‰ß‚Ž‚é‚Æ‹ó”„‚č‚·‚郊ƒXƒN‚Š‚‚Ü‚é‚ĩ
’ĀŽØ–Á•ŋ‚â“Œˆę‚Ɉڍs‚·‚é‘O‚ɐļŽZ‚·‚é‚ņ‚ķ‚á‚Č‚Ē‚Ђȁ[

408ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 08:15:10.56ID:GJvSUXZR0
—ˆT‚Í2000Š„‚ę‚ЁcH

409ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 09:42:23.15ID:93vzYK9ua
ƒ‚ƒ‹ƒKƒ“—l‚ðär‚ß‚ņ‚Č‚æ

410ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 09:46:14.63ID:hkOgGC9Fd
‚ā‚Īƒ_ƒ‚ūŠŪ‘S‚É‚Ļ‚í‚―

411ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 10:48:43.73ID:UWuW65rn0
>>407
‚ķ‚á‚ ‹ó”„‚č’n–‚ÍŒã1”N‘ą‚­‚Ė‚ЁH

412ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 11:04:14.84ID:GJvSUXZR0
>>411
10”N‘ą‚­‚ž

413ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 13:29:01.96ID:5QhJpzgyd
—ˆ”N“Œˆę‚ɍs‚Á‚―‚įƒ}ƒU[ƒY“Á—L‚ĖˆŲí‚Č‹ó”„‚č‚āI‚í‚é‚Đ‚įˆĀS‚ĩ‚ë

414ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 14:14:24.78ID:bgmFxPNc0
‚ą‚ą‚ÉŒĀ‚į‚ļƒ}ƒU[ƒY‚É‚Ē‚é‚ą‚ÆŽĐ‘Ė‚Š‘Ŧˆø‚Á’Ģ‚Á‚Ä‚é‚ņ‚Đ‚į–ó‚í‚Đ‚į‚ņ‚í
‚ŧ‚ņ‚Č’†‚Ń}ƒUæl‚Ķ‚―‚â‚‚͓Á‘勉‚ĖƒAƒz

415ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 16:00:50.89ID:KyTZC7Mt0
ŽŸ‚Č‚é”ō–ô‚ցB’…ŽĀ‚Ȑi’ŧ‚Æ‹Ī‚ɍX‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂĐU‚é‚Ēˆį‚ŋ‚ä‚­‘ŠęBT‚Ķ‚éÞ—ŋ‚Æ‹Ī‚ɐ…€’ųģBÎB
Ž’·ŠúB—\’č‚ģ‚ę‚Ä‚Ē‚―‹ÆŅ‚Ė‹}Ž’·‚Æ‹Ī‚ɍX‚Ȃ鐎’·í—Š‚Ši“WB‡’ē‚ČR&DEPL“™‚ĖŠg[EŠg‘å‚Ė‰Á‘ŽBÎB
EEE
ĶSosei HeptaresFuV”N‚Ė‚ēˆĨŽA “c‘šáÁˆęv•ūŽÐ‚Å‚Í‘n–ō‚Ė‰Ī“đ‚ð—Í‹­‚­i‚Ý‚Č‚Š‚į‚āAŽaV‚ČŠvV“I‹Zp‚ðŒÕŽ‹ážX‚Æ‘_‚Á‚Ä‚Ē‚Ü‚·B2020”N‚ð‚ģ‚į‚Č‚é”ō–ô‚Ė”N‚É‚ĩ‚ÄŽQ‚č‚Ü‚·B(1/1)
ĶMiNA Therapeutics Publications: Molecular Therapy "Liver Activation of Hepatocellular Nuclear Factor-4a by Small Activating RNA Rescues Dyslipidemia and Improves Metabolic Profile". (1/4up)
ĶMiNA Therapeutics: "Announces Research Collaboration with AstraZeneca in Metabolic Diseases". Completion of these studies, AstraZeneca will have the option to negotiate a license agreement to further develop saRNA molecules. (1/7)
ĶRoche HP: Partnering: Example Partnerships: "Heptares - Research Collaboration to Discover and Develop Novel Medicines that Modulate G-protein-Coupled Receptor Targets Across a Range of Diseases." (1/10up, Add)
ĶVectura Group Trading Update: "2020 Financial Guidance: Vectura Would Earn $5m Upon Approval of QVM149 in Europe and Would Earn a Low-Single Digit Royalty on Net Sales of the Product." (1/13)
ĶJ.P. Morgan Healthcare Conference: Novartis Presentation: "Reimagining Medicine": "2020 Catalysts Maintaining Long-Term Momentum: Major Approvals: QVM / QMF 149: Asthma". (1/13 Presented)
ĶSosei HeptaresFuOrexiaŽÐ‚Ļ‚æ‚Ņ InexiaŽÐ‚É‚æ‚éƒIƒŒƒLƒVƒ“Žó—e‘Ėė“Ū–ōƒvƒƒOƒ‰ƒ€‚Ė’˜‚ĩ‚Ēi’ŧ‚É‚æ‚čMedicxiŽÐ‚Š40•S–œƒ†[ƒ(–ņ48‰­6800–œ‰~)‚ĖƒRƒ~ƒbƒgƒƒ“ƒg‚Ė‰š‚ŁAŽŸ‚Ȃ鎑‹ā’ņ‹Ÿ‚ðŽĀsv(1/14)
ĶJ.P. Morgan Healthcare Conference: Sosei Group Presentation: "Drug Dscovery and Erly Dvelopment Trgeting GPCRs": Chris Cargil. (1/15 Presented)
ERobust FY2020 Outlook: Seed Next Wave of Pre-Discovery Projects; Continued Delivery of Candidates In-House and for Partners; Progress Existing Partnered Programs; New Collaborations and Partnerships with World Leaders.
ĶSosei HeptaresFu‘æ38‰ņJ.P.ƒ‚ƒ‹ƒKƒ“Eƒwƒ‹ƒXƒPƒAEƒJƒ“ƒtƒ@ƒŒƒ“ƒX ƒvƒŒƒ[ƒ“ƒe[ƒVƒ‡ƒ“Ž‘—ŋ(‰p•ķ‚Ė‚Ý) https://ssl4.eir-parts.net/doc/4565/announcement/55455/00.pdf v(1/16up)
ĶJP Morgan Healthcare Conference 2020: Vectura Presentation: "Executing on Our Inhaled Specialist CDMO Strategy". (1/16 Presented)
ERe-Shaping Our Business Profile: "Approvals in 2020 Expected for QVM149 Triple (Novartis)". 2020 Guidance: "$5m Milestone on Approval of QVM149 with Low-Single Digit Royalty on Net Sales".
EEE

416ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 16:01:30.08ID:KyTZC7Mt0
ĶPfizer Quarterly Corporate Performance - Q4 2019 Results. (1/28)
ĶNovartis Q4 and Full Year Results 2019 and Annual Report 2019 Publication. (1/29)
ĶRoche Full Year Results for 2019. (1/30)
Ķ‘æˆęŽO‹Ī2020”N3ŒŽŠú‘æ3Žl”žŠúŒˆŽZ (1/31)
Ķ•“c–ō•iH‹Æ 2019”N“x‘æ3Žl”žŠúŒˆŽZ (2/4)
ĶSosei Group 2019”N12ŒŽŠúŒˆŽZ”­•\ (2/13Ķ)
Ķƒyƒvƒ`ƒhƒŠ[ƒ€2019”N12ŒŽŠúŒˆŽZ (2/13)
ĶAstrazeneca Full-Year 2019 Results. (2/14)
ĶAllergan Q4 and Full-Year 2019 Results. (2/19 Projected)
ĶŽl‹G•ņ2020”N2Wt†F(Žl‹G•ņæŽæ‚čF3ŒŽã{AŽl‹G•ņXVF3/16”­”„)
ĶVectura Group 2019 Preliminary results. (3/17)
ĶMorphoSys Year-End Results 2019. (3/18)
ĶSosei Group ‘æ30‰ņ’莞Š”Žå‘‰ï (3ŒŽ‰š{)
EEE

417ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 16:02:08.43ID:KyTZC7Mt0
ĶSOSEI‚ĖŽ’·‘Šę‚Ė“ŪŒüF‘O‰ņ‚Ė‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē’ēŪ‚ŠI‚čAÄ‚Ņ‚Ėãļ(…€’ųģ)‘Šę‚͏‡’ē‚ɐ„ˆÚBÎB‹ÆŅ‘Šę‚Ö‚Ė“ŪˆÓ‘Ō‚ŋBÎB
2010/12/30 (I’l_338) E(2010/10/15ĶÅˆĀ’l_163A2010/12/27Å‚’l_437) ĶQVA149‘æ‡V‘ŠŠJŽn
2011/12/30 (I’l_318) E(2011/_3/15ĶÅˆĀ’l_173A2011/_6/30Å‚’l_420) Ķƒmƒ‹ƒŒƒ{ģ”F(2/23Ķ)
2012/12/28 (I’l_522) E(2012/_6/_6ĶÅˆĀ’l_238A2012/_9/_7Å‚’l_742) ĶSeebri‰ĒBĨ“ú–{ģ”F
2013/12/30 (I’l1079) E(2013/_1/_4ĶÅˆĀ’l_513A2013/_5/_7Å‚’l1525) ĶUltibro‰ĒBĨ“ú–{ģ”F
2014/12/30 (I’l1093) E(2014/_4/12ĶÅˆĀ’l_464A2014/_9/_8Å‚’l1500) Ķ’†’·ŠúŒv‰æ”­•\(5/13Ķ)[E‚ĒęĶ][Ž’·‰ņŽûŠú‚Ė“üŒû]
2015/12/30 (I’l2488) E(2015/_3/16ĶÅˆĀ’l_713A2015/12/14Å‚’l2645) ĶHeptares(2/20Ķ)[ŽŒũ‚Ė˜Í]ĻĶ•Ä‘ģ”F(10/30Ķ)[ŽŸ‚Č‚é”ō–ô‚Ö]
2016/12/30 (I’l3363) E(2016/_1/18ĶÅˆĀ’l2270A2016/_5/_9Å‚’l6545) ĶAllergan(4/7)[‹­‹C‘Šę]ĻĶ“úXŒö•\‰ðœ(6/28)[‹­‹C‘Šę‰ðœ]
2017/12/29 (I’l2735) E(2017/_9/_6ĶÅˆĀ’l2148A2017/_1/_6Å‚’l3645) Ķ[ã”ē‚ŊŒ—‚Å‚ĖŽžŠÔŽē’ēŪ‚͏‡’ē‚ɐ„ˆÚ]ĻĶ[U‚é‚ĒęEE‚Ēę‚Ö]
2018/12/28 (I’l_799) E(2018/12/25ĶÅˆĀ’l_748A2018/_1/25Å‚’l3195) ĶSoseiHeptaresŽn“Ū [Ä‚Ņ‚ĖE‚Ēę(’ę’l)Ķ][‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē’ēŪ‚ŠI—đ]
2019/12/30 (I’l2171) E(2019/_1/_4ĶÅˆĀ’l_780A2019/_8/_5Å‚’l2794) Ķ“c‘šCEO•œ‹AĶ[ãļƒgƒŒƒ“ƒh‚Ö“]Š·]ĶQVM149‰ĒB\ŋ(5/24) [—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋ]
2020/_1/17 (I’l2148) E(2020/_1/_8ĶÅˆĀ’l1977A2020/_1/_6Å‚’l2176) Ķ1/7:MiNA Collabo with AstraZenecaĶ1/14:Orexia&Inexiai’ŧĶ1/15:Presentation

418ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 16:02:29.09ID:KyTZC7Mt0
X‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂāAÄ‚Ņ‚ĖE‚Ēę(’ę’l)‚Đ‚į‚Ė…€’ųģ‚Í3”{Œ—ƒXƒe[ƒW‚ɂē‚ɐ„ˆÚBÎB—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋBÎB200“úü’ēŪBÎB
VķSoseiHeptaresAŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—Š‚́A’…ŽĀ‚Ȑi’ŧEŠg[‚Æ‹Ī‚ɁA‡’ē‚ɐi“WBÎBX‚Ȃ鐎’·‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎB
Œo‰cí—Š‚Ė“]Š·‚É‚æ‚鍕Žš’č’…‰ŧBÎB‹ÆŅ‘Šę‘Ō‚ŋBÎBĄ‰ņ‚Ėãļ‘Šę‚ā–Ę”’‚­‚Č‚čAŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎB

419ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 18:03:15.79ID:NizkSTo60
1ŒŽ29“ú‚Ė’†‘‚ĖƒEƒ‹ƒV[‚Ė”„ã‚Č‚ņ‚ĐŠú‘Ō‚Å‚Ŧ‚ņ‚â‚ë

420ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 18:08:07.54ID:NizkSTo60
”N“ā‚Ü‚―2000‰~Š„‚ę‚Ä1500‰~‚­‚į‚Ē‚ňę“x—Ž‚ŋ’…‚­‚â‚ë

421ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 18:12:13.72ID:NizkSTo60
Žž‘ã‚̓Iƒ“ƒR

422ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 18:14:51.81ID:NizkSTo60
‚ŧ[‚đ‚Ē‚𔄂Á‚ăIƒ“ƒR‚𔃂í‚ļ‚ĩ‚Ä
ƒoƒCƒI“ŠŽ‘‰Æ‚É‚ ‚į‚ļ

423ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 18:30:13.17ID:s7+J6bQHd
ƒTƒ“ƒo‚Đ‚įˆÆ‘Ö‚Ķ‚ĩ‚―‚Ė‚ĐŠî’nŠO

424ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 18:41:27.42ID:GJvSUXZR0
–ūŒã“ú‚Đ‚į–\—Ž‚·‚é
ƒzƒ‹ƒ_[ÅŒã‚Ė”ÓŽ`

425ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 18:53:42.31ID:5QhJpzgyd
“ŒˆęŒˆ‚Ü‚Á‚―‚įŠ”‰ŋ‚͏り‚é‚æB‹ó”„‚č‹@ŠÖ‚āĄX‚ķ‚―‚΂―‚·‚é‚Ė‚Í‚Ý‚Á‚Æ‚ā‚Č‚Ē‚Č

426ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 19:00:27.55ID:j7aMZUiId
‚Ŧ‚ŋ‚Š‚Ē‚Į‚āT––‚Ė•ÛŽį‚ē‹ę˜J
‚ą‚Ė‚Ü‚Ü‘ą‚Ŋ‚Č‚ģ‚Ē

427ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 19:59:38.84ID:ux4EvuIY0
T–ū‚Ŋ‚Ė‚ŧ[‚đ‚Ē‚Í8T˜A‘ą‚Å’·‚ß‚Ė‰Aü‚É‚Č‚Á‚Ä‚é
“Œˆę‚ɍs‚Á‚―‚į`‚ƍŠ‹’‚Ė‚Č‚ĒŠyŠÏ˜_‚ŏT––‚ɛƂߍž‚ņ‚Å’@‚Ŧ”„‚ë‚Ī‚Æ‚ĩ‚Ä‚Č‚Ē‚ЁH

428ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 20:13:10.13ID:5QhJpzgyd
‚ŧ‚ņ‚ČƒIƒJƒ‹ƒg‚æ‚č—LŒūŽĀs‚Ė“c‘š‚Ė•û‚ŠM‚ķ‚į‚ę‚é‚ž

429ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 22:43:50.90ID:NizkSTo60
“ŒˆęĀ‚Á‚Ä‚ā•Ï‚í‚į‚ņ‚â‚ë

430ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 22:53:23.41ID:bgmFxPNc0
10”NŒã‚͕č‘‚ĖGAFA‚Ý‚―‚Ē‚Č‚Æ‚ą‚ĖŽP‰š‚É‚Č‚Á‚Ä‚ņ‚ķ‚á‚Č‚Ē‚ЂȁH
100–œ‰~ƒzƒ‹ƒ_[‚ĖŽ‘ŽY‚Š1‰­‰~‚É‚Č‚Á‚Ä‚é‚Đ‚ā‚æIH

431ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 22:58:45.80ID:oTS9nvQt0
200Š”‚ū‚ŊŽ‚Á‚Ä‚é‚ņ‚Å‚·‚ŠA“K“–‚Č‚Æ‚ą‚ë‚Å”„‚Á‚―•û‚Š—Į‚Ē‚Å‚ĩ‚å‚Ī‚ЁH

432ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 23:31:49.97ID:NizkSTo60
>>431
2000‰~Š„‚ę‚é‘O‚É”„‚Á‚Æ‚ŊI

433ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 23:36:13.87ID:GJvSUXZR0
>>430
ãę15”N‚ĩ‚l‚Đ‚įŠ”‰ŋ‰š‚Š‚Á‚Ä‚é‚ņ‚Å‚·‚Ŋ‚Įc

434ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 23:40:53.14ID:bgmFxPNc0
>>433
‚Ü‚Ÿ‚ŧ‚ę‚ÍŒĐŽĖ‚Ä‚į‚ę‚―l‚―‚ŋ‚ū‚æ‚Ë

435ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/18(“y) 23:50:45.51ID:xgXKekPi0
>>432
‚Ļ‹x‚Ý‚Ė“ú‚ā‚ē‹ę˜J—l‚Å‚·

436ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 00:41:43.68ID:8+XTzqgB0
’†‘‚ĖƒEƒ‹ƒV[‚āƒ_ƒ‚Å‚l1‚āƒ_ƒ‚Å‚p‚u‚l‚āƒ_ƒ‚ū‚ë‚Ī

437ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 01:04:56.12ID:mEqw/Y3J0
‚Å‚ā4‚ãŽs‚ĩ‚Ä‚é‚Đ‚į‚Č‚ 
1‚‚āãŽs‚ĩ‚Ä‚Č‚­‚Ä‚ā6000‰­’BŽ‚Å‚Ŧ‚é‚į‚ĩ‚Ē‚ž

438ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 08:06:07.30ID:cHwLpNYkd
‚ā‚Īƒ_ƒ‚ū

439ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 09:08:20.35ID:GzpvgUY+d
QVM‚Í‚ŧ‚ę‚Č‚č‚É‚Ē‚­‚Å‚ĩ‚å
‚ŧ‚ę‚æ‚čA‚ŧ‚ę‚É‚æ‚čƒƒCŠúŠÔ‚Š‰„’·‚ģ‚ę‚é‚į‚ĩ‚Ē‚Á‚Ä‚ą‚Æ‚Š–{“–‚Č‚įĶ‚­‘å‚Ŧ‚Ē

440ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 10:32:40.87ID:7PVnGsOu0
ƒƒC‰„’·‚Æ‚Đ“c‘š‚Ėƒzƒ‰‚ū‚ë
‚Č‚ÉŒū‚Ķ‚Ί”Žå‚Š‚æ‚ū‚ꐂ‚į‚ĩ‚Ä”ŽčŠ…Ņ‚·‚é‚Аg‚ɐõ‚Ý‚Ä•Š‚Đ‚Á‚Ä‚é‚ņ‚ū‚Đ‚į

441ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 11:21:10.35ID:puKKh62dd
ƒƒC‰„’·‚Í‚Ų‚ÚŠm’č‚ū‚æ
ƒxƒNƒ`ƒ…ƒ‰‚ŠŒðÂ’†

442ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 12:05:47.20ID:mEqw/Y3J0
‚Ē‚â‰ïŽÐ‚Đ‚įIR‚ÅŒöŽŪ‚ɃAƒiƒEƒ“ƒX‚ĩ‚Ä‚Č‚ĒŒĀ‚čƒzƒ‰‚Ŧ‚Æ“Ŋ‹`‚ū‚Đ‚į

443ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 12:52:07.67ID:7WznsOYi0
–{ŒˆŽZ 2020”N2ŒŽ13“ú‚Å‚Í”„ã100‰­‰~–Ē’B‚ŁA
“ŒˆęŠî€‚ðƒNƒŠƒA‚Å‚Ŧ‚ļA
“Œˆę‚ɐĀ‚Ŋ‚ļ‚ÉŽļ–]”„‚č‚Å1500‰~‚­‚į‚Ē‚܂ʼnŸ‚·‚â‚ë

444ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 13:03:56.58ID:mEqw/Y3J0
1500‚ōςނí‚Ŋ–ģ‚Ē‚â‚ë
750‰~Š„‚ę‚ū‚í

445ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 13:06:31.65ID:ECwD+kQE0
‚Ü‚ŸŽž‰ŋ‘Šz‚R‚O‚O‰­‚­‚į‚Ē‚Š“Kģ
‚ĩ‚å‚Ī‚ķ‚Ŧ•—‘D‚Ý‚―‚Ē‚É–c‚į‚ņ‚ūŽž‰ŋ‘Šz‚͉ߑå•]‰ŋ‚·‚Ž‚é

446ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 13:14:26.22ID:ioYeP5R0
ƒ‹ƒTƒ“ƒ`ƒƒ“ƒY‚ĖÅ‚č‚—

ŠŠŒmŠŠŒmiÎj

447ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 13:46:46.33ID:d8wXOGvzd
>>441
ŒðÂ’†‚Č‚Ė‚É‚Ų‚ÚŠm’č‚Á‚Äw
ƒAƒz‚Ė‚đ‚Ē‚ÅŠ”‰ŋ‚ɂ͉„’·D‚荾‚Ü‚ę‚Ä‚é‚Đ‚į‰„’·‚Č‚Đ‚Á‚―‚į‘å•Ï‚Č‚ą‚Æ‚É

448ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 13:48:52.13ID:ioYeP5R0
”MS‚É‚ŧ[‚đ‚Ē‚Ė“ŪŒü‚ð’Į‚Ē‚Đ‚Ŋ‚郋ƒTƒ“ƒ`ƒƒ“ƒY‚ĖŽpiÎj

449ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 14:47:01.09ID:cp3a6vflp
”„“؏łÁ‚ăZƒ‹ƒtƒo[ƒjƒ“ƒOwww

450ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 17:17:06.59ID:7WznsOYi0
‘O‰ņA“c‘šŽÐ’·‚Í“Œˆę‚ɍs‚­‚ÆŒū‚Á‚Ä‚Ļ‚Ē‚āA
ŽĐ•Š‚Í”„‚č”ē‚Ŋ‚ĩ‚Ä‚―‚į‚ĩ‚Ē‚æ

451ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 17:40:51.59ID:7WznsOYi0
‚q‚r‚t‚Ė2249‰~‚Šã’l’ïRü‚É‚Č‚Á‚Ä‚Ē‚é

452ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 18:18:07.64ID:WPAJotfG0
‚ą‚ę‚Đ‚į1ƒ–ŒŽ‚Í2700‰~‘ä‚ō‚’l’Í‚Ý‚ĩ‚―‰šŽč‚­‚ŧ‚―‚ŋ‚ŠM—pŠú“ú“ž—ˆ‚Å‚Ô‚ņ“Š‚°‚Ä‚­‚é‚Đ‚į—v’ˆÓ
”ƒ‚Ī‚Ė‚Í4ŒŽ‚­‚į‚Ē‚Đ‚į‚Å‚ā’x‚­‚Í‚Č‚Ē‚ÆŽv‚Ī

453ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 18:53:51.39ID:pb0FYli7a
Ŧ—ˆ“I‚ɂ͏り‚é‚Á‚Ä‚ą‚Æ‚Đ

454ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 19:19:10.56ID:2houZjcW0
ƒzƒ‹ƒ_[‚æ‚čƒmƒ“ƒzƒ‹‚Ė•û‚Š•KŽ€‚Č‹É‚ß‚ÄŠó—L‚Č–Á•ŋ

455ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 19:28:50.71ID:7ZMM1/hl
ƒlƒKƒLƒƒƒ“‚·‚é‚―‚ß‚É”MS‚ɏî•ņŽûW‚ĩ‚ďłč‚Ü‚­‚郋ƒTƒ“ƒ`ƒƒ“ƒYiÎj

456ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 20:15:53.21ID:BsgMQflZd
‚Æ‚č‚ ‚Ķ‚ļ200Š”‚ū‚Ŋ‚Č‚ņ‚Å–\—Ž‚ĩ‚Ä‚ā’É‚­‚Č‚Ē‚ņ‚ÅŽ‚Á‚Æ‚Ŧ‚Ü‚·‚Ë

457ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 20:29:13.60ID:R4R4L1gX0
^‚ĖƒoƒCƒI‚̓Tƒ“ƒoƒCƒI‚ū‚Ŋ

458ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 20:32:10.95ID:7ZMM1/hl
ƒoƒJƒ‹ƒT‚—

459ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 21:26:03.34ID:qg1URoqJd
200Š”‚Ý‚―‚Ē‚ČŽG‹›‚͏‘‚­Ž‘Ši–ģ‚ĩ
ƒOƒ_ƒOƒ_Œū‚Ī‚ČƒSƒ~

460ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 21:36:12.70ID:mEqw/Y3J0
–ū“ú‚Đ‚į’n–‚Ė–\—Ž‚Đ

461ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 22:31:29.84ID:MfA7DSbC0
‚Ü‚ Šú“ú‚Å—Ž‚ŋ‚ę‚Ε―Í‰ŧ‚ŏり‚é‚Ė‚ÍŽĐ–ū

462ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/19(“ú) 22:35:18.34ID:mEqw/Y3J0
‚Ų‚ņ‚Æ‚§[H

463ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 05:08:56.71ID:F4TW2gor0
•ā

464ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 07:00:07.68ID:yjawBcRs0
ŽŸ‚Č‚é”ō–ô‚ցB’…ŽĀ‚Ȑi’ŧ‚Æ‹Ī‚ɍX‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂĐU‚é‚Ēˆį‚ŋ‚ä‚­‘ŠęBT‚Ķ‚éÞ—ŋ‚Æ‹Ī‚ɐ…€’ųģBÎB
Ž’·ŠúB—\’č‚ģ‚ę‚Ä‚Ē‚―‹ÆŅ‚Ė‹}Ž’·‚Æ‹Ī‚ɍX‚Ȃ鐎’·í—Š‚Ši“WB‡’ē‚ČR&DEPL“™‚ĖŠg[EŠg‘å‚Ė‰Á‘ŽBÎB
EEE
ĶSosei HeptaresFuV”N‚Ė‚ēˆĨŽA ‘ã•\Ž·s–ð‰ï’·Œ“ŽÐ’· CEO “c‘šáÁˆęv(1/1)
E•W“I‚ĖģŠm‚ȍ\‘Ē‚ðŒˆ’č‚ĩ‚―ã‚Å•ŠŽqÝŒv‚ðs‚Īãk–§‚Č‘n–ō‹Zp‚Š•K—v‚Å‚·‚ŠA•ūŽÐ‚É‚Í‚ŧ‚Ė”õ‚Ķ‚Š‚ ‚č‚Ü‚·BŒŧŽž“_‚Å‚ÍGPCR‚É“Á‰ŧ‚ĩ‚Ä‚Ē‚Ü‚·‚ŠA“Ŋ‚ķ‹Zp‚ð‚ŧ‚ęˆČŠO‚Ė–Œƒ^ƒ“ƒpƒNŽŋ‚Ė•W“I‚É‚ā“K—p‚Å‚Ŧ‚Ü‚·B
E•ūŽÐ‚Å‚Í‘n–ō‚Ė‰Ī“đ‚ð—Í‹­‚­i‚Ý‚Č‚Š‚į‚āAŽaV‚ČŠvV“I‹Zp‚ðŒÕŽ‹ážX‚Æ‘_‚Á‚Ä‚Ē‚Ü‚·B56”NU‚č‚Ė“Œ‹žƒIƒŠƒ“ƒsƒbƒN‚ðŒ}‚Ķ‚é2020”N‚ð‚ģ‚į‚Č‚é”ō–ô‚Ė”N‚É‚ĩ‚ÄŽQ‚č‚Ü‚·B
ĶMiNA Therapeutics Publications: Molecular Therapy, Nucleic Acids Vol. 19 March 2020: "Liver Activation of Hepatocellular Nuclear Factor-4a by Small Activating RNA Rescues Dyslipidemia and Improves Metabolic Profile". (1/4up)
ĶMiNA Therapeutics: "MiNA Therapeutics Announces Research Collaboration with AstraZeneca in Metabolic Diseases". (1/7)
EThe collaboration combines MiNA's leading expertise in the discovery and development of saRNA therapeutics with AstraZeneca's experience in identifying and bringing breakthrough treatments to patients with metabolic diseases.
ĶVectura Group Trading Update: "2020 Financial Guidance: Vectura Would Earn $5m Upon Approval of QVM149 in Europe and Would Earn a Low-Single Digit Royalty on Net Sales of the Product." (1/13)
ĶJ.P. Morgan Healthcare Conference: Novartis Presentation: "Reimagining Medicine": "2020 Catalysts Maintaining Long-Term Momentum: Major Approvals: QVM / QMF 149: Asthma". (1/13 Presented)
ĶSosei HeptaresFuOrexiaŽÐ‚Ļ‚æ‚Ņ InexiaŽÐ‚É‚æ‚éƒIƒŒƒLƒVƒ“Žó—e‘Ėė“Ū–ōƒvƒƒOƒ‰ƒ€‚Ė’˜‚ĩ‚Ēi’ŧ‚É‚æ‚čMedicxiŽÐ‚Š40•S–œƒ†[ƒ(–ņ48‰­6800–œ‰~)‚ĖƒRƒ~ƒbƒgƒƒ“ƒg‚Ė‰š‚ŁAŽŸ‚Ȃ鎑‹ā’ņ‹Ÿ‚ðŽĀsv(1/14)
EˆĀ’č‰ŧ‚ģ‚ę‚―ƒIƒŒƒLƒVƒ“Žó—e‘Ė(StaR)ƒAƒSƒjƒXƒg“‡Œ^”zĀ‚É‚æ‚čAÚŨ‚ȍ\‘Ē“I“īŽ@‚ð“ū‚é‚Æ‚Æ‚ā‚ɁA‚ą‚ę‚Ü‚Å‚É‚Č‚Ē‘n–ōƒAƒvƒ[ƒ`‚ðĖ—p‚·‚é‚ą‚ƂŁAŒoŒû‚Ļ‚æ‚Ņ•@o“ā“Š—^‚Ė‰Â”\Ŧ‚ðŽ‚ÂA‘I‘ðŦ‚Š‚‚­‹­—Í‚Č•ŠŽq‚Ė‘nŧ‚Š‰Â”\‚É‚Č‚č‚Ü‚·B
E‚ą‚Ėd—v‚ЂŠė‚΂ĩ‚Ēi’ŧ‚É‚æ‚čAMedicxiŽÐ‚Đ‚į‚ĖƒRƒ~ƒbƒg‚𔚂ĪŽŸ‚Ȃ鎑‹ā’ņ‹Ÿ‚ð‰Â”\‚É‚ģ‚đA‚ą‚ę‚į‚Ė”ņí‚É—L–]‚Č•ŠŽq‚ðv‘Ž‚ɗՏ°ŽŽŒą‚ւƐi‚ß‚Ä‚Ē‚­‚―‚ß‚ÉŽg‚í‚ę‚Ü‚·B
ĶJ.P. Morgan Healthcare Conference: Sosei Group Presentation: "Drug Dscovery and Erly Dvelopment Trgeting GPCRs": Chris Cargil. (1/15 Presented)
ERobust FY2020 Outlook: Seed Next Wave of Pre-Discovery Projects; Continued Delivery of Candidates In-House and for Partners; Progress Existing Partnered Programs; New Collaborations and Partnerships with World Leaders.
ĶSosei HeptaresFu‘æ38‰ņJ.P.ƒ‚ƒ‹ƒKƒ“Eƒwƒ‹ƒXƒPƒAEƒJƒ“ƒtƒ@ƒŒƒ“ƒX ƒvƒŒƒ[ƒ“ƒe[ƒVƒ‡ƒ“Ž‘—ŋ(‰p•ķ‚Ė‚Ý) https://ssl4.eir-parts.net/doc/4565/announcement/55455/00.pdf v(1/16up)
ĶJP Morgan Healthcare Conference 2020: Vectura Presentation: "Executing on Our Inhaled Specialist CDMO Strategy". (1/16 Presented)
ERe-Shaping Our Business Profile: "Approvals in 2020 Expected for QVM149 Triple (Novartis)". 2020 Guidance: "$5m Milestone on Approval of QVM149 with Low-Single Digit Royalty on Net Sales".
EEE

465ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 07:00:22.58ID:yjawBcRs0
ĶASCO 2020: "First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)": Debashis Sarker. (1/24 12:00 Presenting)
ĶPatients as Partners Europe: "Patient Involvement in Regulatory Decisions: How Regulations are Incorporating the Patient Voice": Domenico Merante, MD, VP, Clinical Development, Sosei Heptares. (1/27 16:15-16:45 Presenting)
ĶPfizer Quarterly Corporate Performance - Q4 2019 Results. (1/28)
ĶNovartis Q4 and Full Year Results 2019 and Annual Report 2019 Publication. (1/29)
ĶRoche Full Year Results for 2019. (1/30)
ĶR•DŽx‰‡ƒZƒ“ƒ^[ŽåÃƒyƒvƒ`ƒhƒZƒ~ƒi[uƒyƒvƒ`ƒhˆã–ō•iŒī–ō‚Ėŧ‘ĒƒvƒƒZƒXŠJ”­‚ƃXƒP[ƒ‹ƒAƒbƒv‚Ė—ŊˆÓ“_vJITSUBO ŒĪ‹†ŠJ”­•” •”’· ŽRúą‹MŽjB(1/31 12:30-16:30)
Ķ‘æˆęŽO‹Ī2020”N3ŒŽŠú‘æ3Žl”žŠúŒˆŽZ (1/31)
Ķ•“c–ō•iH‹Æ 2019”N“x‘æ3Žl”žŠúŒˆŽZ (2/4)
ĶSosei Group 2019”N12ŒŽŠúŒˆŽZ”­•\ (2/13Ķ)
Ķƒyƒvƒ`ƒhƒŠ[ƒ€2019”N12ŒŽŠúŒˆŽZ (2/13)
ĶAstrazeneca Full-Year 2019 Results. (2/14)
ĶAllergan Q4 and Full-Year 2019 Results. (2/19 Projected)
ĶSMi RNA Therapeutics: "Small Activating RNAs(saRNAs) - A Novel Therapeutic Class of Oligonucleotides with Broad Therapeutic Potential": David Blakey, MiNA Therapeutics. (2/19 13:20-14:00 Presenting)
ĶICDD (International Conference on Drug Discovery) 2020: Speaker Dr. Jonathan Mason, Sosei Heptares. (2/29-3/2)
ĶŽl‹G•ņ2020”N2Wt†F(Žl‹G•ņæŽæ‚čF3ŒŽã{AŽl‹G•ņXVF3/16”­”„)
ĶVectura Group 2019 Preliminary Results. (3/17)
ĶMorphoSys Year-End Results 2019. (3/18)
ĶSosei Group ‘æ30‰ņ’莞Š”Žå‘‰ï (3ŒŽ‰š{)
EEE

466ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 07:00:50.65ID:yjawBcRs0
ĶSOSEI‚ĖŽ’·‘Šę‚Ė“ŪŒüFÄ‚Ņ‚Ėãļ‘Šę‚͏‡’ē‚ɐ„ˆÚ(2018/12/25:ÅˆĀ’l748ĶA2019/1/4:ˆĀ’l_780A2019/8/5:Å‚’l:2794)BÎB‹ÆŅ‘Šę‚Ö‚Ė“ŪˆÓ‘Ō‚ŋBÎB
2018/12/28 (I’l_799) E(12/25ÅˆĀ’l_748) Ķ12/1:SoseiHeptares–{ŠiŽn“Ū[Ä‚Ņ‚ĖE‚ĒęĶ][‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē’ēŪ‚ŠI—đ]
2019/_1/_4 (I’l_864) E(_1/_4ˆĀ’l_780) Ķ1/1:“c‘šCEO•œ‹AĶ1/7:AZD4635‘æ‡U‘Š[1/8ƒXƒgƒbƒv‚:I’l1078] [ãļƒgƒŒƒ“ƒh‚Ö“]Š·]
2019/_2/_1 (I’l1021) E(_1/30ˆĀ’l_985) Ķ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[’ïG(1/21ˆĀ’l1164, 1/30ˆĀ’l985)Ķ(1/21:‚’lXV:1360)
2019/_3/_1 (I’l1250) E(_2/_4ˆĀ’l1021) Ķ2/14:ŒˆŽZ Ķ2/22:IRā–ū‰ï(ˆĒ”{–ė)ĒŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—ŠĢ
2019/_4/_5 (I’l1593) E(_3/11ˆĀ’l1105) Ķ3/16:’†‘ãŽs Ķ(3/20:‚’lXV:ƒXƒgƒbƒv‚:1526) Ķ3/29:IRā–ū‰ï(–žŒÃ‰ŪE‘åã)
2019/_5/10 (I’l1486) E(_4/22ˆĀ’l1372) Ķ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[’ïG(4/11ˆĀ’l1400) Ķ(4/9:‚’lXV:1717)Ķ(5/15:‚’lXV:1743)
2019/_6/_7 (I’l2014) E(_5/13ˆĀ’l1429) Ķ5/14:Pfizeri’ŧ;‘æ1Žl”žŠúŒˆŽZ Ķ5/24:QVM149\ŋ Ķ‚’lXV:(5/22:1834)(5/23:2149)(5/28:2296)
2019/_7/_5 (I’l2338) E(_6/12ˆĀ’l1969) Ķ6/10:Pfizeri’ŧĶ6/18:IRā–ū‰ï(å‘ä) Ķ‚’lXV:(6/24:2377)(6/26:2420)(7/1:2429)(7/2:2482)
2019/_8/_2 (I’l2544) E(_7/_9ˆĀ’l2216) Ķ7/16:Genentech’ņŒgĶ(7/16ƒXƒgƒbƒv‚:‚’lXV:2773) Ķ7/18:APP13007i’ŧ
2019/_9/_6 (I’l2335) E(_8/30ˆĀ’l2179) Ķ8/5:•“c–ō•i’ņŒg Ķ8/5:‚’lXV:2794) Ķ8/13:‘æ2Žl”žŠúŒˆŽZ [—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋ]
2019/10/_4 (I’l2438) E(_9/17ˆĀ’l2088) Ķ9/12:ƒCƒ“ƒxƒXƒ^[R&D Day Ķ9/28:MTL-CEBPA’PÜ‘æ‡T‘ŠÅIŒ‹‰ĘĶ9/30:QVM149‘æ‡V‘ŠIRIDIUMŒ‹‰Ę
2019/11/_1 (I’l2570) E(10/11ˆĀ’l2130) Ķ10/9:Genentechi’ŧ
2019/12/_6 (I’l2317) E(11/15ˆĀ’l2185) Ķ11/12:‘æ3Žl”žŠúŒˆŽZĶ‹ó”„‚č‰ŋŠi‹K§ƒgƒŠƒK[(11/13)Ķ11/28:’†‘NRDLŽûÚĶ12/6:IRā–ū‰ï(L“‡)
2019/12/30 (I’l2171) E(12/16ˆĀ’l2137) Ķ12/23:Pfizer‘æ‡T‘ŠŠJŽnĶ12/24:Pfizeri’ŧ(ŽO”Ô–Ú) Ķ2019”N‘å”[‰ï
2020/_1/10 (I’l2115) E(_1/_8ˆĀ’l1977) Ķ1/6:‘å”­‰ïŽn’l2150 Ķ1/7:MiNA Collaboration with AstraZeneca
2020/_1/17 (I’l2148) E(_1/14ˆĀ’l2092) Ķ1/14:Orexia&Inexiai’ŧ Ķ1/15:J.P. Morgan Healthcare Conference
E5“úü2131.20(+0.79“) 25“úü2178.24(-1.39“) 75“úü2302.36(-6.70“) 200“úü2152.48(-0.21“) (1/17ˆĀ’l2135)

467ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 07:01:12.86ID:yjawBcRs0
X‚Ȃ鐎’·‚Ėęt–ūŠú‚ɂāA‘O‰ņ‚Ė‹­‹C‘Šę‚Đ‚į‚ĖŽžŠÔŽē‚Å‚Ė’ēŪ‚ŠI‚čAÄ‚Ņ‚ĖE‚Ēę(’ę’l)‚Đ‚į‚Ė…€’ųģ‚́A3”{Œ—ƒXƒe[ƒW‚ɂē‚ɐ„ˆÚBÎB—x‚čę‚É‚Ä“ŪˆÓ‘Ō‚ŋBÎB
VķSoseiHeptaresAŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ÉŒü‚Ŋ‚―Ž’·í—Š‚ā‡’ē‚ɐi“WBÎB’…ŽĀ‚ČŠg[‚Æ‹Ī‚ɁAŒo‰cí—Š‚Ė“]Š·‚É‚æ‚鍕Žš’č’…‰ŧBÎBX‚Ȃ鐎’·‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎB
X‚Č‚éÄŽ’·ŠúA‹ÆŅ‘Šę‚ցBÎBŽŸ‚Ȃ鐎’·ƒXƒe[ƒW‚ŠŠy‚ĩ‚Ý‚Å‚·‚ˁBÎBĄ‰ņ(Ä‚Ņ)‚Ėãļ‘Šę‚ā–Ę”’‚­‚Č‚čAˆŦ’n‡‚Ē‚ɂĐV”N‘Šę‚ŠŠJŽnBÎB200“úü’ēŪBÎB

468ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 07:31:42.50ID:JGgsI1Nm0
‚ŋ‚å‚Ē‘Ō‚Á‚ĉš‚ģ‚Ē‚悧c

469ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 08:08:43.30ID:QDX1Hzkod
52
18

470ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 08:10:57.96ID:3zy0xrG40
‚ā‚Īƒ_ƒ‚ū

471ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 08:44:11.21ID:QDX1Hzkod
75
41

472ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 08:49:30.81ID:QDX1Hzkod
75
45

473ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 08:55:40.45ID:QDX1Hzkod
86
43

474ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 08:59:07.95ID:QDX1Hzkod
97
48

475ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 09:00:00.45ID:QDX1Hzkod
110
49

476ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 09:07:37.85ID:JPfnSQ440
’n–‚Ė‰š—Ž‚Ö

477ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 09:30:38.59ID:JPfnSQ440
–{“ú‚ā‰š—Ž‚Ļ‚ß‚Å‚Æ‚Ī

478ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 09:52:08.89ID:JPfnSQ440
ƒJƒ“ƒtƒ@ƒŒƒ“ƒXs‚­‚ÆŽž‰ŋ‘Šz‚ŠŒļ‚éw

479ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 10:03:01.18ID:JPfnSQ440
ƒJƒ“ƒtƒ@ƒŒƒ“ƒXs‚Á‚Ä’N‚ā”ƒ‚Á‚Ä‚­‚ę‚Č‚Đ‚Á‚―–Í—l

480ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 10:06:06.41ID:JPfnSQ440
ƒIƒƒ^c

481ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 10:20:37.16ID:JGgsI1Nm0
‚ŋ‚å‚Ē‘Ō‚Á‚ĉš‚ģ‚Ē‚悧c

482ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 10:36:41.94ID:JPfnSQ440
ƒTƒ“ƒoƒCƒI{0.8“
‚ŧ[‚đ‚Ē‚́c

w

483ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 11:10:21.77ID:xD0nfzdO0
M1ŽŸ‘æ

484ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 11:11:50.96ID:oj8ku+7ad
‚ā‚Īƒ_ƒ‚ūƒIƒƒ^

485ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 11:11:56.49ID:+S1aCuGia
‚ŧ‚Ī‚Ē‚Ķ‚ΓŒØˆę•”ˆÆ‘Ö‚Ķ‚Á‚ĐD‚荾‚Ü‚ę‚Ä‚é‚ĖH

486ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 11:12:37.46ID:gJv5+vwq0
‚ŧ‚ņ‚Č‚ā‚ņÞ—ŋ‚Å‚·‚į‚Č‚Ē‚í

487ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 11:13:05.69ID:JPfnSQ440
‚ŧ[‚đ‚ĒI—đ

488ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 11:17:28.32ID:/npejj2v0
ƒ‚ƒ‹ƒKƒ“—l‚ðär‚ß‚ņ‚Č‚æ

489ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 11:26:59.54ID:JPfnSQ440
25ma•t‹ß‚Å’e‚Ŧ•Ô‚ģ‚ę‚―‚įŽŸ‚Í1800‰~‚Ёcƒgƒzƒzc

490ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 11:27:29.47ID:JPfnSQ440
‚ ‚ę‚ū‚Ŋ•ŪŠS‚ĩ‚Ä‚―‚Ė‚É“c’†Š”‰ŋ‚Š‚’l–Ú•WŠ”‰ŋ‚É‚Č‚é‚Ė‚Ёc

491ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 11:27:41.25ID:/npejj2v0
–{•Ļ‚̓Tƒ“ƒoƒCƒI‚ū‚Ŋ

492ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 11:30:49.19ID:JGgsI1Nm0
‚ŋ‚å‚Ē‘Ō‚Á‚ĉš‚ģ‚Ē‚悧c

493ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 11:33:16.40ID:JPfnSQ440
ƒJƒ“ƒtƒ@ƒŒƒ“ƒXs‚Á‚Ä”„‚į‚ę‚é‰ïŽÐ

494ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 11:55:35.54ID:JPfnSQ440
ŒßŒã‚ā‰š—Ž‚ŁAĄT‘å‚Ŧ‚ȏT‘Ŧ‰Aüˆø‚Ŧ‚ŧ‚Ī‚ū‚Ë

495ŽRŽt‚ģ‚ņ—ƒgƒŒ[ƒh’†2020/01/20(ŒŽ) 11:59:41.31ID:JPfnSQ440
ŒßŒã‚Í‚â‚΂Ē‚ȁc

V’…ƒŒƒX‚Ė•\ŽĶ
ƒŒƒX‚𓊍e‚·‚é